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Abstract 
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Abstract 
Two thirds of breast cancers express the estrogen receptor alpha (ERα) and are 
estrogen-dependent for growth. In contrast, expression of ERα induces differentiation 
and senescence in normal human mammary epithelial cells. Both embryonic 
development and lineage commitment in the adult mammary gland are governed by 
transcriptional regulators, many of which have also been implicated in 
tumourigenesis. Genome-wide association studies have identified the previously 
uncharacterised putative transcription factor TOX high mobility group box family 
member 3 (TOX3) as a new candidate breast cancer susceptibility gene. 
In the present study, I aimed to characterise TOX3 function in the normal human 
mammary epithelium and in breast cancer. 
Transcriptional profiling of human breast tumours showed that TOX3 was expressed 
in luminal but not in basal-like human breast tumours. Both in the normal human 
breast and mouse mammary gland, TOX3 expression appeared to be restricted almost 
exclusively to mature luminal epithelial cells, suggesting a function for TOX3 in 
luminal differentiation. In addition, TOX3 was shown to inhibit differentiation of 
bipotent MCF-10A cells along the myoepithelial lineage. Microarray analysis of 
MCF-7 luminal breast cancer cells expressing ectopic TOX3 showed that TOX3 
expression resulted in the downregulation of luminal differentiation genes including 
PGR and GREB1. At the same time, TOX3 expression led to a marked induction of 
cell proliferation genes such as MYC and CCNA2. Using tandem affinity purification 
of TOX3 and subsequent mass spectrometric analysis, I identified the 
transcription/translation factor Y-box binding protein 1 (YBX1) as a potential TOX3 
interacting protein. YBX1 has previously been shown to promote breast cancer 
progression through its function in a multitude of signalling pathways. The present 
work further showed that the nuclear protein TOX3 globally affected transcriptional 
regulation in an estrogen-independent manner. Finally, TOX3 promoted tumour 
growth in a luminal xenograft model. 
Combined, my findings suggest that TOX3 regulates differentiation of normal human 
mammary epithelial cells along the luminal lineage by inhibiting myoepithelial 
differentiation. In tumour cells, TOX3 appears to suppress luminal differentiation and 
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promote proliferation, thereby allowing a switch from paracrine to autocrine 
signalling and transformation of ERα-positive cells. 
 
Résumé 
 iii 
Résumé 
Deux tiers des cancers du sein expriment le récepteur à l’estrogène alpha (REα) et 
leur croissance dépend des estrogènes alors que l’expression de REα induit la 
différenciation et la sénescence des cellules humaines mammaires épithéliales 
normales. Le développement embryonnaire et la différenciation de la glande 
mammaire adulte sont contrôlés par des facteurs de transcription, dont beaucoup sont 
aussi impliqués dans la tumorigenèse. Plusieurs études d'association pan-génomiques 
ont identifié le putatif facteur de transcription TOX high mobility group box family 
member 3 (TOX3) comme un nouveau gène de prédisposition au cancer du sein. 
L’objectif de cette étude était la caractérisation fonctionelle de TOX3 dans 
l’épithélium mammaire normal et le cancer du sein. 
L’analyse des tumeurs du sein humaines par puces à ADN a montré que TOX3 est 
exprimé dans les tumeurs luminales mais pas dans les tumeurs basales. Dans le sein 
humain et la glande mammaire murine, l’expression de TOX3 est limitée 
exclusivement aux cellules épithéliales luminales matures, indiquant une fonction de 
TOX3 dans la différenciation luminale. De plus, j’ai démontré que TOX3 inhibe la 
différentiation myoépithéliale des cellules bipotentes MCF-10A. L’analyse 
microarray des cellules luminales cancéreuses MCF-7 exprimant TOX3 a montré que 
l’expression du facteur de transcription mène à une diminution d’expression des gènes 
de différentiation luminale comme PGR et GREB1 ainsi qu’à une augmentation de 
l’expression des gènes de prolifération comme MYC et CCNA2. Par la méthode de 
purification d’affinité en tandem (TAP) combinée à la spectrométrie de masse, j’ai 
identifié le facteur de transcription et traduction Y-box binding protein 1 (YBX1) 
comme potentiel partenaire protéique de TOX3. Or, il est connu que YBX1 favorise 
la progression tumorale du cancer du sein par son rôle dans une multitude des voies 
de signalisation. 
De plus, les présents travaux ont montré que TOX3 est une protéine nucléaire qui 
influence globalement la régulation transcriptionnelle de manière estrogène-
independante. Finalement, TOX3 accélère la formation des tumeurs dans un modèle 
de xénogreffe de cellules luminales. 
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En résumé, mes résultats proposent que TOX3 contrôle la différenciation luminale 
des cellules humaines épithéliales normales en inhibant la différenciation 
myoépithéliale. Dans les cellules cancéreuses, TOX3 paraît de réprimer la 
différentiation luminale et active la prolifération qui permet le passage d’une 
signalisation paracrine à une signalisation autocrine et la transformation des cellules 
REα-positives. 
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1 Introduction 
1.1 Breast cancer 
Breast cancer is the most common type of cancer in women in the industrialized 
world. It is estimated to have accounted for 28% of all female cancer incidences and 
17% of all cancer deaths in women in Europe in 2008 (Ferlay et al., 2010). 
Breast cancer is a very heterogeneous disease both at the molecular and 
histopathological levels, which is reflected in its clinical behaviour. Several distinct 
subtypes have been described based on gene expression profiling (discussed below). 
In addition, individual breast tumours consist of populations of cells with distinct 
phenotypes and molecular profiles, which is already evident at the stage of ductal 
carcinoma in situ (DCIS) before a tumour becomes invasive (Allred et al., 2008). 
The current focus and prevailing notion in the field of breast cancer research is that 
the distinct breast cancer subtypes originate in different types of mammary epithelial 
cells that serve as the “cell of origin”. The identification of the cell of origin of the 
different tumour types is closely related to the question of the epithelial cell hierarchy 
in the normal mammary gland, and both require the identification and characterisation 
of the signalling proteins and transcription factors that govern mammary gland 
development by controlling progression along the mammary lineage. A better 
understanding of tumour heterogeneity is ultimately the basis for the development of 
effective and targeted treatments for the different tumour subtypes. 
 
1.2 Microarray-based classification of breast cancer 
In the last decade, gene expression profiling of breast tumours has led to the discovery 
of molecular subtypes of invasive ductal carcinoma (Farmer et al., 2005; 
Herschkowitz et al., 2007; Perou et al., 2000; Sorlie et al., 2001; Sotiriou et al., 2003). 
Expression of estrogen receptor alpha (ER/ESR1) is a major determinant of the 
tumour subtype, and tumours can broadly be classified into subtypes which express 
ER together with a set of genes that are characteristic of luminal epithelial cells of the 
mammary gland (luminal tumour subtypes), and those that are negative for the 
expression of these luminal genes (basal-like tumours and human epidermal growth 
factor receptor 2 (HER2/ERBB2)-positive tumours). The luminal class can be 
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subdivided further into the luminal A and luminal B subtypes. The luminal A subtype 
is characterised by high expression of ER and its target gene progesterone receptor 
(PGR/PR) and by the expression of a cluster of genes including forkhead box A1 
(FOXA1), X-box binding protein 1 (XBP1) and GATA-binding protein 3 (GATA3), 
termed the luminal or ER cluster. Luminal B tumours generally exhibit low to 
moderate expression of ER and luminal specific genes, including the ER cluster, have 
higher proliferative rates and are of higher grade (Sorlie et al., 2001; Sorlie et al., 
2003). In the clinic, the classification of luminal B tumours has been cause for 
controversy as ER+/ERBB2+ tumours are considered luminal B by some but not by 
others (Bhargava and Dabbs, 2008; Carey et al., 2006; Perou, 2010). The basal-like 
tumour subgroup is characterised by the expression of a set of genes that are 
characteristic of basal epithelial cells, including basal keratins, and lacks expression 
of ER, PR, the luminal gene cluster, as well as ERRB2 (Sorlie et al., 2003). In the 
clinical pathological setting, the basal subtype has traditionally been referred to as 
triple-negative breast cancer due to the lack of ER, PR and ERBB2 expression as 
defined by immunohistochemical staining, although the direct equivalence of these 
classifications is controversial (Gusterson, 2009). Sorlie and colleagues have 
described the ERBB2-positive tumour subtype as characterised by high expression of 
several genes in the ERBB2 amplicon at 17q22.24, yet some tumours classified 
within the ERBB2-positive subgroup lack ERBB2 expression, and vice versa, 
suggesting that ERBB2 expression does not accurately describe the non-basal ER-
negative subgroup. This is consistent with findings from our group following the 
publication of the original classification by Sorlie et al. Our group identified a new 
subgroup of tumours, termed “molecular apocrine” (Farmer et al., 2005), which is 
characterised by expression of the androgen receptor and the lack of ER expression. 
This group at least partially overlaps with the HER2-positive subtype, thereby 
allowing for a more accurate classification of breast tumours. Thus, this alternative 
classification includes the luminal, molecular apocrine and basal subtypes. A recent 
follow-up study by Perou and colleagues identified the claudin-low subtype, which is 
characterised by low expression of genes involved in tight junctions and cell-cell 
adhesion, including claudins 3, 4, 7 and E-cadherin, as well as absence of ER, PR and 
ERBB2 expression. Claudin-low tumours further show low to absent expression of 
luminal genes, high levels of epithelial-to-mesenchymal transition (EMT) markers, 
immune response genes and inconsistent expression of basal genes (Herschkowitz et 
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al., 2007; Prat et al., 2010). Notably, the claudin-low profile resembles the signature 
of putative mammary stem cells (Hennessy et al., 2009; Prat et al., 2010). It appears 
that the remaining normal-like breast cancer subtype does not represent a clinically 
relevant subtype but stems from poorly sampled tumour tissue (Weigelt et al., 2010). 
It is of note that the classification of breast tumours by expression profiling is largely 
based on the tumour phenotype and the expression pattern of the (normal) cell type 
that it resembles rather than the genotype. The only exception to this is the group of 
HER2-positive tumours, which are classified based on an oncogenic mutation, or 
genotype. As mentioned above, our group has previously suggested the term 
“molecular apocrine” to describe this subtype of tumours, reflecting the phenotype of 
this breast cancer subtype which is characterised by increased androgen signalling in 
an ER-negative luminal cell, rather than its genetic make-up (Farmer et al., 2005). 
It is not surprising that the heterogeneous nature of breast cancer has important 
clinical implications for prognosis and treatment of the disease. Several of the 
molecular profiling studies have reported that the definition of a tumour subtype by 
signature genes allows for the prediction of critical clinical parameters such as overall 
prognosis, treatment response, and therapeutic resistance (Sorlie et al., 2003; van't 
Veer et al., 2002; West et al., 2001). 
 
1.3 Development and homeostasis of the mammary gland 
Over the last decades important progress has been made in the understanding of 
signalling pathways that are involved in the morphogenesis of the breast, but the 
molecular mechanisms underlying the different developmental stages are still not 
fully understood. My discussion will be limited to the key events, structures and 
regulatory pathways involved in mammary gland development and structure in 
humans and mice. A more in-depth discussion of the current knowledge of breast 
development and branching morphogenesis can be found in a number of recent 
reviews (Hennighausen and Robinson, 2001; Hens and Wysolmerski, 2005; Howard 
and Gusterson, 2000; Lu et al., 2006; Mikkola and Millar, 2006; Sternlicht, 2006). 
Expression, knockout, and transplantation studies have provided insight into 
mammary gland development in mice, whereas less is known about human breast 
development owing to constraints on tissue availability and the lack of experimental 
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systems. While key events in the early development of the murine and human 
mammary gland are believed to be similar, the morphology of the adult breast differs 
markedly between the species, as addressed below. 
 
The mammary gland consists of an extensive tree-like system of branched ducts that 
is composed of the mammary epithelium, which in turn is embedded in the 
surrounding stroma. Unlike other branched organs, the mammary gland develops 
predominantly after birth in defined stages that are connected to sexual development 
and reproduction. The stages of mammary development are embryogenesis, 
prepubertal development, puberty, pregnancy, lactation, and involution. During 
embryogenesis, a rudimentary ductal tree develops. After birth, the mammary gland 
grows mainly isometrically with the rest of the body until puberty, when the ductal 
tree undergoes extensive branching morphogenesis in response to systemic hormonal 
cues. During adult life, the branched network of ducts is refined in response to cyclic 
ovarian stimulation. Development is governed by the intricate interplay of epithelial-
mesenchymal interactions, systemic steroid and peptide hormone signalling pathways 
and transcriptional networks. 
 
1.3.1 Embryonic development of the mammary gland 
The two main compartments forming the mammary gland are the epithelium and the 
surrounding stroma, which are derived from the embryonic ectoderm and mesoderm, 
respectively. 
Early embryonic development of the mammary gland resembles the formation of 
other skin appendages such as hair follicles and teeth, all of which are controlled by 
epithelial-mesenchymal interactions and are independent of systemic hormonal cues 
(Mikkola and Millar, 2006). However, the notion that the mammary gland is a 
modified apocrine or sebaceous gland is controversial (Howard and Gusterson, 2000). 
In the mouse, mammary development begins at mid-gestation with the formation of 
bilateral milk lines along the ventrolateral surface ectoderm that appear in response to 
mesenchymal signals on embryonic day (E) 10.5. At this stage, epidermal cells within 
the milk line become multilayered and columnar, thus protruding from the single-
layered periderm. On E11.5, five pairs of placodes, local thickenings, form along the 
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mammary lines. This is thought to occur through migration of cells within the 
mammary line. Placode formation is followed by the invagination of cells into the 
underlying mesenchyme to form bulb-shaped mammary buds, the primary mammary 
rudiment or anlage, between E11.5 and E12.5. At the same time, mesenchymal cells 
surrounding the buds condense and differentiate to give rise to a dense mammary 
mesenchyme. Differentiation of the mesenchyme is characterised by expression of the 
androgen receptor, and in many mouse strains the mammary buds eventually 
degenerate in response to foetal androgen signalling in male embryos. In female 
embryos, the epithelial cells start proliferating on E15.5-E16.5 after a period of 
morphological quiescence, and the buds extend through the mesenchyme into the 
preadipocytes of the developing fat pad, forming a mammary sprout that starts to 
branch and forms a lumen in response to signalling from the stromal environment of 
the mammary fat pad. This gives rise to the rudimentary ductal tree consisting of a 
primary duct and 15-20 secondary ducts that are present at birth (Hens and 
Wysolmerski, 2005; Lu et al., 2006). Unlike branching morphogenesis in the adult 
mammary gland, embryonic branching is induced by epithelial-mesenchymal 
interactions and occurs in estrogen receptor (ER) knockout mice, demonstrating its 
independence from hormonal control by estrogens (Bocchinfuso et al., 2000; Curtis 
Hewitt et al., 2000). 
Similar to the mouse, the initiating event in human breast development is the 
formation of a bilateral ridge, or milk line, in the second trimester, which develops 
into the breast bud that is separated from the surrounding mesenchyme by the 
basement membrane (Howard and Gusterson, 2000). By 28 weeks, two distinct cell 
populations can be distinguished in the mammary anlage: a cytokeratin 14 (KRT14)-
negative central cell population and a KRT14- and α-smooth muscle actin (SMA, 
ACTA2)-positive peripheral or basal population (Anbazhagan et al., 1998; Howard 
and Gusterson, 2000). In the later stages of embryonic development, a rudimentary 
ductal tree arises from the growing bud as the lumen enlarges and secondary branches 
emerge, which in turn become canalised, branch and invade the surrounding 
mesenchyme. In contrast to murine development, human mammary morphogenesis is 
indistinguishable in females and males in utero (Howard and Gusterson, 2000). A 
further difference to the mouse is the secretory activity of the human breast and the 
production of milk in the late-term human foetal and newborn breast in response to 
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maternal hormones, which is followed by menopause-like involution upon hormone 
withdrawal (Anbazhagan et al., 1991; Howard and Gusterson, 2000). 
 
1.3.2 Regulators of early mammary gland development and breast cancer 
Embryonic development of the mammary gland is largely determined by 
mesenchymal-epithelial interactions, as mentioned above. Knockout studies in mice 
have provided valuable insight into the signalling pathways that regulate cell fate 
decisions in the developing gland (Mikkola and Millar, 2006). Genes that play an 
important role in the formation of the mammary anlagen and later embryonic 
development include Wnt10b and its target Lef-1, which are the earliest known 
markers of placode formation (Howard and Ashworth, 2006). Their expression in turn 
is dependent on Tbx3, an important regulator of placode induction. Tbx3 was also 
proposed to function in the specification of mammary cell identity (Davenport et al., 
2003; Howard and Ashworth, 2006). The observations made in mice are confirmed by 
human genetic disorders that are characterised by impaired breast development such 
as ulnar-mammary syndrome, which is caused by mutations in the TBX3 gene 
(Bamshad et al., 1997). Further signalling molecules implicated in mammary 
morphogenesis include the fibroblast growth factor 10 (Fgf10), its receptor Fgfr2 and 
the epidermal growth factor receptor ligand neuregulin 3 (Nrg3) (Howard and 
Ashworth, 2006; Howard et al., 2005). Various other signalling factors regulate breast 
development, which has been reviewed elsewhere (Howard and Gusterson, 2000). 
As reassignment of cell identity plays an important role in oncogenic transformation, 
it is conceivable that parallels exist between the latter and normal mammary 
development. For instance, variant single nucleotide polymorphisms in the FGFR2 
gene are associated with an increased risk of breast cancer, as discussed below. The 
intricate relationship of mammary development, differentiation of the adult mammary 
epithelium and tumourigenesis is exemplified by the zinc finger transcription factor 
GATA-3, deletion of which leads to profound defects in early murine development 
and perturbation of the maintenance of luminal cell differentiation in the adult gland 
(Asselin-Labat et al., 2007). 
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1.3.3 Structure and homeostasis of the adult mammary gland 
After birth, development of the human breast remains restricted to isometric growth in 
both females and males until the onset of puberty when the mammary epithelium and 
stroma undergo dramatic changes. This is also seen in rodents. In humans, there is an 
increase in fibrous and adipose tissue in the stroma, which in turn constitutes 80% of 
the adult nonlactating breast tissue. Proliferation of the connective tissue is followed 
by expansion of the epithelium in response to estrogen signalling in the female breast 
at the onset of puberty, while the male breast does not undergo further growth. In the 
human breast, the primary ducts that reach the nipple elongate and branch 
dichotomously and sympodially, giving rise to a branched network of increasingly 
smaller ducts, which in turn end in terminal ducts that give rise to blind-ended 
ductules called acini. Peripubertal proliferation of the epithelium occurs 
predominantly at end bud-like structures. At the tip of the extending duct, the terminal 
ductal lobular unit (TDLU) develops, which consists of a collection of acini 
embedded in a concentric layer of fibroblasts and which is considered the mature 
functional unit of the adult breast, while the ducts are surrounded by loose cellular 
intralobular stroma (Howard and Gusterson, 2000). The TDLUs are also thought to be 
the predominant site of breast cancer formation (Visvader, 2009). Due to the 
unavailability of tissue samples, little is known about the morphological changes 
during pregnancy and lactation that occur in response to systemic hormones in the 
human breast. Limited data confirm similarities to the events seen in mice including 
dramatic proliferative activity of the acinar cells, an increased number of lobules and 
a loss of adipose tissue due to the depletion of fat in adipocytes. At weaning, the 
mammary epithelium undergoes involution, which is characterised by the removal of 
secretory epithelial cells by apoptosis and phagocytosis. The epithelial layers of the 
resting breasts reform in the area of the acini, while the ducts are not affected by 
expansion and involution for the most part. This is in contrast to menopause-
associated involution, when both lobules and ducts are reduced in number and the 
intralobular fibroblastic stroma is replaced by fat (Howard and Gusterson, 2000). 
Knockout and transplantation studies have permitted us to gain a detailed 
understanding of the development of the adult mouse mammary gland. Like in 
humans, peripubertal development of the murine mammary gland occurs in response 
to estrogen-, amphiregulin-, epidermal growth factor (Egf)- and insulin-like growth 
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factor 1 (Igf1)-dependent signalling, resulting in the elongation and bifurcation of the 
rudimentary ductal tree at its bulbous tip structures termed terminal end buds (TEB) 
(Sternlicht, 2006). The mitogenic activity of estrogen, which is thought to be the key 
regulator of development during puberty, is mediated by amphiregulin-dependent 
induction of the epidermal growth factor receptor (Egfr) in a paracrine manner 
(Ciarloni et al., 2007). Once the margins of the mammary fat pad are reached in the 
sexually mature female, ductal branching is refined through tertiary sidebranching in 
response to cyclic ovarian stimulation through progesterone, which is thought to act 
through paracrine activation of Wnt4 and Rank ligand (RankL) (Brisken et al., 2000). 
Finally, during pregnancy, lactogenic differentiation, alveologenesis and further 
sidebranching occur upon prolactin-dependent stimulation (Brisken and O'Malley, 
2010; Sternlicht, 2006). Unlike the human breast, the adult murine ductal tree does 
not end in TDLUs but the lobules are composed of alveolar buds at the site of 
regressed TEBs, which form during each oestrous cycle. The alveoli also contain the 
luminal secretory cells that undergo functional differentiation during pregnancy and 
lactation. Another important difference to the human breast is that the murine 
mammary stroma contains significantly less connective and more adipose tissue 
(Visvader, 2009). 
 
1.3.4 The stem cell hierarchy in the mammary gland 
Despite morphological differences between the human and murine mammary gland, 
the mouse has proved an invaluable model system for normal mammary gland 
biology as well as breast tumourigenesis. In recent years, there has been particular 
focus on the delineation of the cellular hierarchy in the mammary gland as the 
tremendous proliferative capacity and plasticity of the breast inevitably raise the 
question of the existence of a somatic mammary stem cell. 
The normal adult mammary duct has a bi-layered architecture: the lumen of the duct 
is lined by a single layer of luminal epithelial cells, while myoepithelial cells form a 
unicellular layer covering the luminal cell layer. The myoepithelial cells are in contact 
with the basement membrane, a specialised extracellular matrix that separates the 
epithelial cells from the surrounding stroma that consists predominantly of fibroblasts, 
adipocytes, endothelial cells and lymphocytes (Fig. 1). 
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Figure 1. Cross-section of a mammary duct. 
(A) Cross-section of a normal mammary duct. Left, H&E staining; right, schematic 
representation of the epithelial and stromal cell types that are most commonly found 
in the normal breast. (B-E) Immunohistochemical staining of breast ductules and 
TDLUs; (B) CK14 staining of myoepithelial cells; (C) CK18 staining of luminal cells; 
(D) smooth muscle actin staining of myoepithelial cells; ER staining of luminal cells. 
Images were kindly provided by G. MacGrogan. 
 
Luminal and myoepithelial cells express a characteristic subset of epithelial 
cytokeratins and other markers, which are used for diagnostic purposes. Human 
myoepithelial cells express cytokeratins 5 (K5) and 14 (K14), which are markers for 
stratified and glandular epithelial cells that are located along the basement membrane 
(and which are therefore also referred to as basal markers) (Fig. 1). In contrast, 
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luminal epithelial cells express K18, along with its partnering intermediary filament 
K8 (Fig. 1). K19 is sometimes used as a luminal marker but its expression is not 
restricted to the luminal cell fraction and has been proposed to be a “neutral” switch 
cytokeratin that marks common progenitor cells (Stasiak et al., 1989; Taylor-
Papadimitriou et al., 1989; Villadsen et al., 2007). Other markers that have 
traditionally been used for myoepithelial cells include α smooth muscle actin (SMA, 
ACTA2) (Fig. 1), neutral endopeptidase CD10, and p63, while human luminal cells 
are positive for mucin 1 (MUC1) and epithelial cell adhesion molecule (EPCAM) 
(O'Hare et al., 1991; Stingl et al., 2001). 
 
In analogy to the hierarchical differentiation process that has been established for the 
haematopoietic system, there is mounting evidence for the existence of a similar 
differentiation hierarchy in the adult mammary gland. Mammary stem cells (MaSCs) 
are thought to give rise to all cells of the luminal and myoepithelial lineages via a 
series of increasingly lineage-restricted intermediate cell types (Fig. 3). It long proved 
difficult to define, let alone isolate mammary stem cells (MaSC) owing to a lack of 
adequate assays that would sufficiently confirm the “stemness” of the cell in question. 
The development of in vivo mammary reconstitution assays in the mouse and the 
optimisation of tissue dissociation methods over the last 50 years have allowed for the 
recent prospective isolation of mammary stem cells. 
In mice, mammary stem cells are functionally defined as cells that are capable of 
reconstituting a functional mammary gland in a mammary fat pad where the 
rudimentary ductal tree has been surgically removed in female pre-pubertal mice, an 
assay pioneered in 1959 by DeOme and colleagues (DeOme et al., 1959). Removal of 
the epithelium leaves the “cleared fat pad”, the stromal tissue that consists of 
adipocytes, fibroblasts, macrophages and endothelial cells (Neville et al., 1998). 
Classic studies went on to show that mammary epithelial outgrowths could be 
generated from both small explants and cell suspensions. The site from which 
explants were taken had no effect on their ability to reconstitute the gland, suggesting 
that repopulating cells are found throughout the mammary gland. In addition, these 
cells could be serially transplanted several times, suggesting an ability to self-renew. 
Furthermore, the capacity of these cells to repopulate the fat pad was shown to be 
independent of the reproductive history or developmental stage of the donor gland 
(Daniel et al., 2009; Daniel and Young, 1971; Hoshino and Gardner, 1967; Smith, 
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1996; Smith and Medina, 1988). Smith and co-workers further demonstrated the 
existence of different types of progenitor cells that gave rise to ductal or secretory 
(lobular) outgrowths (Smith, 1996). Using stably MMTV-infected donor cells, they 
also showed the ability of a single cell to repopulate the entire mammary gland 
(Kordon and Smith, 1998). They further proposed small light cells (SLC) that 
exhibited a characteristic lack of cytoplasmic differentiation to be potential mammary 
stem or progenitor cells (Chepko and Smith, 1997). While these classic studies 
demonstrated the existence of mammary cells that have the ability to divide 
asymmetrically (thereby giving rise to the luminal and myoepithelial cell lineages) 
and self-renew, which are the two characteristics that are thought to define a stem 
cell, they failed to isolate purified mammary stem cells. 
In recent years, improved tissue dissociation techniques in combination with the 
application of fluorescence-activated cell sorting (FACS) have led to the 
identification and purification of distinct mammary epithelial cell subpopulations and 
the prospective isolation of mouse mammary stem cells. Visvader, Eaves, Stingl, 
Smalley and co-workers first demonstrated the isolation of a discrete mouse 
mammary stem cell-enriched population based on the expression of a combination of 
cell surface markers (Shackleton et al., 2006; Sleeman et al., 2006; Stingl et al., 
2006). Murine MaSC were found to be highly enriched in the mammary epithelial 
subpopulation that is characterised by the marker profile 
CD49fhigh/CD29high/CD24+/med/Sca1- (Shackleton et al., 2006; Sleeman et al., 2006; 
Stingl et al., 2006). These cells are able to self-renew and regenerate a functional 
mammary gland in a cleared fat pad and retain this ability after serial transplantation. 
Based on this property, they were termed mammary repopulating units (MRUs). They 
are distinguished from mammary colony-forming cells (Ma-CFCs) (Stingl et al., 
2006). Their name is derived from the colony-forming cell (CFC) assay, which was 
originally developed to test the ability of haematopoietic progenitor cells to proliferate 
and differentiate into colonies in a semi-solid medium. The Ma-CFC assay is now 
commonly used to characterise mammary progenitors that give rise to discrete 
colonies in low-density adherent culture (Bachelard-Cascales et al., 2010; Stingl et al., 
2001; Stingl et al., 2006). Limiting-dilution analysis showed that a single cell (or 
MRU) had the capability to give rise to the entire ductal tree, impressively 
demonstrating the multipotency of the proposed stem cell (Shackleton et al., 2006; 
Stingl et al., 2006). It has to be noted however that these stem cells represent less than 
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10% of the CD49fhigh/CD29high/CD24+/med/Sca1- subset, which also contains mature 
myoepithelial cells and probably other basal cell intermediates such as myoepithelial 
progenitor cells, which remain to be characterised. The similar FACS profiles of 
MaSC and other myoepithelial/basal cells may reflect their common basal location in 
the duct. FACS has become the method of choice for the purification and analysis of 
mammary epithelial subpopulation but when comparing studies from different 
laboratories, differences in the experimental approach and the antibodies used for cell 
sorting need to be considered. The CD49fhigh/CD24med population described by Stingl 
and co-workers (Stingl et al., 2006) is thus thought to be identical to the 
CD29high/CD24+ population identified by Shackleton and colleagues (Shackleton et 
al., 2006) and the CD49fhigh/CD24low/Sca1- subset described by Sleeman et al. 
(Sleeman et al., 2006). Furthermore, CD24+ cells express both CD49f (α6 integrin) 
and CD29 (β1 integrin) at high levels, suggesting a role for these two integrins in the 
interaction with the extracellular matrix (ECM) in the basal, stem cell-enriched 
compartment. In keeping with this, deletion of β1 integrin from the basal 
compartment results in a reduced repopulation capacity (Taddei et al., 2008). 
Analogous to the MaSC-enriched basal subpopulation, luminal progenitors and their 
mature progeny have been described based on their FACS profile. Luminal 
progenitors were described as CD24+/high/CD29low/CD61+, while mature luminal cells 
were shown to be CD24+/high/CD29low/CD61- in the original publications (Shackleton 
et al., 2006; Sleeman et al., 2006; Stingl et al., 2006). Smalley and colleagues further 
showed that prominin staining distinguishes two different subpopulations within the 
luminal group, where prominin 1+ cells represent a hormone-sensing luminal 
subcompartment, while prominin 1- cells are involved in milk production, as they 
express hormone receptor and milk proteins, respectively. Sca1 staining essentially 
gave the same results (Sleeman et al., 2007). Recently, Visvader and colleagues 
identified the tyrosine receptor kinase Kit as an additional marker for luminal 
progenitor cells (Lim et al., 2009). 
 
Introduction 
 13 
 
Figure 2. Mouse and human stem and progenitor cell assays. 
(A) Mouse MaSC and progenitor assays. Mouse MaSC (or MRU, blue circle) are 
CD24med/CD49fhigh and are able to self-renew and regenerate a functional mammary 
epithelial outgrowth in a cleared fat pad. Mammary progenitor cells are 
CD24high/CD49+ (red box) and form colonies in the Ma-CFC assay. (B) Human 
MaSC and progenitor assays. Human MaSC (or MRU, blue circle) are localised 
within the EpCAMlow/CD49fhigh population and generate epithelial outgrowths when 
xenografted. Human mammary progenitors can be characterised based on their ability 
to give rise to pure luminal (luminal progenitor, EpCAMhigh/CD49f+/MUC1+), pure 
myoepithelial (progenitor remains uncharacterised to date), or mixed colonies (early 
progenitor, EpCAMlow/CD49fhigh/MUC-) in the Ma-CFC assay. Images are taken from 
(Eirew et al., 2010; Sleeman et al., 2006; Stingl, 2009). 
 
Establishing similar stem cell assays for human mammary stem cells has posed a 
particular challenge due to a lack of equivalent model systems. Similar to the mouse 
mammary gland, in vitro assays in combination with FACS analysis of human 
mammary epithelial cells have provided evidence for a hierarchical structure of the 
human breast and identified markers for the different human mammary cell lineages. 
2D and 3D in vitro culture of dissociated cells or organoids derived from reduction 
mammoplasties has been useful to determine the capability of individual epithelial 
subpopulations to give rise to differentiated progeny and thus to define mammary cell 
lineages (Bachelard-Cascales et al., 2010; Duss et al., 2007; Stingl et al., 1998; Stingl 
et al., 2001; Visvader, 2009). Magnetic beads coupled to antibodies directed against 
cell surface markers can be used instead of FACS to sort cells (Proia et al., 2011). 
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However some argue that, albeit less technically challenging and presumably gentler 
on the cells, the immunobead method results in a less exact separation of the different 
epithelial subpopulations. As described above for murine cells, the mammary colony-
forming cell assay is used to investigate the ability of distinct human progenitor cells 
to form colonies in collagen gel-based medium on a layer of irradiated NIH 3T3 
mouse fibroblasts (Bachelard-Cascales et al., 2010; Eirew et al., 2008) (Fig. 2). 
Choosing an alternative approach, Dontu and colleagues established a protocol for the 
non-adherent culture of human primary mammary cells. The suspension culture of 
dissociated cells enriches for mammary stem and progenitor cells, which are thought 
to survive and give rise to spherical structures termed mammospheres. In contrast, the 
non-adherent culture conditions negatively select for more differentiated cell types 
that are thought to die from anoikis. Dontu and co-workers demonstrated that single 
cells derived from dissociated mammospheres were able to differentiate along the 
luminal and myoepithelial lineages, which was confirmed by the presence of 
differentiation markers and the expression of basal and luminal keratins, respectively 
(Dontu et al., 2003). The mammosphere assay has since been employed by several 
groups to select for and maintain normal mammary stem and progenitor cells as well 
as tumour-initiating cells (Duss et al., 2007; Harrison et al., 2010). However, more 
recent findings call the validity of mammosphere culture as a true stem cell assay into 
question as the self-renewal potential of normal mammary epithelial cells in 
suspension is exhausted within five passages (Dey et al., 2009 and my own 
unpublished observation). This may suggest that mammosphere culture allows for the 
short-term maintenance of common progenitors, which are able give rise to luminal 
and myoepithelial cells under differentiating conditions but are not able to self-renew. 
Alternatively, the cell culture conditions may be a limiting factor, allowing true 
mammary stem cells to give rise to more differentiated progeny but not to self-renew. 
Indeed, there is mounting evidence that in vitro cell culture conditions have a 
profound impact on the phenotype of the cultured cells (Ince et al., 2007; Stingl et al., 
2001 and my own unpublished observations). This is addressed in more detail below. 
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Figure 3. Epithelial cell hierarchy in the mammary gland. 
Proposed model of the differentiation hierarchy within the mammary epithelium. Cell 
surface markers commonly used for the isolation of distinct subpopulations of mouse 
(blue) and human (green) mammary epithelial cells are shown. The cell surface 
markers are described in Table 1. 
 
In a pioneering study using an orthotopic xenograft model, Kuperwasser and co-
workers have shown that human primary mammary cells, like their murine 
counterparts, have the ability to reconstitute human mammary tissue when injected 
into the cleared fat pad that was “humanised” by pre-injection of human mammary 
fibroblasts. As in the mouse, this in vivo assay confirmed the existence of multipotent 
cells in the human mammary gland (Kuperwasser et al., 2004; Proia and 
Kuperwasser, 2006). Visvader and co-workers further refined the assay using 
dissociated single cells instead of organoids (Lim et al., 2009). Dontu and colleagues 
have used this xenograft assay to show that human mammary stem and progenitor 
cells in both the normal breast and breast tumours express high levels of aldehyde 
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dehydrogenase 1 (ALDH1) (Ginestier et al., 2007). An alternative non-orthotopic in 
vivo assay was developed by Eaves and colleagues. They showed that dissociated 
human epithelial cells give rise to bilayered ductal structures when implanted under 
the kidney capsule of hormone-treated immunodeficient mice (Eirew et al., 2010; 
Eirew et al., 2008) (Fig. 2). Bachelard-Cascales and colleagues have further shown, 
using a 3D cell-based assay, that human MaSC or early progenitors are able to give 
rise to ductal outgrowths when injected into matrigel (Bachelard-Cascales et al., 
2010). This may be a useful alternative to in vivo reconstitution assays as the cell 
culture-based assay is less labour intensive. Based on the observations from in vitro 
clonogenic and in vivo reconstitution assays, human mammary stem cells are 
currently thought to be CD49fhigh/EpCAM+/low (Eirew et al., 2008; Lim et al., 2009; 
Stingl et al., 1998; Stingl et al., 2001) as well as ALDH1+ (Ginestier et al., 2007). 
Human CD49fhigh/EpCAM+/low cells are able to repopulate the cleared fat pad and 
have, albeit limited, self-renewal capacity (Eirew et al., 2008; Lim et al., 2009). 
ALDH1+ cells can also reconstitute the mammary gland but their self-renewal 
properties have not been defined (Ginestier et al., 2007). Bipotent common 
progenitors exhibit high levels of CD10 in addition to high levels of CD49f and low 
levels of EpCAM (Bachelard-Cascales et al., 2010; Stingl et al., 1998; Stingl et al., 
2001). CD10+ cells form mammospheres and give rise to luminal and myoepithelial 
lineages in vitro but as their in vivo repopulating capacity has not been determined, it 
is unclear whether they are true stem cells or common progenitors (Bachelard-
Cascales et al., 2010). Luminal-restricted progenitors are 
CD49fhigh/EpCAM+/CD133+/CD24+ (Lim et al., 2009; Stingl et al., 1998; Stingl et al., 
2001) and also express high levels of KIT, as recently shown by the Visvader group 
(Lim et al., 2009). In contrast, mature luminal cells have the phenotype CD49f-
/EpCAM+ and express the classic luminal marker MUC1 but are CD10- (Stingl et al., 
1998; Stingl et al., 2001). No specific myoepithelial progenitor marker has emerged 
thus far, although this compartment can be distinguished from the luminal lineage by 
the absence of MUC1 and EpCAM expression and the presence of CD10 expression 
(Stingl et al., 1998; Stingl et al., 2001). As seen in the mouse, human mature 
myoepithelial cells share the expression profile of the stem cell compartment 
(CD49fhigh/EpCAM-). As mentioned, this may reflect their shared basal position in the 
duct but underlines the requirement for reliable functional stem cell assays to 
distinguish between phenotypically similar cells. The expression of cell surface 
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markers suggests that the epithelial hierarchies in the human and murine mammary 
gland are generally conserved, as reflected for instance by the high CD49f expression 
that is common to both human and murine mammary stem and progenitor cells. 
However, not all cell surface markers are conserved in their expression pattern. While 
the expression of CD24 is restricted to luminal cells in the human breast, it appears to 
be more widely expressed in the mouse mammary gland, marking all epithelial cells 
to varying degrees (Lim et al., 2009; Raouf et al., 2008; Shackleton et al., 2006; 
Sleeman et al., 2006; Stingl et al., 2006). 
In addition to the cell types discussed, there is evidence for the existence of an 
alveolar progenitor cell as well as pregnancy-associated cell types, which are 
addressed in more extensive reviews (Stingl, 2009; Visvader, 2009). 
 
The cell surface markers commonly used for the purification of mouse and human 
mammary epithelial cells are detailed in Table 1. For a summary of the current 
understanding of the epithelial cell hierarchy in the mouse and human mammary 
glands, see Figure 3. Although the cornerstones have been confirmed, the model 
remains somewhat speculative at this point, as it is unclear how many different 
intermediates exist between the stem cell, bipotent progenitor (or transit-amplifying) 
cell and their most differentiated progeny. Similarly, it is not known at what point 
exactly the ductal lineage divides into the different specialised ductal cell types. An 
alternative model to the one depicted may involve individual ductal and alveolar 
lineages (Smith, 1996). 
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 Table 1. Cell surface markers used for mammary epithelial cell sorting 
Marker 
Official 
gene 
symbol 
Name 
Biological Function (Reference) 
- 
Mammary epithelial subpopulation (Reference) 
Mouse    
CD24 CD24 
CD24 molecule, 
heat stable 
antigen 
Glycosyl phosphatidylinositol-anchored glycoprotein, 
expressed on a variety of cell types including granulocytes 
and B cells (Fang et al., 2010). 
 
CD24high: luminal, MaSC-enriched, myoepithelial progenitor 
CD24low: myoepithelial 
(Shackleton et al., 2006; Sleeman et al., 2006) 
CD29 Itgb1 Integrin β1 
Adhesion receptor, binds to various ECM components 
(collagen, fibronectin, laminin) upon heterodimerisation 
with different α integrins. Expressed on leukocytes, 
endothelial cells and epithelial cells (Hynes, 2002; Plow et 
al., 2000; Visvader, 2009). 
 
CD29high: MaSC 
CD29low: luminal progenitor, mature luminal 
(Shackleton et al., 2006) 
CD49f Itga6 Integrin α6 
Adhesion receptor, heterodimers bind laminin expressed 
ubiquitously. Expressed on T cells, monocytes, endothelial 
cells and epithelial cells (Hynes, 2002; Plow et al., 2000). 
 
CD49fhigh: MaSC, myoepithelial 
CD49flow: luminal 
(Sleeman et al., 2006; Stingl et al., 2006) 
CD61 Itgb3 Integrin β3 
Adhesion receptor, heterodimers bind RGD-containing 
proteins, expressed on endothelial cells and angiogenic 
vascular tissue (Hynes, 2002; Plow et al., 2000). 
 
CD61+: luminal progenitor, cancer initiating cell 
CD61-: mature luminal 
(Shackleton et al., 2006; Vaillant et al., 2008) 
CD133 PROM1 Prominin 1 
Pentaspan transmembrane glycoprotein, expressed on 
adult stem cells, thought to contribute to stem cell 
maintenance by inhibiting differentiation (Meregalli et al., 
2010). 
 
Prominin 1+: mature ER+ luminal 
Prominin 1-: luminal progenitor, mature ER- luminal, 
alveolar 
(Sleeman et al., 2007) 
Sca1 Ly6a 
Lymphocyte 
antigen 6 
complex, stem 
cell antigen 1 
Phosphatidylinositol-anchored protein, expressed on 
subpopulations of bone marrow, T lymphocytes, B 
lymphocytes, early thymic cells and non-haematopoietic 
tissues (Visvader, 2009). 
 
Sca1+: ER+ luminal (Shackleton et al., 2006; Sleeman et 
al., 2007); progenitor? (Welm et al., 2002) 
Sca1-: MaSC (Shackleton et al., 2006) 
CD31 Pecam 1 
Platelet/endo-
thelial cell 
adhesion 
molecule 1 
CD45 Ptprc 
Protein tyrosine 
phosphatase, 
receptor type, C 
TER119 Ly76 
Lymphocyte 
antigen 76 
Endothelial marker CD31 and haematopoietic markers 
CD45 and Ter119 taken together are termed lineage (Lin); 
used to pre-sort mammary cells in order to deplete the 
heterogeneous mammary cell mixture from these cells, 
leaving the epithelial compartment (Lin-) (Shackleton et 
al., 2006). 
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Table 1. continued 
Marker 
Official 
gene 
symbol 
Name 
Biological Function (Reference) 
- 
Mammary epithelial subpopulation (Reference) 
Human 
ALDH1 ALDH1A1 
Aldehyde 
dehydrogenase 
1 family, 
member A1 
Cytosolic member of the aldehyde dehydrogenase family, 
functions as detoxifying enzyme responsible for the 
oxidation of intracellular aldehydes. Role in 
haematopoietic stem cell differentiation by oxidizing 
retinol to retinoic acid (Chute et al., 2006). 
 
ALDH1+: MaSC, cancer stem cells (Ginestier et al., 2007) 
CD10 
CALLA MME 
Membrane 
metallo-endo-
peptidase 
Transmembrane neutral endopeptidase that inactivates 
several peptide hormones including glucagons, 
enkephalins, substance P, neurotensin, oxytocin and 
bradykinin. Expressed on normal and malignant cell 
types including fibroblasts, granulocytes and certain 
leukemias (Maguer-Satta et al., 2011). 
 
CD10+: stem cells and early progenitors (Bachelard-
Cascales et al.); myoepithelial cells (O'Hare et al., 1991; 
Shipitsin et al., 2007; Stingl et al., 1998); myoepithelial 
progenitor (Stingl et al., 2001) 
CD10-: luminal progenitor  (Stingl et al., 2001) 
CD10 variable: common progenitor (Stingl et al., 2001) 
CD24 CD24 CD24 molecule 
Function see above. 
 
CD24+: luminal (Shipitsin et al., 2007), luminal 
progenitors (Lim et al., 2009) 
CD24-/low: tumour-initiating cells (Al-Hajj et al., 2003; 
Ponti et al., 2005), MaSC (Lim et al., 2009) 
CD29 ITGB1 Integrin β1 
Function see above. 
 
CD29high: MaSC and myoepithelial cell (Bachelard-
Cascales et al., 2010) 
CD44 CD44 CD44 molecule 
Haematopoietic cell E- and L-selectin ligand; heparan 
sulfate proteoglycan 
- 
CD44+: tumour-initiating cells (Al-Hajj et al., 2003; Ponti 
et al., 2005); progenitors (Shipitsin et al., 2007) 
CD49d ITGA4 Integrin α4 
CD49dhigh: myoepithelial (E. Bachelard-Cascales, 
personal communication) 
CD49f ITGA6 Integrin α6 
Function see above. 
- 
CD49fhigh: common progenitors, MaSC, myoepithelial 
CD49flow: mature luminal 
(Bachelard-Cascales et al., 2010; Eirew et al., 2008; Lim 
et al., 2009; Stingl et al., 2001) 
CD90 THY1 Thy-1 cell 
surface antigen 
Heavily glycosylated glycophosphatidylinositol-anchored 
member of the immunoglobulin superfamily. Expressed 
on haematopoietic stem cels, thymocytes and neurons. 
Role in adhesion and signal transduction in T cells 
(Visvader, 2009). 
 
CD90+: Bipotent progenitor, myoepithelial differentiated 
(Raouf et al., 2008) 
CD133 PROM1 Prominin 1 
Function see above. 
 
CD133+: luminal progenitor 
CD133-: mature luminal (Lim et al., 2009) 
EpCAM 
ESA EPCAM 
Epithelial cell 
adhesion 
molecule 
Homotypic calcium-independent cell adhesion molecule, 
expressed basolaterally most normal epithelial cells 
(Visvader, 2009). 
 
EpCAM+: luminal progenitor, mature luminal  
EpCAM-: myoepithelial progenitor, mature myoepithelial 
(Stingl et al., 2001; Stingl et al., 2006) 
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Table 1. continued 
Human 
c-KIT 
CD1117 KIT 
v-kit Hardy-
Zuckerman 4 
feline sarcoma 
viral oncogene 
homolog 
Receptor tyrosine kinase receptor for mast cell growth 
factor (also known as stem cell factor). Proto-oncogene. 
Expressed by haematopoietic stem and progenitor cells 
and in several non-haematopoietic tissues (Edling and 
Hallberg, 2007). 
 
KIT+: Luminal progenitor (Lim et al., 2009) 
MUC1 
CD227 MUC1 
Mucin 1, cell 
surface 
associated 
Glycosylated phosphoprotein, anchored to apical surface 
of epithelial cells by transmembrance domain. The 
degree of glycolysation depends on cell type. Role in 
pathogen inactivation and signalling (Mukhopadhyay et 
al., 2011). 
 
MUC1+: luminal progenitor, mature luminal 
MUC1low: common progenitor 
MUC1-: myoepithelial progenitor (O'Hare et al., 1991; 
Shipitsin et al., 2007; Stingl et al., 1998; Stingl et al., 
2001) 
 
Like most cell types, mammary stem cell function is dependent on the interactions 
between the stem cell and stromal components constituting its environment, which is 
referred to as the stem cell niche. The local environment surrounding the stem cell is 
in turn influenced by systemic hormonal cues as the breast undergoes developmental 
and cyclic changes (reviewed in Brisken and Duss, 2007). The requirement of 
interactions between the mammary stem cell and its stromal environment itself may 
pose a problem for the isolation and subsequent characterisation of the mammary 
stem cell as the available purification techniques may compromise the viability and 
functionality of the stem cell merely by removing the environment that allows for 
maintenance of “stemness”. Mammary gland reconstitution from a single cell has 
shown convincingly that interactions between mammary stem cells and neighbouring 
epithelial cells are not required for repopulation activity of the stem cell (Shackleton 
et al., 2006), suggesting a role for the stromal environment in the maintenance of stem 
cell function. However, Smith and colleagues recently demonstrated that normal 
mammary epithelial cells are able to redirect malignant MMTV-neu tumour cells to 
form normal mammary structures (Booth et al., 2011), refuting the notion that 
neighbouring epithelial cells do not contribute to the stem cell niche. It has long been 
known that stromal cues are important for the early development of the mammary 
gland (Howard and Gusterson, 2000). Studies by Smith and co-workers have shown 
that in the mouse, the mammary stroma is able to reprogram stem cells from other 
organs, such as neural stem cells and testicular cells, to adopt a mammary epithelial 
cell fate during gland regeneration (Booth et al., 2008; Boulanger et al., 2007). 
Notably, the murine mammary microenvironment is also capable of redirecting 
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human embryonal carcinoma cells to produce differentiated mammary epithelial cell 
progeny in xenografts (Bussard et al., 2010). This is consistent with a study by Bissel 
and colleagues showing instructive effects of the human extracellular matrix on cell 
fate determination (LaBarge et al., 2009). The capacity of murine cells to 
reprogramme human epithelial cell fate calls into question the need for a 
“humanisation” of the murine mammary gland prior to xenografting human cells 
(Kuperwasser et al., 2004). The stromal components that constitute the mammary 
stem cell niche are yet to be identified. Macrophages may play a role because the 
regenerative capacity of MaSC is reduced in the mouse fat pad that has been depleted 
of macrophages but the signalling pathways involved remain to be identified (Gyorki 
et al., 2009). Further evidence that the stromal microenvironment is essential to the 
adequate functioning of MaSC or early progenitors comes from in vitro assays. 
Human progenitors require the presence of feeder cells in order to produce 
differentiated progeny, and in the 3D in vitro TDLU assay, single FACS-sorted cells 
are able to give rise to ductal outgrowths in matrigel only when supplemented with 
fibroblasts (Bachelard-Cascales et al., 2010; Eirew et al., 2008). In the mouse, MaSC 
activity is predominantly found in the region of the peripheral cap cells of terminal 
end buds (TEBs). As mentioned above, in the human breast, TEBs are not a 
prominent structure. Human MaSC are thought to be located in the ducts, rather than 
in the terminal ductal lobular units (TDLUs) (LaBarge et al., 2007; Villadsen et al., 
2007). As the developing gland expands and the location of the TLDUs changes, it 
appears likely that MaSC present in mature ducts are silenced by stromal signals. 
Similarly, during periods where MaSC activity is not required, for instance at 
involution, MaSC activity may be inhibited. One such candidate negative regulator of 
MaSC proliferation is TGFβ1, which appears to act via stromal intermediates 
(Boulanger et al., 2005; Pierce et al., 1993; Silberstein et al., 1992). The existing data 
suggest an important function for the stromal microenvironment in MaSC 
homeostasis. However, hormonal control of MaSC proliferation appears to be 
predominantly mediated by the mammary epithelium, as discussed below. 
 
Currently available methods have provided great insight into the hierarchical structure 
of the mammary gland but the isolation, dissociation and culture of primary epithelial 
cells remain a challenge as they may significantly alter the phenotype of the cells of 
interest. The truly physiological assay to delineate the hierarchy and location of 
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mammary epithelial subtypes in the normal breast and to identify the cell of origin of 
the different tumour subtypes will be lineage-tracing of individual mammary cells, 
which was elegantly shown for stem cells in the colon by Clevers and co-workers 
using the stem cell marker Lgr5 (Barker et al., 2007). 
 
1.3.5 Regulation of mammary gland development and homeostasis by steroid 
hormone receptors 
The importance of hormonal signalling for the development of the mammary gland is 
well established. While most of the early development is dependent on epithelial-
mesenchymal interactions, hormonal control of mammary gland development begins 
with the onset of puberty. In both humans and mice, pubertal development is 
controlled by hormones that are released by the hypothalamus, ovaries and pituitary. 
In the human, puberty begins with the first release of gonadotropin-releasing hormone 
(GnRH) from the hypothalamus. GnRH stimulates the release of leutinising hormone 
(LH) and follicle stimulation hormone (FSH) from the pituitary, which in turn induce 
the maturation of the ovarian follicles and the subsequent release of estrogen and 
progesterone from the corpus luteum (Jones and Lopez, 2006). In the mouse, ovarian 
estrogen and growth hormone (GH) stimulation leads to the elongation and 
bifurcation of the growing ductal tree in the first weeks of puberty by inducing a rapid 
increase in proliferation at the terminal end buds, followed by secondary and tertiary 
side branching in sexually mature females, which require ovarian progesterone 
signalling (Brisken and O'Malley, 2010). Ductal morphogenesis is thus predominantly 
controlled by estrogen and progesterone signalling, whereas alveolar morphogenesis 
during pregnancy is regulated by prolactin and progesterone (Oakes et al., 2008b). 17-
β-estradiol (E2) acts directly on the normal mammary epithelium to induce 
proliferation (Daniel et al., 1987; Silberstein et al., 1994). In addition, it activates 
downstream mammogenic hormone signalling, for instance by inducing progesterone 
receptor expression (Shyamala et al., 1990). Conversely, ERα knockout mice fail to 
undergo normal breast development and possess only a rudimental ductal tree 
(Bocchinfuso and Korach, 1997; Korach et al., 1996; Mallepell et al., 2006). ERα has 
thus emerged as a master regulator of mammary gland development but there are 
conflicting views as to the identity of the ERα-expressing epithelial cell in the normal 
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breast, as discussed below. Like in normal development, 17-β-estradiol has a 
mitogenic effect in hormone-sensitive breast cancer cells. As mentioned above, about 
70% of all breast cancers are defined by the expression of ERα, and there is evidence 
that cumulative exposure to high estrogen levels increases breast cancer risk 
(Andersen and Poulsen, 1989; Anderson et al., 1998; Yager and Davidson, 2006). At 
the end of the 1980s it became clear that ERα activates the transcription of the MYC 
and cyclin D1 (CCND1) genes in response to 17-β-estradiol, thereby promoting entry 
into S phase of the cell cycle and inducing proliferation in cell cycle-arrested breast 
cancer cells (Altucci et al., 1996; Dubik et al., 1987; Dubik and Shiu, 1988; Prall et 
al., 1998). Accordingly, successful anti-estrogen therapy in patients with ERα-
positive breast cancer demonstrates that estrogen signalling is required for the 
proliferation of ERα-positive (ER+) tumour cells. Paradoxically, there appears to exist 
a crucial difference between ERα-dependent signalling in the normal breast and in 
breast cancer. ER+ breast tumour cells themselves proliferate. This is in contrast to the 
situation in the normal breast. It has long been known that only a subset of cells in the 
mammary epithelium expresses ERα but their identity has been subject to 
controversy. Even within the luminal population in the mouse, only about 5% of 
CD61+ luminal progenitor cells and about 30-40% of the mature luminal cells express 
the estrogen receptor. Several groups proposed that putative mammary stem cells 
express ERα, which would correspond to the autocrine mitogenic function of estrogen 
in breast cancer (Booth and Smith, 2006; Cheng et al., 2004; Clarke et al., 2005). 
However, more recent data demonstrate that MaSC themselves do not expresses ERα 
but are stimulated by neighbouring ERα+ cells in a paracrine manner (Asselin-Labat 
et al., 2006; Lim et al., 2009; Mallepell et al., 2006). To address this question, 
Smalley and co-workers prospectively isolated ER+ and ER- cells from the mouse 
using the surface markers CD24, Prominin-1 and Sca-1. They showed that cells that 
are CD24high/Sca-1+/Prominin-1+ are also ER+, express the progesterone and prolactin 
receptors and show higher expression of luminal keratins than ER- luminal cells, 
which have the phenotype CD24high/Sca-1-/Prominin-1-. ER- luminal cells showed 
higher expression of the milk proteins lactotransferrin and β-casein, indicating 
alveolar differentiation, and were enriched for mammary colony-forming cells. 
Importantly, neither ER-, nor ER+ luminal subpopulations produced outgrowths when 
transplanted in the cleared fat pad, while only the CD24low/Sca-1-/Prominin-1- 
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myoepithelial subpopulation was enriched for mammary repopulating cells (Sleeman 
et al., 2007). This study provided direct proof that MaSC in the mouse mammary 
gland are not ER+ but rather that the ER+/PR+/PrlR+ cells are part of a hormone-
sensing epithelial subcompartment that relays a mitogenic signal to neighbouring 
MaSC and progenitors in a paracrine manner. The mechanism of paracrine 
stimulation of MaSC remains poorly understood at this point. One candidate for a 
mediator of estrogen signalling in the normal breast is the EGFR ligand and ERα 
transcriptional target amphiregulin (Ciarloni et al., 2007). A recent study proposes 
FGF, its receptor FGFR and the transcription factor TBX3 as mediators of estrogen 
signalling-dependent expansion of cancer-initiating cells in a paracrine fashion 
(Fillmore et al., 2010). 
It appears that estrogen is not the only hormone that exerts its proliferative effect in an 
indirect manner. Several recent studies have shown that progesterone signalling 
induces proliferation of MaSC as well as tumour cells in a paracrine fashion that is 
mediated by the osteoclast differentiation factor RANKL (Asselin-Labat et al., 2010; 
Beleut et al., 2010; Fernandez-Gonzalez et al., 2010; Joshi et al., 2010; Schramek et 
al., 2010). 
Although the underlying mechanisms are still not well understood, it appears clear at 
this point that estrogen signalling has opposite effects in the normal mammary gland 
and during tumourigenesis. In the normal gland, ER+ cells do not proliferate 
themselves but merely act as sensors that relay the mitogenic signal to MaSC and, 
presumably, progenitors or transit-amplifying cells. Moreover, forced expression of 
ERα in normal human mammary epithelial cells rapidly leads to their growth arrest 
and differentiation (Duss et al., 2007 and my own unpublished observation). This is in 
stark contrast to the situation seen in primary luminal breast tumours and breast 
cancer cell lines, where ER+ expression and estrogen signalling are directly correlated 
with the proliferative state of the cancer cell. This suggests that during the 
development of luminal breast cancer, ER+ cells gain the ability to proliferate by 
inhibiting the differentiating and anti-proliferative effects of estrogen signalling, 
presumably through the inappropriate expression of a regulator of ER-dependent 
signalling. It is therefore crucial to identify genes that co-regulate or modulate ER-
dependent transcriptional programmes, as resolving this paradox is central to the 
understanding of the origin of luminal breast cancer. 
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1.3.6 Regulators of stem cell activity, lineage commitment and differentiation 
Much effort has been put into the identification and isolation of prospective mammary 
stem cells, yet little is known about the factors that regulate cell fate decisions in the 
mammary gland. Perturbation of the signalling pathways that determine self-renewal 
of stem cells and differentiation of progenitor cells along a particular lineage likely 
results in oncogenic transformation. Insight into the regulation of mammary lineage 
specification comes from expression profiling of the individual epithelial 
subpopulations in the normal mammary gland as well as of the different breast cancer 
subtypes (Kendrick et al., 2008; Kouros-Mehr and Werb, 2006; Lim et al., 2010; 
Raouf et al., 2008). The information obtained from these studies is vast but 
knowledge of transcriptional co-regulation of genes in a certain subpopulation or 
tumour subgroup alone does not necessarily help to discern the genes that drive 
lineage commitment from the genes that are merely co-expressed and play a minor 
role in the respective cell type. A valuable method to validate candidate regulators of 
stem cell activity, lineage commitment and differentiation is viral-based stable 
expression of the gene of interest in normal mammary epithelial cells, followed by 
characterisation of the resulting phenotype of the transduced cells in transplants or in 
culture. Amongst the genes identified by expression microarrays are a myriad of 
transcription factors. For instance, Sox6 was identified exclusively in murine ER- 
luminal cells, and ectopic expression of Sox6 was shown to promote luminal 
differentiation (Kendrick et al., 2008). Similarly, knockdown of the Notch target Cbf-
1 results in increased MaSC proliferation, while expression of Notch commits MaSC 
to differentiate exclusively along the luminal lineage (Bouras et al., 2008). Other 
transcription factors that are involved in the regulation of stem cell renewal, lineage 
commitment and terminally differentiated cell function in the adult mammary gland 
include GATA3, FOXA1, ELF5, WNT and TBX3 (Asselin-Labat et al., 2007; 
Brisken et al., 2000; Fillmore et al., 2010; Kouros-Mehr et al., 2006; Lupien et al., 
2008; Oakes et al., 2008a). Considering their role in the regulation of cell fate in the 
adult mammy gland, it is not surprising that many of these transcription factors also 
have a function in embryonic development. Conversely, aberrant expression of these 
transcriptional regulators leads to oncogenic transformation. This general pattern is 
exemplified by the transcription factor GATA3, which is required for embryonic 
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development of the mammary gland and which acts as a luminal differentiation factor 
in the adult gland (Asselin-Labat et al., 2007; Kouros-Mehr et al., 2008). Conversely, 
GATA3 deficiency marks a loss of luminal differentiation and is linked to tumour 
progression (Kouros-Mehr et al., 2008). Similarly, the Forkhead transcription factor 
FOXA1 is a marker of differentiated luminal cells and has been implicated in the 
control of mammary epithelial cell fate. FOXA1 is thought to act as a pioneer factor 
in the recruitment of ERα to promoter elements and subsequent transcriptional 
induction. Using chromosome-wide binding site mapping, Brown and colleagues have 
demonstrated that FOXA1 regulates ERα-dependent transcription in a lineage-specific 
manner in estrogen-dependent MCF-7 breast cancer cells versus androgen-dependent 
LNCaP prostate cancer cells (Carroll et al., 2005; Lupien et al., 2008). Like the 
differentiation of mammary epithelial cells, stem cell self-renewal and proliferation 
are controlled by transcriptional regulators, and factors promoting or repressing stem 
cell properties are attractive candidates for oncogenes and tumour suppressor genes, 
respectively. Notably, a number of transcription factor genes, including the FOXA1-
related Forkhead protein FOXC1, appear to be differentially methylated depending on 
mammary epithelial cell type and state of differentiation (Bloushtain-Qimron et al., 
2008). The polycomb protein BMI1 has emerged as an important regulator of both 
MaSC activity and luminal differentiation (Pietersen et al., 2008). BMI1 represses 
p53- and retinoblastoma protein (RB)-induced senescence by silencing p14ARF and 
p16INK4A expression and at the same time inhibiting MYC-dependent apoptosis 
(Jacobs et al., 1999a; Jacobs et al., 1999b). Wicha, Dontu and colleagues 
demonstrated that BMI1 is a downstream target of the hedgehog, Notch and Wnt 
signalling pathways. Its stem cell self-renewal promoting properties were measured as 
an increase in mammosphere-initiating cells (Liu et al., 2006). Like other 
transcriptional regulators that are involved in the control of lineage commitment in 
the mammary gland, members of the polycomb family including BMI1 are 
overexpressed in breast cancer, and BMI1 in particular is overexpressed in ER+ breast 
tumours (Duss et al., 2007; Kim et al., 2004; Sparmann and van Lohuizen, 2006). 
The study of transcriptional regulators in the mammary gland thus provides valuable 
insight into the pathways implicated in breast development and differentiation as well 
as oncogenesis. 
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1.4 Breast cancer subtypes and the cell of origin 
As discussed above, human breast cancers are heterogeneous, both in their molecular 
profiles and pathology. One interpretation of the remarkable differences found 
between the individual breast cancer subtypes is that tumours can originate in 
different mammary epithelial cell types, either in mammary stem cells or in their 
progeny, at any level of differentiation. Alternatively, cancer may arise in a restricted 
set of more primitive cells that have a differing potential to differentiate. The 
delineation of the epithelial cell hierarchy in the normal mammary gland is thus 
intimately linked to the identification of the cell of breast cancer origin. In addition to 
this inter-tumoural heterogeneity, differences are found within a patient’s tumour. 
This intra-tumoural heterogeneity is exemplified by variable ER expression levels 
within a single tumour (Allred et al., 2004). 
Two models of cancer progression, which both account for tumour heterogeneity, 
have been proposed. For many years, the clonal evolution model of breast 
tumourigenesis predominated, according to which a normal epithelial cell over time 
acquires a number of driver mutations, which promote oncogenic transformation of 
that cell. In this model, all cells in a tumour originally have a similar capacity for 
tumour propagation and dissemination, and intra-tumoural heterogeneity results from 
the evolution of distinct clones following a series of mutations. 
In contrast, the cancer stem cell hypothesis proposes a hierarchical model, whereby 
normal mammary stem cells or early progenitor cells are the target of transforming 
events, which convert them into the cell of cancer origin. In analogy to the model of 
hierarchical differentiation in the normal mammary gland, these cancer stem cells 
(CSC) or tumour-initiating cells give rise to tumour cell progeny, thereby promoting 
tumour formation. The cancer stem cell hypothesis is based on the observation that a 
subset of cells in primary breast tumours exhibit similarities to stem cells in adult 
tissues, including the abilities to self-renew and to give rise to heterogeneous and 
differentiated progeny. A combination of the two models is likely to reflect the actual 
order of events that lead to tumour formation. It is conceivable that tumour-initiating 
cells arise from differentiated epithelial cells that acquire one or more mutations 
causing them to revert back to a less differentiated state and to acquire stem cell 
properties. Alternatively, adult MaSCs themselves may be the target of oncogenic 
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transformation, thereby gaining independence from external regulatory cues while at 
the same time retaining their original ability to self-renew and to give rise to quickly 
dividing progeny. It also appears possible that early progenitor cells are subject to a 
block to differentiation at a certain developmental stage or that they undergo aberrant 
differentiation. Evidence for the cancer stem cell model comes from studies 
demonstrating that only a subset of primary breast tumour cells exhibits tumour-
initiating properties in vivo and in vitro. These stem-like cancer cells were isolated 
using markers that had previously been used to purify putative adult stem cells from 
various organs (Table 1). Putative human breast tumour-initiating cells with the 
phenotype CD44+/CD24-/low and ALDH1+ give rise to mammospheres under non-
adherent culture conditions and are able to form tumours when injected into the 
mammary fat pad of immunodeficient mice (Al-Hajj et al., 2003; Ginestier et al., 
2007; Grimshaw et al., 2008; Ponti et al., 2005).  The latter in vivo approach is 
arguably the most meaningful CSC assay. Using expression and DNA methylation 
profiling, Polyak and colleagues further demonstrated the expression of known stem 
cell markers in the CD44+ subset, which was correlated with decreased patient 
survival (Bloushtain-Qimron et al., 2008; Shipitsin et al., 2007). This is consistent 
with a study by Pece and colleagues, who demonstrated by labelling non-dividing 
putative CSC with the lipophilic dye PKH26 that poorly differentiated, higher grade 
tumours are enriched in mammosphere-forming and tumour-initiating cells (Pece et 
al., 2010). Putative mammary cancer stem cells have also been identified in mouse 
models of cancer using various stem cell surface markers. Tumour-forming CSC were 
thus described in MMTV-wnt-1 mice as Thy1+/CD24+ as well as CD61+ (Cho et al., 
2008; Vaillant et al., 2008). The CD44+/CD24-/low phenotype has further been 
employed to isolate putative tumour-initiating cells in established breast cancer lines 
such as MCF-7 and MDA-MB-231. A subset of these cells indeed express the stem 
cell marker combination and were shown to generate mammospheres at a higher 
frequency than their CD44- and CD24high counterparts but their tumourigenicity in 
vivo has not been examined (Harrison et al., 2010; Ponti et al., 2005). It appears 
somewhat surprising that, after long-term in vitro culture of established carcinoma 
cell lines, tumour-initiating cells with stem cell properties are contained in what was 
traditionally presumed to be a rather homogenous population of more or less 
differentiated tumour cells. On the other hand, if what distinguishes cancer-initiating 
cells from their non-tumourigenic counterparts in heterogeneous tumour tissue is their 
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“stemness”, it is plausible that established breast cancer cell lines are constantly 
replenished from a small pool of cancer stem cells that also allows them to form 
tumours in mice. 
Irrespective of the model of tumour formation, it is plausible that the individual breast 
tumour subtypes reflect different cells of origin within the mammary epithelium. The 
fact that the MaSC-enriched myoepithelial subcompartment lacks ER, PR and HER2 
expression led to the speculation that it might also give rise to basal-like breast 
cancers. In keeping with this notion, BRCA1 mutation carriers often develop basal-
like breast cancers, and BRCA1 has been shown to play a role in the regulation of 
stem cell fate (Foulkes, 2004; Liu et al., 2008). However, recent expression array 
studies did not confirm the relationship between MaSC and basal breast cancers but 
demonstrated that the basal BRCA1-associated cancer subtype showed a marked 
similarity with the luminal progenitor subpopulation (Herschkowitz et al., 2007; Lim 
et al., 2010). This is consistent with the recent finding by Molyneux et al., who 
showed that targeted deletion of Brca1 in mouse mammary epithelial luminal 
progenitors produced tumours that resemble human BRCA1-associated breast cancers 
with a basal phenotype, while Brca1 deficiency in the myoepithelial compartment led 
to the formation of tumours that do not phenotypically resemble BRCA1-associated 
basal human breast tumours (Molyneux et al., 2010). This is at odds with the previous 
observation that Bcra1 mutant tumours originate in the basal subcompartment (Liu et 
al., 2007). This discrepancy may be explained by differences in the mouse model and 
method of targeted deletion used. Support for Molyneux’s finding comes from the 
Visvader group, who demonstrated that human breast tissue heterozygous for a 
BRCA1 mutation contains an increased luminal progenitor population. They further 
showed that tissue from BRCA1 mutant carriers as well as tissue from basal-like 
breast cancers were more similar in their gene expression profiles to the luminal 
progenitor subset than to any other epithelial subpopulation (Lim et al., 2009). The 
answer to the question of the cell of origin of luminal breast cancers appears more 
straightforward as the expression signature of differentiated normal luminal cells 
exhibits great similarity with that of luminal A and B subtypes (Lim et al., 2010), 
suggesting that luminal tumours arise from epithelial cells that are committed to a 
luminal cell fate, presumably at any stage of differentiation. However, based on 
available data it cannot be ruled out that ER+ tumours may also arise from an ER- 
stem cell population whose progeny differentiate into ER+ tumour cells with a luminal 
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phenotype. As mentioned above, a fraction of HER2-positive tumours can be 
reclassified as molecular apocrine, thus being defined by the presence of androgen 
signalling rather than their HER2 status. Irrespective of the exact classification 
though, current evidence suggests that both molecular apocrine and HER2-positive 
breast tumours arise from epithelial cells committed to the luminal lineage. Lastly, 
Perou and colleagues have reported that the MaSC signature has the greatest overlap 
with the claudin-low breast cancer subtype, which is characterised by the expression 
of EMT, immune response and stem cell genes, suggesting a basal origin for this 
subtype (Herschkowitz et al., 2007; Prat et al., 2010). Perou and co-workers have 
extensively discussed and characterised the claudin-low subtype but few other groups 
have reported it in human tumour samples. It appears to be a subset of basal-like or 
normal-like tumours that is most easily seen in cell lines. 
A model of the current understanding of the cell of breast cancer origin is depicted in 
Figure 4. 
 
 
Figure 4. The cell of origin of the different breast cancer subtypes. 
Schematic model of the epithelial hierarchy in the normal human breast and putative 
relationships with breast cancer subtypes. The different subtypes are grouped with 
their closest normal epithelial counterpart based on gene expression analysis.  
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1.5 A model system for human breast cancer 
The lack of good experimental models that faithfully recapitulate the normal human 
mammary epithelial lineages and the different breast cancer subtypes is a major 
barrier to understanding breast cancer and developing better treatments. Commonly 
used model systems include established breast carcinoma cell lines, xenograft models 
and genetically engineered mice, all of which have their strengths and weaknesses. 
While established human breast cancer cell lines have been widely used to study the 
molecular biology of breast cancer, it is controversial how faithfully they represent 
primary tumours as they often derive from advanced-stage tumours and pleural 
effusions. Another weakness is that long-term propagation in culture is likely to have 
caused them to adapt to culture conditions and to accumulate further mutations and 
genomic changes over time (Hampton et al., 2009). These limitations also make them 
a poor model for the study of the normal human breast. Primary human epithelial cells 
are the ultimate model system to investigate the biology of the normal human breast, 
and defined transformation of normal human cells should produce tumour cells that 
resemble human primary tumours more closely than established cell lines that have 
been cultured over decades. 
Transgenic mouse models faithfully recapitulate a wide range of properties of the 
human disease, as gene expression and phenotypic analyses demonstrate (Lim et al., 
2010). However, despite the conservation between the two species, important 
differences exist. For instance, mouse luminal progenitor cells express significantly 
lower levels of ERα than their human counterparts (Visvader, 2009), and endogenous 
serum estradiol levels in sexually mature female mice are comparable to those found 
in post-menopausal women (Anderson et al., 1998; Laidlaw et al., 1995). These 
differences in estrogen signalling could potentially reduce the relevance of mouse 
models to human luminal breast cancer. 
Human-in-mouse xenograft models involving the injection of dissociated human 
mammary cells or the transplantation of fractions of mammary tissue (organoids) into 
the fat pad of immunocompromised mice allow for the study of human cells in the 
context of a whole organism. Furthermore, orthotopic xenograft assays are considered 
the gold standard to assess the tumourigenic, or cancer stem cell, potential of a given 
cell. 
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Taking into consideration the advantages and limitations of the different currently 
available model systems to study the biology of the normal breast and breast cancer, it 
is conceivable that models derived from normal human primary cells will reproduce 
the features of the normal breast and breast cancer most faithfully. Such model 
systems are discussed in detail in the following section. 
 
1.5.1 Human mammary epithelial cell culture 
The difficulties associated with the propagation of human mammary epithelial cells in 
culture have hampered the creation of a faithful model system for human breast 
cancer. Protocols vary between laboratories but normal human primary mammary 
epithelial cells are generally obtained from reduction mammoplasty tissue, which, 
after gross macroscopic examination by a pathologist, is mechanically dissociated and 
enzymatically digested to remove the extracellular matrix. The resulting small 
fragments of epithelial tissue, termed organoids, are separated from stromal 
components of the mixture (including fibroblasts and adipocytes) by gentle 
centrifugation. Organoids can then be plated directly onto tissue culture plastic or 
alternatively epithelial fragments can be digested enzymatically further in order to 
obtain dissociated single cells. While standard media are convenient for the culture of 
established tumour cell lines, they are not chemically defined due to the 
supplementation with fetal bovine serum as a source of growth factors, anti-oxidants 
and vitamins. Human mammary epithelial cells quickly undergo growth arrest after 
only a few passages when maintained in serum-containing medium unless plated on a 
layer of fibroblast feeder cells (Smith et al., 1981). Stampfer and colleagues were the 
first to successfully culture human mammary epithelial cells (HMEC) in chemically 
defined medium (MCDB 170) for several passages by directly plating organoids and 
then subculturing single HMEC growing out from adherent tissue fragements 
(Hammond et al., 1984). However, HMEC cultured in this way still undergo growth 
arrest after about 5 to 20 populations doublings. This state of “stasis”, commonly 
known as “culture shock”, is associated with a senescent phenotype and the 
expression of p16 (CDKN2A; p16INK4A), which is thought to be induced by perturbed 
growth factor signalling and oxidative stress due to suboptimal culture conditions 
(Hammond et al., 1984; Romanov et al., 2001; Yaswen and Stampfer, 2001; Yaswen 
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and Stampfer, 2002). When cultured in serum-free medium, a small variant subset of 
HMEC (vHMEC) is able to spontaneously overcome senescence by silencing the 
p16INK4A promoter through methylation (Holst et al., 2003). Variations in p16 
expression are also observed in breast tissue in situ, and it has been proposed that 
silencing of the promoter is an early step during malignant transformation (Tlsty et 
al., 2004). Despite the suppression of p16, vHMEC invariably stop proliferating, 
triggered by telomere shortening (Stampfer et al., 1997). It is thus of immediate 
interest for the study of normal as well as transformed primary mammary epithelial 
cells to develop cell culture conditions that allow for long-term propagation in vitro 
without inducing a senescence. Since the pioneering experiments carried out by 
Stampfer and colleagues using chemically defined medium, it has become evident 
that the composition of a medium has not only profound effects on the lifespan of 
primary mammary cells but also determines which epithelial cell type predominates 
after repeated passaging. Generally, it appears that conventional serum-free media 
favour the proliferation of myoepithelial cells, while the percentage of luminal 
epithelial cells already decreases after a single passage (Petersen and van Deurs, 
1988; Stingl et al., 1998; Taylor-Papadimitriou et al., 1989). Dontu and co-workers 
showed that dissociated mammary epithelial cells give rise to so-called 
mammospheres when cultured in suspension in defined medium that had originally 
been used to maintain neural stem cells for multiple passages (MEGM, supplemented 
with EGF, bFGF, heparin and the serum-free B27 mixture of growth factors and 
vitamins) (Brewer et al., 1993; Dontu et al., 2003). As mentioned above, 
mammospheres are enriched for early progenitors and possibly MaSC, which are able 
to differentiate into cells of the different epithelial lineages when subsequently 
cultured under adherent conditions. Although nonadherent conditions allow for the 
propagation of progenitor cells, the cells’ capacity to self-renew and proliferate is 
exhausted after approximately four passages. Nevertheless, many laboratories have 
used MEGM as the conventional medium to propagate HMEC. Our group has 
obtained essentially the same results using a very similar medium for mammosphere 
culture that is based on Hepes-buffered Dulbecco’s Modified Eagle Medium 
(DMEM)/Ham F-12, supplemented with EGF, bFGF, heparin and B27 (Duss et al., 
2007). In addition, we routinely propagate transformed HMEC in a modified version 
of the mammosphere medium additionally containing insulin, o-
phosphoethanolamine, apotransferrin, hydrocortisone and isoproterenol (HMM+ 
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medium). Notably, MEGM and HMM+ media may allow for the propagation of 
transformed HMEC for several population doublings, but longer-term culture in these 
media compromises the phenotype of HMEC. Evidence for this cell culture-related 
problem comes from the observation that tumours derived from xenograft assays of 
transformed HMEC commonly are of squamous differentiation, a phenotype rarely 
seen in human breast cancer (Elenbaas et al., 2001). A recent study from the 
Weinberg lab provides further evidence for the notion that adaptation to the in vitro 
culture conditions is a major determinant of the tumour phenotype observed in 
xenografts later on (Ince et al., 2007). By culturing primary human mammary 
epithelial cells (termed breast primary epithelial cells, BPEC, to distinguish them 
from HMEC grown in conventional medium) in a novel defined medium (so-called 
WIT medium) on positively charged plastic (Primaria, BD Biosciences), Ince and 
colleagues were able to change the phenotype of the derived tumours from squamous 
to more adenocarcinoma-like, which more faithfully reproduces the predominant 
phenotype of human primary breast tumours. These findings suggest further that 
adaptation to the cell culture conditions goes along with a change in cell fate, more 
specifically a change from a glandular phenotype to a skin-like phenotype. In 
addition, tumours derived from transformed BPEC cultured in WIT/Primaria 
conditions are characterised by an abundant stromal response and form metastases in 
immunodeficient mice (McAllister et al., 2008). Importantly, the total culture time 
and number of passages prior to xenografting of transformed HMEC into mice 
appears to influence their metastatic potential (our unpublished observations), which 
is consistent with the importance of cell culture conditions for the cellular phenotype 
observed by Ince and co-workers. A second medium that is currently widely used is 
EpiCult-B medium, a commercially available medium for the culture of bipotent 
progenitor, myoepithelial and luminal cells (Stingl et al., 2006). Unfortunately, 
Stemcell Technologies, the supplier of EpiCult-B medium and MammoCult medium, 
which has been optimised for the culture of mammospheres and tumourspheres, has 
not disclosed the ingredients, and data on long-term culture of primary cells in these 
media are not available. 
Considering the various culture media and techniques, it is evident that when working 
with human primary mammary epithelial cells, at present the most reliable way to 
avoid cell culture artefacts is still to minimise the in vitro culture time. 
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1.5.2 Modelling human breast cancer by quantitative transformation of normal 
human mammary epithelial cells 
As discussed above, the presence or absence of expression of the estrogen receptor α 
is a central characteristic of breast tumours, as it determines not only the pathology of 
a tumour but also the choice of treatment. Thus, the availability of adequate models of 
luminal breast cancer is crucial to study the biology of this subtype of the disease and 
ultimately to optimise therapies targeting ERα-dependent signalling pathways. 
However, to date, models of ERα-positive breast cancer are limited to established 
breast cancer lines, such as the widely used MCF-7 cell line, which produce tumours 
in mice that, at least in part, resemble the human disease but which also bear the 
aforementioned caveats. Most transgenic mouse models are ERα-negative, but some, 
such as MMTV-PyMT and the C3(1)/SV40 T-antigen transgenic mouse do produce 
ERα-positive tumours (Fantozzi and Christofori, 2006; Vargo-Gogola and Rosen, 
2007). However, tumourigenesis in both models is based on tumour virus-dependent 
transformation. Thus, available ERα-positive human breast cancer lines and 
transgenic models bear the limitation that they are genetically undefined, which 
means that the exact causes of tumour formation are difficult to determine. 
Problems associated with long-term in vitro culture aside, oncogenic transformation 
of normal human mammary epithelial cells (HMEC or BPEC) and subsequent 
xenografting in immunocompromised mice represent an attractive alternative to the 
aforementioned model systems. The clear advantage of transformed primary human 
mammary cells is that cells genetically resemble their normal human counterparts as 
closely as possible if maintained in culture for a short time. At the same time, the 
expression of a defined set of oncogenes allows for the “quantitative transformation” 
of normal cells, which means that the effect of oncogene expression is directly 
reflected in the resulting tumour phenotypes. Previous studies have shown that viral-
based expression of a combination of genes, including simian virus 40 small- and 
large-T antigen (SV40 S/LT), constitutively active RAS, the stabilised MYC T58A 
mutant, a dominant-negative form of p53 and the telomerase catalytic subunit (TERT) 
results in the oncogenic transformation of HMEC and tumour formation in mice 
(Elenbaas et al., 2001; Hahn et al., 1999; Kendall et al., 2005; Rangarajan et al., 
2004). However, the transformed HMEC and resulting tumours were ERα-negative as 
ERα is rapidly lost in culture. Our group has previously created an ERα-positive 
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tumour model by defined transformation of normal HMEC by expression of ESR1, 
TERT, BMI1 and MYC (Duss et al., 2007). The transformed HMEC produced ERα-
positive tumours that were estrogen-dependent for growth, sensitive to the ERα 
antagonist fulvestrant, and metastasised to multiple organs, thus reproducing several 
characteristics of human luminal breast cancer. Forced expression of ERα was 
ensured by lentiviral-based expression of the gene, and ERα-dependent growth arrest 
and terminal differentiation of HMEC was prevented by expression of the polycomb 
gene BMI1. BMI1 was chosen as it is overexpressed in luminal primary breast 
tumours and because of its role in stem cell self-renewal and repression of p53- and 
retinoblastoma protein (RB)-induced senescence by silencing the CDKN2A locus. 
BMI1 further inhibits MYC-induced apoptosis through the same targets (Jacobs et al., 
1999b). The tumours that formed in the mouse mammary fat pad were a mixture of 
invasive ductal carcinoma and squamous carcinoma. Squamous differentiation is rare 
in human breast cancer but common in HMEC xenograft assays (Elenbaas et al., 
2001; Ince et al., 2007). As discussed above, this change in cell fate is most likely a 
consequence of adaptation to a suboptimal in vitro culture environment. Ince and 
colleagues thus proposed that human mammary epithelial cells maintained in 
WIT/Primaria conditions and transformed with TERT, SV40 large-T antigen and 
oncogenic RAS form adenocarcinomas in their xenograft model, while cells cultured 
in conventional conditions give rise to tumours of predominantly squamous 
differentiation (Ince et al., 2007). However, the authors gave no explanation of what 
exactly may cause WIT/Primaria-derived BPEC to maintain their original glandular 
phenotype. Further evidence for the importance of cell culture conditions comes from 
the observation that transformed HMEC increasingly lose their metastatic potential 
after long-term in vitro culture (Stephan Duss, unpublished observation). 
Alternatively, the discrepancy in tumour phenotype may be due to differences 
between the microenvironment of the human breast and mouse mammary gland 
(Parmar and Cunha, 2004). “Humanising” the mammary gland by co-injection of 
human mammary fibroblasts (HMF) with transformed HMEC did not change the 
observed tumour phenotype (Duss et al., 2007). However, normal HMF may not 
accurately resemble the paracrine environment of tumour-associated stroma in 
primary human tumours (Karnoub et al., 2007; Orimo et al., 2005). Related to the 
question of the tumour cell environment is the choice of xenograft model. While adult 
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mammary stem cell assays generally require the “clearing” of the mouse mammary 
fat pad, HMEC-derived tumour cells can be xenografted directly by injection into the 
forth inguinal mammary gland (Duss et al., 2007). An alternative to orthotopic 
xenografts is injection under the renal capsule or subcutaneously. A recent 
comparative xenograft study suggests that the site of injection (subcutaneous versus 
third or forth mammary gland) impacts the size and vascularisation of the resulting 
tumours and that optimal tumour take occurs with orthotopic injections into the forth 
gland (Fleming et al., 2010). In an effort to mimic non-invasive human ductal 
carcinoma in situ (DCIS), Medina and colleagues recently developed an intraductal 
human-in-mouse xenograft model (Behbod et al., 2009). This is an intriguing model 
system as it reproduces the physiological site of ductal tumour origin far more closely 
than injections into the stromal part of the mouse mammary gland. The original study 
only reported the successful engraftment of malignant and DCIS cell lines and it 
remains to be determined if this potentially very valuable model system supports the 
growth of transformed primary cells. 
Another possible explanation for the observed phenotypic differences between human 
luminal breast cancers and the tumours in our ERα-positive mouse model may be that 
ERα expression alone is not sufficient to define the luminal subtype. As mentioned 
above, gene expression analysis of primary breast tumours shows the co-expression of 
a cluster of genes that are consistently co-expressed with ERα in luminal A tumours, 
including GATA3, FOXA1 and XBP1 (Sorlie et al., 2001). Thus, it is likely that ERα 
requires co-factors other than BMI1 and MYC to activate the full range of its target 
genes in luminal tumours. Transcriptional regulators are therefore of particular 
interest as candidate genes that regulate luminal cell fate, both in the normal 
mammary gland and in luminal tumours, and a combination of our model with the 
improved culture conditions described by the Weinberg lab is potentially an excellent 
model system to study the oncogenic potential of such genes of interest. 
 
1.6 Identification of new mammary oncogenes and tumour 
suppressor genes 
Advances in technology now allow for high-throughput analyses to identify new 
oncogenes and tumour suppressors but the increasing sophistication of these 
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techniques also impedes the interpretation of the resulting complex data. Sequencing 
studies, first of candidate genes, then of classes of genes, then of all exons and finally 
of whole genomes have identified cancer-associated point mutations in genes such as 
BRAF and ERBB2 (reviewed by Stratton et al., 2009) but the vast number of 
mutations discovered by recent whole cancer genome sequencing efforts (Forbes et 
al., 2010) is itself a major challenge because it is difficult to distinguish causative 
oncogenic “driver” mutations from “passenger” mutations.  
A second technique that has been employed to study genetic alterations associated 
with breast cancer is the analysis of copy number changes. Comparative genome 
hybridisation (CGH) analysis and similar genomic array methods have been used 
successfully to identify copy number alterations in known breast cancer genes such as 
CCND1, MYC, ERBB2, TBX2 as well as previously unknown genes located in 
amplicons (Chin et al., 2006; Chin et al., 2007; Hicks et al., 2006). 
Human genetics represents an alternative and possibly more reliable way to identify 
new breast cancer genes as it directly associates breast cancer risk with the presence 
of a genomic variation. Classic linkage studies that identified breast cancer 
susceptibility genes such as breast cancer susceptibility genes 1 and 2 (BRCA1 and 2) 
(Hall et al., 1990; Wooster et al., 1994) have been succeeded by large-scale genome-
wide association studies (GWAS) in recent years (Easton et al., 2007; Stacey et al., 
2007; Stacey et al., 2008; Walsh and King, 2007). Given a sufficient number of 
samples, GWAS are a powerful tool for the discovery of genetic variants that are 
associated with an increased breast cancer risk but which would go otherwise 
unnoticed due to their low penetrance. The discovery of a large number of new low-
penetrance breast cancer susceptibility genes may not bear immediate importance for 
clinical prevention at this point. However the identification of previously unknown 
susceptibility genes is valuable for the understanding of breast oncogenesis as a 
positive family history is still considered the most important risk factor for the 
development of the disease, underscoring the importance of hereditary factors. 
Mutations in the known high-penetrance breast cancer susceptibility genes including 
BRCA1, BRCA2, TP53 and PTEN account for less than 25% of familial breast cancer 
cases, suggesting the existence of a number of low-penetrance genes that have yet to 
be identified (Easton, 1999; Walsh and King, 2007). In recent years, several DNA 
damage repair and cell cycle checkpoint genes such as CHEK2 and PALB2 have 
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emerged as such low-penetrance factors (Mavaddat et al., 2010a; Walsh and King, 
2007). 
In the search for new low-risk breast cancer genes, several independent GWAS have 
recently identified five loci containing single nucleotide polymorphisms (SNPs) that 
are strongly associated with increased breast cancer risk (Easton et al., 2007; Hunter 
et al., 2007; Stacey et al., 2007). Four of these loci contain plausible causative genes: 
fibroblast growth factor receptor 2 (FGFR2), mitogen activated protein 3 kinase 1 
(MAP3K1), lymphocyte-specific protein 1 (LSP1) and TOX high mobility group box 
family member 3 (TOX3). Experimental evidence confirming a role in breast 
tumourigenesis has been most convincing for the receptor tyrosine kinase FGFR2 thus 
far. The FGFR2 gene is frequently amplified in breast tumours (Adelaide et al., 2007; 
Adnane et al., 1991). FGFR2 is able to transform normal mammary epithelial cells 
(Moffa et al., 2004), while breast cancer cell lines bearing an FGFR2 amplification 
are highly sensitive to FGFR2 inhibitors (Turner et al., 2010).  Follow-up studies have 
confirmed the association of common variants in the FGFR2 gene with increased 
breast cancer risk, in particular with ER-positive cancer (Meyer et al., 2008; Reeves et 
al., 2010; Stacey et al., 2008), possibly due to increased FGFR2 expression caused by 
a mutation in the binding site for a transcriptional activator in the FGFR2 promoter 
(Meyer et al., 2008). A recent study by Rosen and colleagues demonstrated that 
FGFR signalling accelerates tumour formation in a MMTV-Wnt1 mouse model (Pond 
et al., 2010), confirming further that GWAS are useful for the identification of 
biologically relevant breast cancer genes. 
 
1.7 Thymocyte selection-associated high mobility group box protein 
family member 3 (TOX3) 
1.7.1 Identification of TOX3 as a breast cancer susceptibility gene in GWAS 
The second new candidate breast susceptibility gene of great interest is TOX3. The 
synonymous SNP rs3803662 was strongly associated with increased breast cancer 
risk in the original GWAS (Easton et al., 2007; Stacey et al., 2007). It is located on 
chromosome 16q12.1, 8 kb upstream of the TOX3 coding region. At the same time it 
lies in the fourth exon of the predicted gene LOC643714 (Fig. 5). It cannot be ruled 
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out that the uncharacterised hypothetical gene LOC643714 is the causative gene that 
is associated with increased breast cancer risk (Ruiz-Narvaez et al., 2010). However, 
we found TOX3 (formerly called trinucleotide containing 9, TNRC9) to be the more 
convincing candidate gene as it is expressed in the gene cluster that defines luminal 
tumours (see Results), which is consistent with the findings of Stacey and colleagues, 
who showed in their original GWAS that SNP rs3803662 was exclusively associated 
with an increased risk of ER-positive breast cancer (Stacey et al., 2007). A follow-up 
study also confirmed the upregulation of TOX3 expression in luminal tumours 
(Nordgard et al., 2007). At the time of the publication of the original GWAS, TOX3 
gene function was uncharacterised although sequence predictions had previously 
placed it in the TOX family of HMG-box transcription factors, as discussed below 
(O'Flaherty and Kaye, 2003). TOX3 mRNA upregulation had been shown in response 
to expression of severe acute respiratory virus syndrome corona virus (SARS-CoV) 
3a protein in lung epithelial cells but the significance of this finding is unclear (Tan et 
al., 2005). TOX3 had also previously been identified as a gene potentially involved in 
metastasis of breast cancer to the bone, a characteristic of ER-positive breast tumours 
(Smid et al., 2006), further suggesting a role for TOX3 in luminal breast cancer. 
 
 
Figure 5. The TOX3 locus. 
Linkage disequilibrium plot of the 16q12 locus which encompasses the TOX3 and 
LOC643714 genes. The arrow marks SNP rs3803662. Figure taken from (Udler et al., 
2010). 
 
Mounting evidence has since implicated TOX3 in breast cancer. A multitude of 
follow-up studies using large sample numbers have investigated the correlation 
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between the common variants found in the five novel breast cancer susceptibility loci 
and clinical parameters including tumour grade, steroid receptor status, node 
involvement, disease onset, survival and family history of breast cancer (Garcia-
Closas et al., 2008; Latif et al., 2009; Long et al., 2010; Mavaddat et al., 2010b; 
Tapper et al., 2008; Udler et al., 2010). A recent meta-analysis of previous studies 
taking into account 62,00 subjects confirmed a significant correlation between SNP 
rs3803662 and increased breast cancer risk (Chen et al., 2011). The results 
consistently confirm a role for TOX3 in breast oncogenesis. Fine-scale mapping of 
the 16q12 locus has identified additional SNPs in this region that are associated with 
increased breast cancer risk, albeit less strongly than rs3803662, underlining the 
significance of earlier findings. The majority of variants identified by Udler and 
colleagues in the latter study were located in the intergenic region between the TOX3 
and LOC643714 (Fig. 5). They further showed that this intergenic region is highly 
conserved and, based on DNase I hypersensitivity profiles, has an open chromatin 
conformation consistent with active transcription (Udler et al., 2010). It should be 
noted that studies addressing the association of TOX3 with ER status (specifically an 
increased risk for ER-positive breast cancer) are somewhat contradictory, although 
the majority of follow-up studies has thus far confirmed the correlation (Garcia-
Closas et al., 2008; Mavaddat et al., 2010b; Tapper et al., 2008). 
As mentioned above, the TOX3 gene is located on the long arm of chromosome 16. 
Notably, loss of heterozygosity (LOH) on 16q12 is one of the most frequent genetic 
events in breast cancer, suggesting the presence of one or more tumour suppressor 
genes in this area (Rakha et al., 2006). SNP rs3803662 was shown to correlate with 
disease onset before the age of 60 years (Huijts et al., 2007). It is thus tempting to 
speculate that TOX3 may be one of the tumour suppressor genes on 16q12 and that 
the presence of the SNP causes an increase in breast cancer risk due to 
downregulation of TOX3 expression. 
Taken together, the existing data implicate TOX3 in the development of ER-positive 
breast cancer, making it an interesting candidate gene to test in our luminal tumour 
model. 
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1.7.2 The high mobility group (HMG) box protein family 
Based on sequence alignment, TOX3 belongs to the TOX subfamily of high mobility 
group (HMG) proteins (O'Flaherty and Kaye, 2003). The HMG protein family is a 
diverse superfamily of nonhistone chromosomal proteins that were discovered in 
mammalian cells more than 30 years ago. The HMG proteins were originally named 
based on their unusually rapid gel electrophoretic mobility compared to other 
chromatin proteins. This is caused by their high content of charged amino acid 
residues, which also explains their extractability from chromatin in 350 mM NaCl and 
5% perchloric- or trichloroacetic acid (Goodwin and Johns, 1973; Goodwin et al., 
1973; Reeves, 2010). The recently reclassified ‘HMG-motif proteins’ are subdivided 
into three superfamilies based on the sequence of their DNA binding domain: the 
functional motif of the HMGB family is the ‘HMG-box’, that of the HMGN family is 
called ‘nucleosomal binding domain’ and that of the HMGA family is termed ‘AT-
hook’ (Bustin, 2001). While each of the different subfamilies has a unique protein 
signature and a characteristic functional DNA binding sequence motif, all HMG 
proteins have in common that they bind to specific structures in DNA or chromatin 
with little if any specificity for the target DNA sequence (Bustin, 1999). The 
functional DNA binding motifs that are characteristic of each HMG subfamily have 
been identified in numerous other nuclear proteins that interact with chromatin but 
these differ from the canonical HMG family members in several aspects. The 
archetypal HMG proteins are ubiquitous and generally expressed in all cells of higher 
eukaryotes; they are relatively abundant and bind to DNA in a sequence-independent 
manner. In contrast, non-canonical HMG proteins are cell type-specific, not abundant 
and often bind to DNA with sequence specificity. In addition to the HMG motif, the 
latter proteins frequently contain other non-HMG functional motifs (Bustin, 1999). 
Based on sequence alignment, TOX3 best fits into the HMGB (or HMG-box) family 
(O'Flaherty and Kaye, 2003). I will thus focus my discussion on this HMG subfamily. 
As mentioned above, all HMGB proteins possess a DNA-binding motif related to the 
HMG-box that was originally identified in HMGB1 and HMGB2 (previously termed 
HMG1/2) (Goodwin and Johns, 1973). Beyond the similarity in their DNA-binding 
motifs, the HMG-box family members are classified into either of two subgroups 
distinguished by their abundance, function, DNA specificity and number of HMG-
boxes. In humans, the first subgroup contains proteins that comprise two HMG-boxes 
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(HMGB1-4, discussed below) and the RNA polymerase I transcription factor UBF 
with four to six HMG-boxes (Stros et al., 2007). Proteins in this subgroup generally 
have two or more HMG-boxes, are abundant in all cell types and bind to DNA and 
chromatin without sequence specificity. The second subgroup consists of a multitude 
of highly diverse proteins that predominantly contain a single HMG-box, are cell 
type-specific and much less abundant. They recognize specific DNA sequences, albeit 
with relatively low specificity due to the limited number of hydrogen bonds that can 
be formed within the minor groove (Bustin, 1999; Stros, 2010; Stros et al., 2007). 
This subgroup includes family of the T cell transcription factors/lymphoid enhancer-
binding factors (TCF/LEF), sex-determining factors SRY and related SOX proteins, 
chromatin remodelling factors SMARCE1/BAF57 and PB1, as well as the T 
lymphocyte differentiation factor TOX (reviewed in Stros et al., 2007). 
The human HMGB family has three canonical members, HMGB1, HMGB2 and 
HMGB3, and the recently identified HMGB4 (Catena et al., 2009), which are 
encoded by individual genes, are abundant in most cell types and bind to DNA 
without sequence specificity. HMGB1-3 are approximately 25 kDa in molecular 
mass, share 80% sequence identity, and are highly conserved across species. All four 
proteins contain a bipartite DNA binding motif encompassing an N-terminal HMG-
box A and a central HMG-box B (Fig. 6 A). The HMG-box consists of approximately 
80 amino acids that form a characteristic, twisted, L-shaped fold formed by three α 
helices, which binds to the minor groove of AT-rich B-DNA, thereby bending the 
DNA (Bustin, 1999 and references therein) (Fig. 6 B). HMG-box B, more than HMG-
box A, is predominantly responsible for DNA bending in HMGB1/2 proteins (Paull et 
al., 1993; Teo et al., 1995). A second characteristic of the canonical HMGB1-3 
proteins (but which is not present in HMGB4) is their acidic tail (Fig. 6 A). HMGB1 
has been shown to interact with a multitude of proteins including transcription factors, 
viral proteins and DNA repair proteins via its HMG-boxes, while the acidic tail 
mediates the interaction with histones, e.g. histone H1. The interaction with chromatin 
and other nuclear proteins via the HMG boxes and concomitant binding to histones 
via the acidic tail thus enable HMG-box proteins to function as architectural proteins 
and to promote the formation of complex nucleoprotein structures (Gerlitz et al., 
2009). HMGB binding to other proteins has been observed in vitro and in vivo but it 
has been suggested that the presence of chromatin is required for at least some of 
these interactions (Stros, 2010). The interaction of HMGB proteins with other factors 
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is beyond the scope of this chapter but has been extensively reviewed elsewhere 
(Stros, 2010; Stros et al., 2007 and references therein). However, it is of interest that 
HMGB1 interacts with all class I steroid receptors (Reeves, 2010). In particular, it 
interacts with ERα and promotes its binding to the estrogen response element (ERE) 
in a dose-dependent manner (Verrier et al., 1997; Zhang et al., 1999). Furthermore, it 
facilitates low-specificity binding of ERα to half-site binding elements to an extent 
that resembles high affinity consensus binding (Das et al., 2004; El Marzouk et al., 
2008). 
 
 
Figure 6. Model of HMG-box structure and function. 
(A) Amino acid sequence HMGB1 (accession CAE48262) and domain structure of 
the canonical HMGB family member HMGB1. The HMG boxes A and B are 
indicated by a red and blue box, respectively; the positions of the individual α-helices 
constituting the HMG boxes are indicated by red and blue bars, respectively. The 
acidic tail is marked by an orange box. (B) Structure of the HMG box A of HMGB1 
(left) (Hardman et al., 1995) and of the HMG box B of SRY (Stott et al., 2006), as 
determined by NMR spectroscopy. (C) Putative modes of action of HMGB proteins 
as architectural factors in transcription. The HMGB factor interacts with a 
transcription factor (TF1, top left) and recruits it to its DNA binding site, which has 
been pre-bent by the HMGB factor, to form an intermediate ternary complex (bottom 
left). Another factor (TF2) is recruited to the TF1-DNA-HMGB complex and the 
HMGB factor is released (bottom right). Alternatively, the DNA is bent by HMGB 
resulting in enhanced binding of the specific transcription factors without direct 
interaction with the HMGB factor (top right). Figures taken from (Stros, 2010). 
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In keeping with the number of their interacting proteins and chromatin-binding 
properties, a multitude of functions has been ascribed to HMGB proteins, albeit 
important differences exist between the abundant HMGB1 and its closely related 
proteins and the cell type-specific HMGB factors. HMGB1 in particular has been 
implicated in various biologically important processes including transcription, 
chromatin remodelling including DNA repair, DNA replication, translocation 
between nucleus and cytoplasm as well as V(D)J recombination. In addition to its 
nuclear function, HMGB1 can also act as a cytokine and plays a role in necrosis, 
inflammation and apoptosis (Scaffidi et al., 2002). Considering its various functions, 
it is not surprising that HMGB1 is the most abundant nonhistone protein found in the 
nucleus with approximately 1 molecule per 10-15 nucleosomes (Reeves, 2010). Its 
abundance also allows a fraction of HMGB1 protein to always be in contact with 
chromatin despite its high mobility within the nucleus. There are several models of 
how nuclear HMGB proteins interact with chromatin and protein partners. The HMG-
box is a versatile DNA binding motif that can bind to already distorted DNA 
structures with high affinity including four-way junctions, bulges, kinks and modified 
DNA such as cisplatin adducts (Pil and Lippard, 1992), which is consistent with a 
function in the recognition and repair of damaged DNA. It can also bind to and then 
bend DNA, thus making the chromatin more accessible for transcription factors and 
other chromatin-remodelling proteins. It is unclear at this point whether HMGB 
proteins facilitate access to DNA by forming intermediate tertiary complexes with the 
DNA and other transcription factors or by first distorting the DNA, thereby allowing 
subsequent binding of other proteins (Fig. 6 C). 
 
1.7.3 The thymocyte selection-associated HMG box (TOX) protein family 
As discussed above, in addition to the canonical HMGB proteins, the HMGB family 
comprises a plethora of non-canonical, cell type-specific nuclear proteins, including 
the thymocyte selection-associated HMG-box (TOX) protein family named after the 
thymocyte transcription factor TOX. Based on sequence predictions, the TOX family 
contains four proteins, TOX1-4, as well as two pseudogenes in the mouse. The 
members of the TOX family are approximately 500-600 amino acids and 60-70 kDa 
in size. TOX3 in particular is predicted to encode a 576-amino acid protein with a 
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calculated molecular mass of 63.3 kDa (O'Flaherty and Kaye, 2003). The founding 
member of this HMGB subfamily is the murine Tox gene, which was identified by 
Kaye and co-workers in a gene expression study investigating thymocyte 
differentiation (Wilkinson et al., 2002). The function of murine Tox is discussed in 
more detail below. Human TOX had previously been cloned from brain but its 
function remains to be characterised in human cells (Nagase et al., 1998). 
The family member TOX2 (also called GCX-1) was cloned from a rat ovarian 
granulosa cell cDNA library. It is exclusively expressed in reproductive tissues 
involving the hypothalamic-pituitary-gonadal axis and appears to function as a 
transcriptional activator during follicular development (Kajitani et al., 2004). 
Aside from its identification as a putative breast cancer predisposition gene in GWAS, 
TOX3 was recently identified and cloned from a rat cortical cDNA library in a screen 
designed to find new transcriptional transactivators. The authors showed that TOX3 
interacts with both cAMP response element (CRE)-binding protein (CREB) and 
CREB-binding protein (CBP) to activate transcription in neurons in a calcium-
dependent manner (Yuan et al., 2009). Recently, TOX3 was further identified as a 
downstream target of the orphan G-protein-coupled-receptor GPR39, whose 
overexpression promotes neuronal survival by induction of serum-response element 
(SRE)-containing promoters. Along with TOX3, the transcriptional co-activator 
CITED1 was induced by GPR39 (Dittmer et al., 2008). Consistent with a role as a 
survival factor, TOX3 activated the expression of pro-apoptotic genes and 
downregulated anti-apoptotic genes. The study further showed that TOX3 interacted 
with phosphorylated CREB to activate CRE-containing promoters and with CITED1 
to activate ERE-containing promoters (Dittmer et al., 2010). The implication of these 
findings for TOX3 function in the breast is addressed below. 
The fourth family member, TOX4 (also termed LCP1), was identified in a yeast two-
hybrid screen as an interacting partner of protein phosphatase 1, regulatory (inhibitor) 
subunit 10 (PPP1R10, also called PNUTS). Using co-immunoprecipitation and TOX4 
deletion constructs, TOX4 was shown to interact with PPP1R10 through its extreme 
C-terminus, and it co-localises with PPP1R10 in HeLa cells. It was further shown to 
act as transcriptional activator in HEK 293T cells. A second study confirmed the 
interaction between TOX4 and PNUTS, which form a stable multimeric complex with 
protein phosphatase 1 (PP1) and WDR82, a regulatory subunit of the SETD1 Histone 
histone 3 lysine 4 methyltransferase complex in HEK293T cells. This finding 
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confirms a potential role for TOX4 in the regulation of transcriptional activation (Lee 
et al., 2010). Notably, the region of TOX4 that is required for binding to PNUTS is 
not conserved between TOX4 and TOX3 (Lee et al., 2009). Furthermore, a recent 
screen for proteins binding to damaged DNA has shown that a complex containing 
TOX4 and PNUTS is able to recognise DNA adducts caused by platinating anticancer 
agents (Puch et al., 2010), a known property of other members of the HMG box 
family. The currently known functions of the TOX family members are summarised 
in Table 2. 
 
Table 2. Human TOX family members and their murine homologues. 
Human 
gene 
(official 
gene 
symbol) 
Human 
gene 
aliases 
Chromo-
some 
location 
Murine 
homologue Identification, biological functions Reference 
TOX KIAA0808, 
TOX1 8q12.1 Tox 
Regulator of lineage commitment 
during T lymphocyte, natural 
killer  (NK) cell and lymphoid 
tissue-inducer cell development 
in mice. Regulator of 
differentiation of human NK cells. 
Cloned from human brain. 
(Aliahmad 
and Kaye, 
2008; 
Aliahmad et 
al., 2004; 
Nagase et 
al., 1998; 
O'Flaherty 
and Kaye, 
2003; 
Wilkinson et 
al., 2002) 
(Aliahmad et 
al., 2010; 
Yun et al.) 
TOX2 GCX-1 20q13.12 Tox2 
First cloned from rat ovarian 
granulosa cell cDNA library. 
Transcriptional activator, 
exclusively expressed in 
reproductive tissues. 
(Kajitani et 
al., 2004) 
TOX3 TNRC9, 
CAGF9 16q12.1 Tox3 
Identified as breast cancer 
predisposition gene in GWAS. 
First cloned from rat cortical 
cDNA library. Regulation of 
calcium-dependent transcription 
via interaction with CREB and 
CBP in neurons. Interacts with 
phosphorylated CREB and CITED1 
in neurons to activate 
transcription of CRE- and ERE-
containing promoters. 
(Dittmer et 
al., 2010; 
Dittmer et 
al., 2008; 
Udler et al., 
2010; Yuan 
et al., 2009) 
TOX4 KIAA0737, 
LCP1 14q11.2 Tox4 
Identified in yeast two-hybrid 
screen as protein phosphatase 1 
(PP1) nuclear targeting subunit 
(PNUTS); transcriptional 
activator, forms stable multimeric 
complex with PNUTS, PP1 
catalytic subunit and WDR82, 
disruption of which results in cell 
cycle arrest and apoptosis. 
Binds to DNA adducts. 
(Lee et al., 
2010; Lee et 
al., 2009; 
Puch et al., 
2010) 
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1.7.4 TOX family members are evolutionarily conserved and share common 
functional domains 
TOX family members are highly conserved between humans and mice. Furthermore, 
conservation of the TOX subfamily, and the TOX HMG-box motif in particular, 
extends to evolutionarily more distant species, as TOX-like proteins have also been 
identified in pufferfish and mosquito. Comparison of TOX family members shows 
that human and murine homologues share an almost identical HMG-box motif (Fig. 7, 
8) (O'Flaherty and Kaye, 2003). Interestingly, the HMG-box motif found in all TOX 
family members is most closely related to the archetypal HMGB motif of HMGB 
proteins that bind to DNA without sequence specificity and are ubiquitous and 
abundant, such as HMGB1 (HMG-box A) and UBF/UBTF (Fig. 7 A). This is 
surprising as all TOX proteins appear to be expressed in a spatially and temporally 
regulated fashion at only moderate levels (Dittmer et al., 2010; Kajitani et al., 2004; 
Lee et al., 2009; O'Flaherty and Kaye, 2003; Wilkinson et al., 2002). For instance, 
Kaye and colleagues showed in their original study that TOX mRNA expression was 
highest in the thymus, followed by the liver and brain but TOX was not expressed in 
other tissues (Wilkinson et al., 2002). In this respect, the TOX family members fit 
better into the subgroup of non-canonical HMGB proteins that have a single HMG-
box and bind to DNA with sequence specificity, such as SRY, SOX or LEF1 (Fig. 7 
A). Furthermore, a common consensus sequence within HMG-box motifs, GXXW, is 
replaced with AXXW in TOX family members (Fig. 7 B). This unique combination 
of conserved properties may suggest a very specialised function for TOX proteins. 
In addition to the conservation between TOX family members, TOX3 itself is 
evolutionarily conserved across species (Fig. 8). Furthermore, fine scale mapping 
analysis of the 133 kB region on 16q12 that is associated with increased breast cancer 
risk, and in particular the putative TOX3 promoter region, showed evolutionary 
conservation (Udler et al., 2010) (Fig. 5) 
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A 
 
TOX3   230 EKRAAPDSGKKPKTPKKKKKKDPNEPQKPVSAYALFFRDTQAAIKGQNPNATFGEVSKIV 289 
TOX    236 EKRPASDMGKKPKTPKKKKKKDPNEPQKPVSAYALFFRDTQAAIKGQNPNATFGEVSKIV 295 
HMGB1   70 RYEREMKTYIPPKGETKKKFKDPNAPKRPPSAFFLFCSEYRPKIKGEHPGLSIGDVAKKL 129 
UBTF    87 ELILDAQEHVKNPYKGKKLKKHPDFPKKPLTPYFRFFMEKRAKYAKLHPEMSNLDLTKIL 146 
SRY     35 LCTESCNSKYQCETGENSKGNVQDRVKRPMNAFIVWSRDQRRKMALENPRMRNSEISKQL  94 
SOX4    34 PTPGSTASTGGKADDPSWCKTPSGHIKRPMNAFMVWSQIERRKIMEQSPDMHNAEISKRL  93 
LEF1    74 HTDSDLMHVKPQHEQRKEQEPKRPHIKKPLNAFMLYMKEMRANVVAECTLKESAAINQIL 133 
 
TOX3   290 ASMWDSLGEEQKQVYKRKTEAAKKEYLKALAAYRASLVSKAAAESAEAQTIRSVQQTLAS 349 
TOX    296 ASMWDGLGEEQKQVYKKKTEAAKKEYLKQLAAYRASLVSKSYSEPVDVKTSQPPQLINSK 355 
HMGB1  130 GEMWNNTAADDKQPYEKKAAKLKEKYEKDIAAYRAKGKPDAAKKGVVKAEKSKKKKEEEE 189 
UBTF   147 SKKYKELPEKKKMKYIQDFQREKQEFERNLARFREDHPDLIQNAKKSDIPEKPKTPQQLW 206 
SRY     95 GYQWKMLTEAEKWPFFQEAQKLQAMHREKYPNYKYRPRRKAKMLPKNCSLLPADPASVLC 154 
SOX4    94 GKRWKLLKDSDKIPFIREAERLRLKHMADYPDYKYRPRKKVKSGNANSSSSAAASSKPGE 153 
LEF1   134 GRRWHALSREEQAKYYELARKERQLHMQLYPGWSARDNYGKKKKRKREKLQESASGTGPR 193 
 
 
B 
 
TOX    236 EKRPASDMGKKPKTPKKKKKKDPNEPQKPVSAYALFFRDTQAAIKGQNPNATFGEVSKIV 295 
TOX2   221 EKRPSADPGKKAKNPKKKKKKDPNEPQKPVSAYALFFRDTQAAIKGQNPSATFGDVSKIV 280 
TOX3   230 EKRAAPDSGKKPKTPKKKKKKDPNEPQKPVSAYALFFRDTQAAIKGQNPNATFGEVSKIV 289 
TOX4   189 QKTVVVEAGKKQKAPKKRKKKDPNEPQKPVSAYALFFRDTQAAIKGQNPNATFGEVSKIV 257 
 
TOX    296 ASMWDGLGEEQKQVYKKKTEAAKKEYLKQLAAYRASLVSKSYSEPVDVKTSQPPQLINSK 355 
TOX2   281 ASMWDSLGEEQKQAYKRKTEAAKKEYLKALAAYRASLVSKSSPDQGETKSTQANPPAKML 340 
TOX3   290 ASMWDSLGEEQKQVYKRKTEAAKKEYLKALAAYRASLVSKAAAESAEAQTIRSVQQTLAS 349 
TOX4   258 ASMWDSLGEEQKQVYKRKTEAAKKEYLKALAAYKDNQECQATVETVELDPAPPSQTPSPP 31 7   
Figure 7. Conservation of the HMG-box motif. 
(A) Comparison of the TOX and TOX3 HMG-box motifs with those of HMGB 
proteins shows that the TOX family members are more closely related to ubiquitous 
HMGB proteins that bind DNA without sequence specificity (above line) than 
sequence-and cell type-specific HMGB proteins (below line). Similarities between 
both groups and the HMG-box consensus sequence (Pfam accession number pf00505) 
are highlighted in grey. Residues in red and green distinguish the HMGB-like HMG-
box from the non-canonical HMG-box. The commonly found consensus sequence 
(G/A)XXW is highlighted in yellow. (B) Comparison of the HMG-box motifs and 
putative nuclear localisation signals (in purple) of the TOX family members. The 
AXXW consensus sequence is highlighted in yellow. The conserved exon-exon 
boundary present in all four genes is marked in turquoise. 
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Figure 8. TOX3 is evolutionarily conserved across species. 
(A) Alignment of TOX3 amino acid sequences from human, mouse, rat, and clawed 
frog. (B) Phylogenetic tree showing evolutionary conservation of TOX3 amino acid 
sequences. Alignment analysis was performed with ClustalW version 2.1; colours 
reflect physicochemical properties of the amino acids; the ASMW consensus 
sequence within the HMG-box is underlined. 
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The TOX family members are less conserved outside of the HMG-box but do share 
common domains (Fig. 7-9). A conserved lysine-rich putative bipartite nuclear 
localisation signal (NLS) is located N-terminally adjacent to the HMG-box (Fig. 7 B, 
9) (O'Flaherty and Kaye, 2003). The wild-type forms of all four TOX family 
members localise to the nucleus (Kajitani et al., 2004; Lee et al., 2009; Wilkinson et 
al., 2002; Yuan et al., 2009), while deletion of this basic region prevents nuclear 
localisation of TOX2 and TOX4 (Kajitani et al., 2004; Lee et al., 2009). All four 
family members can act as activators of transcription in mammalian cells (Aliahmad 
and Kaye, 2006; Dittmer et al., 2010; Kajitani et al., 2004; Lee et al., 2009; Yuan et 
al., 2009). The transactivation domain was mapped to the N-terminal amino acid 
residues 25-63 of TOX2 and the N-terminal 250 amino acid residues of TOX4, 
respectively (Kajitani et al., 2004; Lee et al., 2009). The transcriptional activation 
ability of full-length rat TOX3 fused to the GAL4 DNA-binding domain is reduced by 
50% through deletion of the part of the protein that is C-terminal to the HMG-box. 
Further deletion of the DNA-binding domain has no effect on transcriptional 
activation in this context. However, the ability to activate transcription is completely 
abrogated by deletion of the N-terminal part of the protein, further demonstrating the 
conservation between the functional domains of the TOX family members (Yuan et 
al., 2009). TOX activity may be regulated by post-translational modifications, as the 
N-terminus of TOX is subject to phosphorylation but the exact residues are unknown 
at this point (Aliahmad and Kaye, 2006). 
Further functional motifs that have been identified in the TOX family members 
include a protein interaction domain at the carboxy-terminus of TOX4 that is required 
for its interaction with PNUTS (Lee et al., 2009). Notably, the domain that mediates 
calcium responsiveness of TOX3 was also mapped to the C-terminus, suggesting that 
this region of the protein is also important for its interaction with CREB and CBP 
(Yuan et al., 2009). TOX3 interaction with CITED1 is mediated by the HMG-box and 
the N-terminally adjacent part of the protein (Dittmer et al., 2010). A unique feature 
of human TOX3 is a CAG trinucleotide repeat coding for a C-terminal glutamine 
stretch, which is not present in any of the other TOX proteins but conserved between 
the TOX3 gene in different species (Fig. 8). Longer glutamine stretches have been 
found in a number of transcription factors including the androgen receptor and TATA 
binding protein, where they appear to activate transcription (Gerber et al., 1994). 
Notably, the murine HMGB protein SRY also contains a C-terminal glutamine 
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stretch, which is required for male sex determination (Bowles et al., 1999). The 
expansion of CAG repeats has been shown to be associated with neurodegenerative 
disorders in the past, where they are thought to cause conformational changes and 
protein misfolding (Margolis et al., 1997; Masino and Pastore, 2002; Ross, 2002). The 
function of the CAG repeat in the carboxy-terminus of TOX3 and whether it plays a 
role in breast tumourigenesis remains to be determined. Northern blot analysis 
showed the presence of a 3-kb and a 5-kb TOX transcript in thymocytes expressing a 
transgenic cDNA-derived TOX, the former of which was more abundant. In addition, 
Western blot analysis showed two forms of TOX that were ca. 57 kDa and ca. 63 kDa 
in size (Wilkinson et al., 2002). Similarly, two transcripts of endogenous TOX3 (3 kb 
and 5 kb) and TOX4 (4 kb and 6 kb) have been detected (O'Flaherty and Kaye, 2003; 
Yuan et al., 2009). NCBI GenBank contains two entries for human TOX3 (NM 
001080430.2 and NM 001146188.1). Transcript variant 2 differs from variant 1 in the 
5’ UTR and coding sequence, and the resulting isoform is predicted to have a shorter 
and distinct N-terminus compared to isoform 1. It remains to be investigated whether 
the different isoforms found at the mRNA and protein level represent splice isoforms 
or post-translational modifications. 
 
 
Figure 9. TOX protein domains. 
Schematic drawing of the four TOX family members that have been experimentally 
analysed and the domains present in the individual proteins. The exact location of the 
phosphorylation site in TOX is unknown. Lys, lysine; Pro, proline; Ser, serine; Glu, 
glutamine; Ca, calcium. 
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In summary, currently available data describe the TOX proteins as transcriptional 
activators that contain a central DNA-binding domain, which is flanked on the N-
terminal side by a basic nuclear localisation signal and an acidic transactivation 
domain and on the C-terminal side by a protein interaction domain. 
1.7.5 TOX is a regulator of lineage commitment in the innate and adaptive 
immune system 
The TOX protein family member that has been studied in most detail is TOX itself. 
Interestingly, TOX plays an important role in the regulation of lineage commitment 
both in the adaptive and innate immune system. As parallels are often drawn between 
the haematopoietic and mammary epithelial stem cell hierarchies, it is tempting to 
speculate that TOX3 may play a role in the regulation of mammary epithelial cell fate 
that is similar to the function of TOX in haematopoiesis. 
 
Thymocytes are immature T cell precursors that are derived from haematopoietic 
progenitor cells in the bone marrow, which migrate through the blood stream to the 
thymus, where they develop into mature T cells. T cell maturation is a complex 
process of selection and differentiation of functional T cells in an antigen-dependent 
manner, which involves several rearrangements of the T cell receptor (TCR) gene, 
resulting in a pool of T cells that are able to respond to foreign pathogens but tolerate 
self-antigens. T cells recognise foreign antigens through the TCR, a dimeric surface 
receptor that recognises peptides presented on major histocompatibility complex 
(MHC) proteins expressed on neighbouring cells. Immature thymocytes express 
neither the TCR nor its co-receptors CD4 and CD8 and are therefore called double 
negative (DN) cells (Fig. 10). During so-called β-selection, DN cells undergo 
rearrangement of the T cell receptor TCRβ gene locus through V(D)J recombination. 
Only thymocytes that have successfully rearranged their TCR genes and express a 
functional TCRβ chain that is able to assemble with the TCRα chain and the CD3 co-
receptor to form the pre-TCR pass the β-selection checkpoint and undergo pre-TCR-
dependent proliferation and differentiation to give rise to double positive (DP) cells 
that express both CD4 and CD8 receptors as well as the mature TCR. DP cells 
subsequently undergo so-called positive selection and lineage commitment, whereby 
the interaction of a DP cell’s TCR with either MHC class I or class II molecules on 
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the surface of neighbouring stromal cells activates TCR-dependent signalling, which 
in turn induces differentiation of the DP cell into a CD8 or CD4 single positive (SP) 
cell, depending on the specificity of their TCR (Fig. 10). Nonfunctional DN and DP 
cells whose (pre-)TCRs are unable interact with their respective MHC receptor 
undergo apoptosis (Ciofani and Zuniga-Pflucker, 2007). 
The murine Tox gene was originally identified by Kaye and co-workers in DP 
thymocytes activated with phorbol 12-myristate 13-acetate (PMA) and ionomycin, 
suggesting a role for TOX in the initial stages of positive selection, consistent with its 
high expression in the transitional CD4+CD8lo cells (Fig. 10). In contrast to its 
expression in activated thymocytes, TOX3 levels in most immature thymocytes were 
found to be low. Importantly, upregulation of TOX expression was observed during 
positive selection to both CD4 and CD8 single positive cell lineages in wild-type 
mice. Surprisingly though, transgenic TOX expression driven by the lymphocyte-
specific lck promoter resulted in an increase of the total number of CD8 SP cells at 
the expense of the CD4 SP population (Wilkinson et al., 2002), suggesting different 
roles for TOX in the regulation of the CD4 and CD8 thymocyte lineages. 
Interestingly, forced TOX expression is able to commit DP cells to differentiate 
directly into the CD8 SP phenotype without undergoing intermediate stages observed 
in wild-type mice. In a follow-up study, Kaye and colleagues showed that TOX 
initiates differentiation of DP thymocytes into CD8 SP, even in the absence of MHC-
dependent positive selection. This upregulation of TOX expression in DP cells is 
mediated by the protein phosphatase calcineurin, an important regulator of both CD4+ 
and CD8+ lineage commitment. However, these CD8 SP cells are unable to fully 
mature and to populate peripheral lymphoid organs. In contrast, the relative number 
of CD4 SP cells is decreased during positive selection in TOX transgenic mice 
(Aliahmad et al., 2004). 
Tox-/- mice show no gross abnormalities outside the immune system although TOX 
expression is not restricted to the latter, suggesting that other TOX family members 
may be able to compensate for the loss of TOX (Aliahmad and Kaye, 2008). 
Furthermore, B lymphocyte development is not affected. In contrast, TOX-deficient 
mice suffer from a severe block at the transition from the double dull (DD) to the 
CD4+8lo stage, a transitional stage at the beginning of positive selection that is 
characterised by high TOX expression in wild-type animals. As a consequence, Tox-/- 
mice fail to complete the development of all cell types of the CD4+ lineage, the most 
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striking phenotypic effect of TOX deficiency. In contrast, the development of CD8+ 
cells was not affected by loss of TOX, indicating that the CD4+8lo transitional stage is 
not required for lineage commitment of CD8+ cells. This dependence of CD4 SP 
differentiation on TOX was likely due to a requirement for MHC class II signalling, 
which is not necessary for the development of CD8+ cells, and vice versa (Aliahmad 
and Kaye, 2008). 
In addition to its role in the later stages of thymocyte development, TOX plays a role 
in differentiation of DN to DP cells, as forced TOX expression midway during TCR 
β-chain selection is able to induce differentiation, but not proliferation of DP 
precursor cells (Aliahmad et al., 2004). It is therefore somewhat surprising that β-
selection appears largely uncompromised by loss of TOX (Aliahmad and Kaye, 
2008). The findings of Kaye and colleagues do not fully explain the obvious paradox 
that TOX transgenic mice exhibit an increase of the CD8 SP population at the 
expense of the number of CD4 SP cells, while knockout of the Tox gene results in a 
loss of CD4+ cells but has no obvious effect on the development of CD8+ cells. This 
may be at least partially explained by the interplay between MHC class II-dependent 
signalling in CD4+ precursor cells, which may be mediated by TOX, while the same 
may not be the case for MHC class I signalling in immature CD8+ thymocytes. 
Alternatively, TOX-dependent regulation earlier in the thymocyte lineage, notably 
during TCR β-selection may exert its CD4-specific effect not until later during 
lineage commitment.  
In addition to its role in the thymus, two recent studies have demonstrated a function 
for TOX in the development and differentiation of both mouse and human natural 
killer cells. In addition, lymphoid tissue organogenesis was inhibited in the absence of 
TOX (Aliahmad et al., 2010; Yun et al., 2010). In both cases this can be considered 
analogous to the function of TOX in the T cell lineage: TOX3 influences lineage 
choice in the innate system, and it does so at times when its expression is highest. 
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Figure 10. TOX function in thymocyte lineage commitment. 
Simplified schematic of thymocyte maturation in the thymus of the mouse. Tox is 
expressed at distinct stages during β-selection and positive selection, thereby 
regulating the differentiation of CD4 and CD8 single positive thymocytes. DN, 
double negative cell; DP, double positive cell; SP, single positive cell; DD, double 
dull cell; MHC, major histocompatibility complex. 
 
1.7.6 A function for TOX3 in the mammary gland and breast cancer 
Considering the role of TOX in thymocyte development, it is intriguing to speculate 
that TOX3 plays a similar role in the lineage commitment of the mammary gland, in 
particular in the regulation of luminal cell fate. The complex expression pattern of 
TOX and the intricate interplay with other factors that regulate cell fate demonstrate 
that the fine-tuning of TOX expression levels throughout thymocyte development has 
significant consequences for the development of the individual T cell compartments. 
By analogy to TOX expression in early CD4+CD8lo precursor cells, one could 
envision that TOX3 expression in bipotent progenitor or luminal progenitor cells 
induces commitment to the luminal cell lineage. As a consequence, perturbation of 
TOX3-dependent regulation may result in inappropriate cell fate decisions and 
ultimately breast tumourigenesis. An example of a transcription factor that plays a 
role in the differentiation of both the haematopoietic system and the mammary gland 
is GATA3. Knockout studies have shown that GATA3 is expressed at all stages of 
thymocyte development, from early progenitors to effector T cells, and like TOX, it is 
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indispensable for the differentiation of CD4 SP cells (Hosoya et al., 2009; Pai et al., 
2003; Ting et al., 1996). Thymocytes from GATA3-deficient mice cannot be 
redirected to differentiate into the CD8+ lineage, suggesting that GATA3 expression 
promotes maintenance or survival of thymocytes that have already chosen the CD4+ 
cell fate. Similarly, GATA3 is thought to play a role late in luminal cell 
differentiation, and in keeping with this notion, re-expression of GATA3 in tumour 
cells induces their differentiation. Based on the available data it is difficult to predict 
whether TOX3 acts early or late in luminal cell development and tumourigenesis but 
one could envision a situation where TOX3 may inhibit activation of a subset of ERα 
target genes early in the luminal lineage, thus blocking terminal differentiation of 
ERα-positive cells, while at the same time allowing expansion of progenitors. The 
resulting cells would be ERα-positive and able to respond to estrogen stimulation but 
would fail to differentiate, thus giving rise to ERα-positive tumour cells. In this 
model, selected activation of ERα target genes may be caused by interaction of TOX3 
with a distinct subset of ERα co-factors, such as GATA3 or FOXA1, thus committing 
the epithelial cell to a luminal cell fate. Interestingly, TOX3 has recently been shown 
cooperate with CITED1 to activate ERE-containing promoters in neurons. However, 
this transactivation appeared to be independent of E2 stimulation (Dittmer et al., 
2010). Despite the lack of a DNA-binding domain CITED1 acts as a transcriptional 
co-activator in various contexts, notably including ERα-dependent transcription 
(McBryan et al., 2007; Yahata et al., 2001). CITED1 induces ERα target genes, 
including amphiregulin, in an E2-dependent manner in the pubertal mouse mammary 
gland, in particular in luminal cells (McBryan et al., 2007). Furthermore, CITED1 
null mice display aberrant mammary gland development during puberty including 
growth retardation and dilated ducts (Howlin et al., 2006). The expression of both 
TOX3 and CITED1 is upregulated in the mature luminal mammary epithelial 
population in human and mice, which in the context of a physical interaction of TOX3 
and CITED1 suggests that they may exert their function in concert (Lim et al., 2010). 
The available data suggest a role for TOX3 in the regulation of luminal mammary 
epithelial cell fate or differentiation, however the underlying mechanisms are not 
understood. Moreover, SNPs in the regulatory region of the TOX3 gene are 
associated with increased breast cancer susceptibility, suggesting that changes in 
TOX3 expression cause breast cancer by aberrant luminal cell differentiation, but, 
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once again, the mechanisms are unknown. A recent study showed that the TOX3 gene 
along with other known developmental regulators selectively lack polycomb 
repression marks H3K27me3 in pancreatic beta-cells as well as in the cortex and 
cerebellum or the brain (van Arensbergen et al., 2010). It is tempting to speculate that 
an inappropriate lack of polycomb repression of the TOX3 gene in cells of the 
luminal lineage may cause the selective activation of proliferation genes, ultimately 
leading to transformation. 
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1.8 Aim of this study and hypothesis 
The goal of this PhD project was to characterise new breast cancer genes and 
ultimately, to create new models for human breast cancer. In this context, I was 
interested to analyse the function of the putative breast cancer predisposition gene 
TOX3 in the normal mammary epithelium and breast cancer. Genes that confer 
susceptibility to breast cancer and/or regulate the mammary epithelial cell are 
potential targets for therapy and may also serve as predictive markers. 
 
My working hypothesis has been that single nucleotide polymorphisms in the TOX3 
regulatory region predispose to luminal breast cancer by increasing the expression of 
TOX3. This increases the propensity of mammary epithelial cells to differentiate 
along the luminal lineage rather than become myoepithelial cells but at the same time 
blocks the final steps of differentiation. At the molecular level TOX3 acts at 
promoters of estrogen receptor α target genes to recruit factors required for the 
expression of proliferation genes but inhibits recruitment of factors required for 
expression of differentiation genes. 
 
Three main objectives evolved for this project. The first was the identification of 
TOX3 interacting proteins by tandem affinity purification and mass spectrometric 
analysis. The second was the identification of TOX3 target genes and the signalling 
pathways that TOX3 is implicated in. The final objective was to create a TOX3 
tumour model to test our hypothesis. 
Aim 
 60 
 
 
Materials and Methods 
 61 
2 Materials and Methods 
2.1 Cell culture 
2.1.1 Preparation of organoids from reduction mammoplasty tissue 
The culture of normal breast tissue from reduction mammoplasty samples obtained 
from Ninewells Hospital, Dundee, UK, was approved by the Tayside Tissue Bank 
ethics committee, and patients gave informed consent. Patients were healthy, pre-
menopausal women between the ages of 21 and 40 years with no previous history of 
breast cancer. The absence of malignancy was confirmed by histopathological 
examination of all tissue samples. 
In order to obtain organoids from reduction mammoplasty samples, ductal tissue was 
isolated from mammoplasty samples by a pathologist. The adipose tissue was 
removed from the fibrous mammary tissue, and the remaining tissue was 
mechanically dissociated using scalpels. The resulting minced tissue was digested in 
phenol red-free HEPES-buffered Dulbecco’s Modified Eagle Medium (DMEM)/F12 
nutrient mixture (Invitrogen, Cergy Pontoise, France), supplemented with 1 mg/ml 
collagenase A (Roche Diagnostics, Meylan, France), 100 units/ml penicillin and 100 
µg/ml streptomycin (Invitrogen) with agitation at 37ºC overnight. The following day, 
organoids were washed twice in phosphate buffered saline (PBS; Invitrogen) or 
Hank’s balanced salt solution (HBSS; Invitrogen) and centrifuged to separate 
fractions containing epithelial cells (500 × g) and fibroblasts (900 × g). Organoids 
were then either dissociated further to obtain single cells as described below or 
directly cultured on conventional tissue culture plastic (Thermo Fisher Scientific 
Nunc, St Herblain, France) or Primaria plastic (BD Biosciences, Le Point de Claix, 
France). In order to distinguish cell lines derived from different reduction 
mammoplasty tissue samples, cell lines were designated XS, followed by 
chronologically increasing numbers. For instance, XS03 denotes reduction 
mammoplasty number three. 
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2.1.2 Preparation of single primary mammary epithelial cells 
To prepare a single cell suspension, organoids were incubated in 0.25% trypsin 
(Invitrogen) at 37ºC and subsequently mechanically dissociated by pipetting. The 
enzymatic reaction was stopped with trypsin neutralising solution (Lonza, Cologne, 
Germany) or 5% heat-inactivated fetal bovine serum (FBS; Pan-Biotech, Aidenbach, 
Germany) in PBS. Cells were centrifuged at 300 × g and the cell pellet was 
resuspended in 5 mg/ml warm dispase solution and 1 mg/ml DNase or HyQtase 
(Thermo Fisher Scientific HyClone) and dissociated further by pipetting. The cell 
suspension was passed through a 40 µm cell strainer and centrifuged at 300 × g. 
Single cells were then resuspended in mammosphere medium (MSPM), HMEC 
medium (HMM+) or WIT medium as described below (Duss et al., 2007; Ince et al., 
2007). To distinguish the cells arising from the different culture methods, human 
mammary epithelial cells grown in HMM+ medium on conventional plastic are in the 
following referred to as human mammary epithelial cells (HMEC), whereas epithelial 
cells grown in WIT medium on Primaria dishes were termed breast primary epithelial 
cells (BPEC) (Ince et al., 2007). All primary cells were cultured at 37ºC and 5% CO2 
as well as 5% O2. 
 
2.1.3 Mammosphere culture of primary mammary epithelial cells 
To form mammospheres in suspension, single mammary epithelial cells were seeded 
at a density of 1x105 cells/ml in suspension on ultra-low attachment dishes (Corning 
Life Sciences, Lowell, USA) in mammosphere medium (MSPM; phenol red-free 
HEPES-buffered DMEM/F12 nutrient mixture supplemented with B-27 (Invitrogen) 
(Brewer et al., 1993), 10 units/ml penicillin and 10 µg/ml streptomycin (Invitrogen), 4 
µg/ml heparin (Sigma), 20 ng/ml EGF (Invitrogen), and 20 ng/ml bFGF). HMEC and 
BPEC maintained as mammospheres were passaged every four to seven days. To this 
end, mammospheres were centrifuged in a 15-ml conical tube (BD Falcon) at 500 × g, 
digested enzymatically in 0.05% trypsin-EDTA (Invitrogen) or HyQtase (Thermo 
Scientific HyClone) and passed through a 40 µm cell strainer (BD Biosciences). 
Mammospheres were analysed using an Olympus CKX41 microscope and a 
PixeLINK CMOS camera (PixeLINK, Ottawa, Canada). 
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2.1.4 Adherent culture of primary mammary epithelial cells 
Single mammary epithelial cells were maintained in adherent culture either 
immediately following dissociation of organoids or following one to several rounds of 
mammosphere culture. Adherent cells were cultured either on conventional plastic 
dishes in HMM+ medium (HEPES-buffered DMEM/F12, supplemented with 100 
units/ml penicillin and 100 µg/ml streptomycin, 10 mM HEPES (Invitrogen), 5 ng/ml 
EGF, 10 µg/ml insulin, 20 ng/ml bFGF, 0.5 µg/ml hydrocortisone, 5 µg/ml apo-
transferrin, 0.1 µM isoproterenol, 1 µM ethanolamine, 1 µM O-phosphoethanolamine 
and, in the case of ESR1-expressing cell lines, 1 nM β-estradiol) or in WIT medium 
for primary cells as described by Ince and colleagues (Ince et al., 2007) on Primaria 
dishes (BD Biosciences). All chemicals were purchased from Sigma (Sigma-Aldrich, 
Lyon, France) unless otherwise noted. Cells were passaged every three to four days 
and maintained in filtered conditioned medium. Dissociated cells were seeded at a 
density of 105 cells/ml. 
 
2.1.5 Isolation and culture of primary mammary fibroblasts 
Single primary human mammary fibroblasts (HMF) were isolated from reduction 
mammoplasty tissue samples as described above for epithelial cells. HMF were 
separated from epithelial cells by centrifugation at the organoid stage and then 
processed separately. HMF were cultured on conventional plastic dishes in RPMI-
1640 medium (Invitrogen), supplemented with 100 units/ml penicillin and 100 µg/ml 
streptomycin and 10-20% FBS at high density but without being permitted to reach 
confluency. 
 
2.1.6 Culture of established tumour cell lines 
The cell lines ZR-75-1 and CAMA-1 were a kind gift from Françoise Bonnet, Institut 
Bergonié, Bordeaux, France, and Paul Reynolds, University of St Andrews, UK, 
respectively. All other established cell lines were obtained from the American Type 
Culture Collection (ATCC). Human breast cancer cell lines MCF-7, T-47D, BT-474, 
and ZR-75-1 were maintained in RMPI-1640 medium supplemented with 100 
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units/ml penicillin and 100 µg/ml streptomycin and 10-20% FBS. Human breast 
cancer cell lines CAMA-1, MDA-MB-231, MDA-MB-361, MDA-MB-415, and 
UACC-812, and human embryonic kidney cells transformed with SV40 large-T 
antigen (HEK 293T) were maintained in DMEM supplemented with 100 units/ml 
penicillin and 100 µg/ml streptomycin and 10-20% FBS. MCF-10A cells were 
maintained in HEPES-buffered DMEM/F12, supplemented with 100 units/ml 
penicillin and 100 µg/ml streptomycin, 10% FBS, 20 ng/ml EGF, 10 µg/ml insulin, 
0.5 µg/ml hydrocortisone, and 100 ng/ml cholera toxin (Sigma). The transformed 
HMEC line AJ4 expressing ESR1, BMI1, TERT, and MYC and enhanced cyan 
fluorescent protein (ECFP) has been described previously and was maintained in 
HMM+ medium (Duss et al., 2007). 
 
2.1.7 Colony forming cell (CFC) assay 
CFC assays to assess progenitor properties of primary mammary epithelial cells and 
MCF-10A cells were performed essentially as described (Bachelard-Cascales et al., 
2010). Briefly, 105 cells/ml unsorted single primary mammary cells from freshly 
dissociated organoids or MCF-10A cells were seeded onto adherent irradiated mouse 
embryonic fibroblasts (MEF) in the respective culture medium. Colony formation, 
phenotype and size were assessed at different time points by fixation of the cells in 
ice-cold methanol and subsequent staining with May-Grünwald colorant.  
 
2.1.8 Terminal ductal lobular unit (TDLU) assay 
The TDLU assay was used as a 3D in vitro stem cell assay and was performed as 
described (Bachelard-Cascales et al., 2010). In brief, Lab-Tek chamber slides 
(Thermo Scientific Nunc) were filled growth factor-reduced matrigel (BD 
Biosciences). For primary cells, matrigel was mixed with irradiated MEF feeder cells. 
For established tumour cell lines, matrigel alone was used. Matrigel was allowed to 
set briefly and 5x103 cells resuspended in 2 µl PBS were injected into the middle of 
the semi-hardened matrigel. Lab-Tek chambers were immediately placed at 37ºC to 
cause matrigel to harden and in order to prevent diffusion of the injected cells. 
Matrigel was subsequently covered with the respective medium. After 15-20 days, 
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epithelial outgrowths were paraffin-embedded, sectioned, and haematoxylin and eosin 
(H&E)-stained for histological analysis. 
 
2.1.9 Flow cytometry 
For phenotypic analysis of epithelial subpopulations, cells were resuspended in 
HBSS, supplemented with 2% FBS and incubated for 30 minutes to 1 hour with 0.1 
ug of the following antibodies per 106 cells: IgG1-PE-Cy5, CD10 PE-Cy7, 
EpCAM/CD326-APC, CD29-PeCy5, CD24-PE, CD49f-PE, CD49d-PE (all BD 
Biosciences). Cells were centrifuged, washed and fixed in 2% paraformaldehyde 
(Sigma) in PBS. Fluorescence-activated cell sorting (FACS) analysis was performed 
using a FACSCalibur flow cytometer (BD Biosciences). 
 
2.1.10 Production of lentiviral particles 
Lentiviral particles were produced by calcium phosphate transfection of HEK 293T 
cells using a second-generation lentiviral packaging system according to standard 
techniques (Dull et al., 1998). Briefly, a total of 4.5 x 106 cells were seeded in 
standard medium on a 10 cm dish 24 hours prior to transfection. One hour prior to 
transfection, the medium was replaced with 4.5 ml standard medium, supplemented 
with 25 µM chloroquine. 15-20 µg of lentiviral expression plasmid DNA, 4 µg of 
vesicular stomatitis virus glycoprotein (VSV-G) expression plasmid (pMD2.G) and 
10 µg of gag-pol packaging plasmid (PCMVdR8.74) were diluted with 25 mM 
HEPES to a final volume of 250 µl (Dull et al., 1998; Follenzi and Naldini, 2002). 
After the addition of 250 µl of 0.5 M CaCl2, the DNA mix was added drop-wise to 
500 µl 2x HEPES-buffered saline (Sigma) while vortexting. The transfection mix was 
incubated for 20 minutes and added drop-wise to the cells. 6 hours post transfection, 
the medium was replaced with 5 ml of fresh medium. The supernatant containing the 
lentiviral particles was collected 48 hours post transfection and filtered using a 22-µm 
mixed cellulose ester filter (Millipore) and stored at -80ºC. Lentiviral titres were 
determined for each viral batch by serial dilution infections of MCF-7 cells or primary 
mammary cells and subsequent puromycin treatment or detection of marker gene 
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fluorescence, according to the viral construct. Typical viral titres obtained were 107 
infectious units/ml. 
 
2.1.11 Lentiviral infection 
For lentiviral infection of mammosphere-forming HMEC and BPEC, cells isolated 
from freshly dissociated organoids were allowed to recover in suspension overnight. 
Primary cells were infected in suspension for 6 hours at a multiplicity of infection 
(MOI) of 5-50, depending on the lentiviral construct and experiment, and seeded on 
ultra low attachment dishes at a density of 105 cells/ml. Infections were carried out in 
the respective culture medium supplemented with 8 µg/ml polybrene (Sigma). 
Alternatively, single HMEC and BPEC were seeded in adherent culture and infected 
24 hours later as described for cells in suspension. Established breast cancer cell lines 
were infected essentially as described for HMEC and BPEC in adherent culture with 
the modification that the infection was allowed to take place overnight at a MOI of 5-
20. 48 hours post infection, transduced cells were selected by puromycin treatment for 
72 hours. Alternatively, successful transduction was confirmed by the presence of a 
fluorescent marker gene. For infection with multiple viruses, cells were subjected to 
several rounds of infection, and successful transduction was confirmed after each 
round. 
 
2.1.12 Dual-luciferase assay 
To analyse the effect of TOX3 expression on the transcriptional activity of minimal 
promoters containing estrogen receptor response elements (ERE), MCF-7 and T-47D 
cells were transiently transfected in triplicate using ExGen 500 polyethylenimine 
transfection reagent (Euromedex) according to the manufacturer’s recommendations. 
Briefly, 3x105 cells per well were seeded on a 12-well plate 24 hours prior to 
transfection. For dual-luciferase reporter assays, 225-400 ng of firefly luciferase 
control vector pGL3-basic (Clontech, Saint-Germain-en-Laye, France) or the reporter 
plasmids pGL3-pS2-luc or pGL3-ERE-TK-luc were co-transfected with 50-225 ng 
lentiviral TOX3 or DsRed2 control expression plasmid. The firefly luciferase reporter 
plasmids pGL3-pS2-luc containing the proximal pS2 (trefoil factor 1, TFF1) promoter 
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and pGL3-ERE-TK-luc containing the Vitellogenin ERE along with a minimal 
thymidine kinase promoter were a kind gift from George Reid, EMBL, Heidelberg, 
Germany. 50 ng of the pRL-TK or pRL-SV40 Renilla luciferase reporter plasmids 
(Clontech) were co-transfected as an internal control. Lentiviral expression plasmids 
are described below. 24 hours post transfection, cells were treated with 100 nM 17-
beta-estradiol (Sigma) or 1 µM fulvestrant/ICI 182,780 (Tocris Bioscience, Bristol, 
UK) and subsequently incubated for an additional 24 hours. Preliminary experiments 
had shown that cells maintained in phenol red-free RPMI-1640 medium (Invitrogen) 
supplemented with 5% charcoal dextran-treated FBS (Invitrogen) to exclude potential 
estrogenic effects of phenol-red displayed an abnormal morphology. I therefore chose 
to use the estrogen receptor antagonist fulvestrant in complete medium instead of an 
untreated control. Cell lysates were prepared and the luciferase assay was carried out 
using the Dual-Luciferase Reporter Assay System (Promega) according to the 
manufacturer’s recommendations on a LUMIstar Galaxy luminometer (BMG 
Labtechnologies, Offenburg, Germany). Data were analysed using Microsoft Excel 
software. 
 
2.2 Xenografts 
Animal experiments were authorised by the United Kingdom Home Office and the 
French Ministère de l’alimentation, de l’agriculture et de la pêche. For xenograft 
experiments using transformed primary cells, 75,000 HMEC AJ4, BPEC XS08.4 or 
BPEC XS08.ctrl and 25,000 HMF were mixed with 12.5 vol% Matrigel (BD 
Biosciences) and injected into the fourth mammary gland of 30 week-old female 
nonobese diabetic/Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (commonly know as NOD scid 
gamma or NSG) mice (Jackson Laboratory, Bar Harbor, USA). NSG mice are 
severely immunocompromised due to the absence of mature T or B cells, as well as 
lack of functional NK cells and deficiency in cytokine signalling. One week prior to 
the injection of human mammary cells, 0.5 mg beta-estradiol slow-release silicon 
pellets were inserted subcutaneously into the neck region of animals as described 
(Duss et al., 2007). Mice were sacrificed and examined for tumour and metastasis 
incidence at different time points using a Leica MZ FLIII fluorescence 
stereomicroscope (Leica, Wetzlar, Germany) and a PixeLINK CMOS camera. 
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Tumours were paraffin-embedded and sectioned. H&E staining was carried out using 
standard methods. 
For MCF-7 xenografts, 100,000 cells transduced with hPGK-TOX3 (pXS-36) 
lentiviral vector or a luciferase control vector (pER-6) at a MOI of 20, were injected. 
Cells had additionally been transduced with a hPGK-GFP vector (pXS-17) for 
tracking of cells in the mouse. Cells were grafted by intraductual injection without 
supplementation of matrigel or HMF in 6-8-week old female NSG mice as previously 
described (Behbod et al., 2009). Beta-estradiol pellets were inserted on the day of 
xenografts. Tumour formation was monitored by in vivo fluorescence imaging using a 
Photon Imager with M3 Vision software (Biospace Labs, Paris, France) for 21 days, 
and mice were sacrificed and examined for tumour incidence at day 7 and 21 post 
injection. 
 
2.3 Lentiviral vectors 
Lentiviral expression vectors were created by Gateway cloning (Invitrogen) of the 
open reading frame (ORF) of interest into one of three different lentiviral destination 
vectors, which provided the backbone for the viral expression plasmid. The lentiviral 
destination vector pSD-69 has been described previously (Duss et al., 2007). It 
contains the human phosphoglycerate kinase (PGK) promoter to drive the expression 
of the gene of interest adjacent to a Gateway attR cassette as well as the puromycin 
acetyltransferase gene under the control of the murine PGK promoter, cloned into the 
pRRLhPGK.GFP.SIN18 backbone (Dull et al., 1998). The lentiviral destination 
vectors pJH-3982 and pJH-4282 were a kind gift from J. Huelsken, ISREC, 
Switzerland. pJH-3982 contains the human ubiquitin C promoter (UbiC) to drive the 
expression of the gene of interest, an attR cassette, as well as the enhanced GFP 
(EGFP) gene under the control of the human hPGK promoter. The lentiviral 
destination vector pJH-4282 contains the CMV promoter upstream of an attR cassette 
as well as the marker gene EGFP under the control of the human PGK promoter. 
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2.3.1 TOX3 lentiviral expression vectors 
The TOX3 ORF was transferred from the TOX3 UltimateORF clone IOH61112 
(corresponding to transcript variant 1, accession NM_001080430) pDONR entry 
plasmid (Invitrogen) into pSD-69 and pJH-3982 by Gateway LR recombination 
(Invitrogen) to create the lentiviral expression vectors pXS-36 and pXS-39, 
respectively. Lentiviral vectors derived from pSD-69 used as a control encoded β-
glucuronidase (gusA, GUS; pSD-86) or the fluorescent marker genes green 
fluorescent protein (GFP; pER-15) or DsRed2 (pSD-136) (Duss et al., 2007). The 
control vector derived from pJH-3982 contained the DsRed2 ORF (pXS-41). 
Lentiviral vectors were amplified using electrocompetent E.coli strains Stbl2 or Stbl3, 
and plasmid DNA was purified using Qiagen Plasmid Kits (Qiagen, Courtaboeuf, 
France) according to the manufacturer’s instructions. 
 
2.3.2 NTAP-TOX3 lentiviral expression vectors 
Lentiviral expression constructs for tandem affinity purification (TAP) of TOX3 and 
its interacting proteins were created by a splice PCR-based strategy combined with 
Gateway cloning (Invitrogen). In the first two PCR steps, the TOX3 open reading 
frame (transcript variant 1, accession NM_001080430) was amplified from the 
Ultimate ORF clone IOH61112 (Invitrogen), while the TAP-tag was amplified from 
pNTAP (Agilent Technologies, Massy, France). At the same time, a linker region was 
introduced to allow the fusion of the sequences in a third overlap PCR. The primers 
(Eurogentec, Angers, France) are listed in Table 3. The final PCR product was 
flanked by attB sites and was cloned into the pDONR201 entry vector (Invitrogen) by 
Gateway BP recombination. The N-terminally TAP-tagged TOX3 ORF was 
subsequently cloned into the pSD-69, pJH-3982 and pJH-4282 lentiviral destination 
vectors by Gateway LR recombination to give pXS-95, pXS-96, and pXS-85, 
respectively. The corresponding control lentiviral vectors pXS-98, pXS-99, and pXS-
72 containing the TAP-tag and a linker region only were cloned accordingly. Entry 
and expression vectors were confirmed by sequencing.  
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Table 3. PCR primers used for TAP-TOX3 and TAP control cloning 
Name Sequence (5’-3’) 
oXS6 (attB1_TAP_fwd) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTGCCACCATGAAGCGACG 
ATGGAAAAAGAATTTC 
oXS7 (TAP_linker_rev) TCCACCGGTACCTCCTGAACCGCCCAGCTTGCAGCCGCCGGAG 
oXS8 (NTAP-TOX3_fwd) GCTGCAAGCTGGGCGGTTCAGGAGGTACCGGTGGAGATGTGAGGTTCTACC 
oXS9 (TOX3_attB2_rev) GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGAAAATACTGACCTGCGAT 
oXS10 (attB1) GGGGACAAGTTTGTACAAAAAAGCAGGCT 
oXS11 (attB2) GGGGACCACTTTGTACAAGAAAGCTGGGT 
oXS13 
(TAPtag_control_rev) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCTAGCCTCGAGGAAGCTTG 
GATCCTCCACCGGTACCTCCTGAACC 
 
2.3.3 TOX3-GFP lentiviral expression vector 
A C-terminal TOX3-GFP lentiviral fusion construct was created by a splice PCR-
based strategy combined with Gateway cloning (Invitrogen). In the first two PCR 
steps, the TOX3 open reading frame was amplified from the Ultimate ORF clone 
IOH61112 (Invitrogen), while EGFP was amplified from pEGFP-N1 (Clontech). The 
complete fusion TOX3-GFP ORF was created by a third overlap PCR. The PCR 
primers (Eurogentec) are listed in Table 4. The final PCR product contained flanking 
attB sites and was cloned into the pDONR201 entry vector (Invitrogen) by Gateway 
BP recombination. The TOX3-GFP fusion ORF was subsequently cloned into the 
pSD-69 lentiviral destination vector by Gateway LR recombination to give pXS-71. 
Entry and expression vectors were confirmed by sequencing. 
 
Table 4. PCR primers used for TOX3-GFP cloning 
Name Sequence (5’-3’) 
oXS14 (attB1_TOX3_fwd) 
GGGGACAAGTTTGTACAAAAAAGCAGGCTGCCACCGGTACCATGGATGTG 
AGGTTCTACCCCGCGG 
oXS15 (TOX3_MCS_rev) 
GGTGGCGACCGGTGGATCCCGGGCGAAAATACTGACCTGCGATAATACTT 
GAG 
oXS16 (MCS_EGFP_fwd) GCCCGGGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGCTG 
oXS17 (EGFP_attB2_rev) 
GGGGACCACTTTGTACAAGAAAGCTGGGTCGGTACCGCGGCCGCTTTACT 
TGTACAGCTCGTCCATGC 
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2.3.4 HA-TOX3 lentiviral expression vector 
To create an N-terminal haemagglutinin (HA)-tagged TOX3 lentiviral expression 
vector, the TOX3 ORF was PCR-amplified from the pXS-36 (hPGK-TOX3) plasmid 
using the primers given in Table 5. The forward primer comprised the HA sequence. 
The PCR product was cloned into the pDONR201 entry vector (Invitrogen) by 
Gateway BP recombination via flanking attB sites, and the insert was subsequently 
transferred into the pSD-69 lentiviral hPGK destination vector by LR recombination 
to give the HA-TOX3 lentiviral expression vector pER-47. 
 
Table 5. PCR primers used for HA-TOX3 cloning 
Name Sequence (5’-3’) 
oER20 (attB1_HA-TOX3 
fwd) 
GGCAAGTTTGTACAAAAAAGCAGGCCACCATGTACCCATACGATGTTCCA 
GATTACGCTGGCGGATCCATGGATGTGAGGTTCTACCCCGCGGCGGCC 
oER21 (TOX3_attB2_rev) 
CCACTTTGTACAAGAAAGCTGGGTCTAGATTCAGAAAATACTGACCTGC 
GATAATACTTGAGTCTGTGTCTGAG 
 
2.3.5 TOX3 lentiviral small hairpin microRNA vectors 
A set of two pGIPZ lentiviral small hairpin microRNA constructs directed against  
sequences in the 3’ untranslated region of TOX3 (pXS-88 and pXS-89) and a 
scrambled pGIPZ control vector (pXS-62) were purchased from Open Biosystems 
(Huntsville, USA). 
 
2.3.6 Other lentiviral vectors 
The GFP-expressing lentiviral vectors pRRLsin.PPTs.hCMV.GFPpre (pXS-3) and 
pRRLsin.PPTs.hPGK.GFPpre (pXS-17) used to fluorescently label cells for 
xenografts without conferring antibiotic resistance were a kind gift from L. Naldini, 
San Raffaele Scientific Institute, Italy. pRLLsin.cPPT.MND.LUC.wpre (pER-6) 
pRLLsin.cPPT.MND.Tomato.wpre (pER-8) expressing luciferase and Tomato, 
respectively, under the control of the synthetic MND promoter were generously 
provided by H. de Verneuil, U876 INSERM, Bordeaux, France. The MND promoter 
comprises the U3 region of a modified Moloney murine leukemia virus (MoMuLV) 
LTR with myeloproliferative sarcoma virus enhancer (Li et al., 2010). The pSD-69-
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derived lentiviral expression vectors coding for ESR1 (pSD-82), TERT (pSD-83), 
BMI1 (pSD-84), and MYC (pSD-94) have been described previously (Duss et al., 
2007). 
A complete list of plasmids used in this study is included in the Appendix. 
 
2.4 RNA expression analysis 
2.4.1 Isolation and reverse transcription of RNA 
Total RNA was isolated using the Qiagen RNeasy Kit (Qiagen) according to the 
manufacturer’s recommendations. The integrity of RNA for subsequent microarray 
analysis was confirmed using the Agilent Bioanalyzer system (Agilent Technologies, 
Massy, France). RNA was quantified using a NanoDrop spectrophotometer (Thermo 
Scientific NanoDrop, Wilmington, USA). 100 ng-1 µg of total RNA were reverse 
transcribed using random hexamers and SuperScript II reverse transcriptase 
(Invitrogen). 
 
2.4.2 Quantitative PCR 
Following reverse transcription, cDNA was amplified by quantitative PCR (qPCR) 
using the Power SYBR Green PCR Master Mix and the primers detailed in Table 6 on 
the GeneAmp PCR System 9700 (both Applied Biosystems, Courtaboeuf, France). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was selected as reference 
gene by geNorm analysis (Vandesompele et al., 2002). 
 
Table 6. Primers used for quantitative PCR 
Name Sequence (5’-3’) 
oXS20 
GAPDH_qPCR_fwd 
ACATCGCTCAGACACCATGGGGA 
oXS23 
GAPDH_qPCR_rev 
CCAGGCGCCCAATACGACCAAA 
oXS24 
TOX3_qPCR_fwd 
CATACAGGGCCAGCCTCGTTTCTAAG 
oXS25 
TOX3_qPCR_rev 
TGAACAGAACGGATGGTCTGGGCTT 
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2.4.3 Microarray analysis 
Gene expression analysis of 162 primary pre-treatment tumour biopsies and 3 samples 
of normal tissue from the neoadjuvant clinical trial EORTC 10994/BIG 00-01 using 
Affymetrix GeneChip Human X3P Arrays has been described previously (Farmer et 
al., 2009; Farmer et al., 2005). Microarray analysis of TOX3 target genes was 
performed using Illumina HumanHT-12 Expression BeadChips (IntegraGen, Evry, 
France). Data were processed as described below. 
 
2.5 Protein expression analysis 
2.5.1 TOX3 antibodies 
A rabbit polyclonal peptide antibody raised against amino acids NEEDADEANR (aa 
217-226) contained in both isoforms of human TOX3 was custom-made (Abgent, 
Milton Park, UK). Two rabbits were immunised with the peptide conjugated with 
KLH (Keyhole limpet hemocyanin) in six boosts with one week between individual 
boosts. The corresponding protein A-purified sera were termed TOX3 Rb57 and 
TOX3 Rb58, respectively. TOX3 Rb57 was further affinity-purified as described 
below. A goat polyclonal peptide TOX3 antibody (ab77432) raised against amino 
acids AGDPASLDFAQC was purchased from Abcam (Abcam, Cambridge, UK). The 
latter peptide sequence corresponds to N-terminal amino acids 10-21 of human TOX3 
isoform 1 and is not contained in isoform 2. 
 
2.5.2 Preparation of whole cell extracts and protein quantitation 
Cells were washed twice in cold PBS and whole cell extracts (whole cell lysates) for 
Western blot analysis were prepared by direct lysis of cells in 2x protein loading 
buffer (4% SDS, 20% glycerol, 0.004% bromophenol blue, 160 mM Tris-HCl, pH 
6.8, 200 mM DTT). Equal protein loading was confirmed by Coomassie blue staining 
of a separate SDS-PAGE gel prior to Western blot analysis and by Ponceau S (Sigma) 
staining of nitrocellulose membranes following transfer. For TAP purification and co-
immunoprecipitation, cells were lysed in TAP lysis buffer, RIPA buffer, modified 
RIPA buffer or NET buffer, depending on the experiment, as described below. The 
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protein concentration was then determined using the Bio-Rad DC Protein Assay (Bio-
Rad, Hercules, USA) according to the manufacturer’s recommendations. 
 
2.5.3 Western blot analysis 
Western blotting was carried out according to standard techniques. Antibodies were 
diluted in 5% milk in PBS-Tween 20 (Sigma). The following other antibodies were 
used: TOX3 antibodies as described above, AGR2 (Abnova, Taipei City, Taiwan), 
BMI1 (Millipore), CBP epitope tag (Millipore), CITED1 (Abcam), ESR1 (Labvision 
Thermo Fisher Scientific, Fremont, USA), GFP (Santa Cruz Biotechnologies, Santa 
Cruz, USA), HA probe (Santa Cruz Biotechnologies, Santa Cruz, USA), HSP70 
(Stressgen, Enzo Life Sciences, Villeurbanne, France), IRS1 (Millipore), p16 
(Novocastra, Newcastle, UK), p21 (Santa Cruz Biotechnologies), p53 DO1 (kind gift 
from David Lane, University of Dundee, UK), PGR isoforms A and B (Dako, 
Trappes, France), α-tubulin (Sigma), YBX1 (Abcam), donkey secondary antibodies 
against rabbit and mouse IgG (GE Healthcare, Orsay, France). A comprehensive list 
of antibody clones and working concentrations is given in the Appendix. 
For peptide blocking experiments, TOX3 immunising peptide (Abgent) was added to 
the antibody solution at a concentration that was two-fold higher by mass (~150-fold 
molar excess) than the concentration of the respective TOX3 antibody. 
 
2.5.4 Co-immunoprecipitation 
For immunoprecipitation of TOX3 and interacting proteins, HEK 293T were 
transfected using calcium phosphate as described above, MCF-7 and BT-474 cells 
were transduced with lentiviruses. 107 cells were lysed in 500 µl of RIPA buffer (50 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1% 
SDS, 1 mM EDTA) or modified RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA), supplemented with 
cOmplete protease inhibitor cocktail (Roche Diagnostics, Meylan, France) and 1 mM 
PMSF. Lysates were diluted two- to ten-fold in NET buffer (50 mM Tris, pH 8.0, 150 
mM NaCl, 1% Nonidet-P40, 5 mM EDTA), supplemented with protease inhibitors 
and incubated with 1-2 µg of antibody. Antibody-antigen complexes were 
Materials and Methods 
 75 
subsequently incubated with protein A- or protein G-coupled Dynabeads (Invitrogen). 
Protein complexes were eluted in 2x protein loading buffer and analysed by Western 
blotting. 
 
2.5.5 Immunofluorescent staining 
For indirect immunofluorescent staining, established cell lines were seeded on glass 
coverslips. HEK 293T cells were calcium phosphate transfected as described above. 
MCF-7 cells were either transfected using FuGENE HD transfection reagent (Roche 
Diagnostics) according to the manufacturer’s recommendations or transduced with 
lentiviruses. Cells were fixed in 3.7% formaldehyde in PBS, incubated in 50 mM 
NH4Cl, permeabilised in 0.5% Triton X-100 and subsequently blocked in 0.2% 
gelatine. Cells were incubated with primary antibody overnight at 4ºC. The following 
day, cells were washed and incubated with fluorophore-conjugated secondary 
antibody for 1 hour at room temperature in the dark, followed by staining with 100 
ng/ml DAPI (Sigma) in PBS. Primary HMEC and BPEC were grown on conventional 
cell culture plastic or Primaria plastic, respectively, and fixed using a 1:1 mix of ice-
cold methanol and acetone. Subsequent immunofluorescent staining of primary cells 
was carried out directly on cell culture dishes as described (Duss et al., 2007). The 
following primary antibodies were used for indirect immunofluorescence: cytokeratin 
14, cytokeratin 18 (both kind gifts from Birgit Lane, University of Dundee, UK), and 
γ-H2AX (Millipore). Secondary antibodies used were: Alexa 488- or 568-conjugated 
anti-rabbit or anti-mouse (Invitrogen Molecular Probes). 
For immunofluorescent analysis of TOX3-GFP fusion protein, HEK 293T cells were 
seeded on polylysine-covered glass coverslips (Sigma) and calcium phosphate-
transfected as described above. MCF-7 cells were transduced with the TOX3-GFP 
lentivirus and seeded on coverslips. Confluent cells were washed twice with cold PBS 
and fixed using a 1:1 mix of methanol and acetone. Fixed cells were allowed to dry 
before staining with 100 ng/ml DAPI in PBS. 
For confocal microscopy, coverslips were mounted onto microscope slides using 10 
µl of Vectashield mounting medium (Vector Laboratories, Burlingame, USA) or 5 µl 
of Fluoromount-G mounting medium (SouthernBiotech, Birmingham, USA) and 
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sealed with nail polish. Slides were allowed to dry at 4ºC overnight. Analysis of 
stained cells was performed using a Zeiss LSM 510 confocal microscope. 
 
2.5.6 Immunohistochemistry 
Tissue microarrays were prepared as previously described (Banneau et al., 2010). 
Haematoxylin and eosin staining was on paraffin-embedded cell lines and tissue 
microarrays was carried out according to standard protocols. Immunohistochemical 
staining of paraffin-embedded cell lines and tissue microarrays was carried out by the 
pathology service at Institut Bergonié, Bordeaux using the Ventana ultraView 
Universal DAB Detection Kit and the automated slide stainer Ventana BenchMark 
XT (Ventana Medical Systems, Tuscon, USA) according to the manufacturer’s 
instructions. Staining conditions were optimised for each antibody: TOX3 (Abcam), 
TOX3 (Abgent), ERα, cytokeratin 14 (both Dako, Trappes, France). Stained sections 
and tissue microarrays were analysed using a Leica Leitz DMRB microscope with a 
Nikon DXM1200 camera. 
 
2.6 Tandem affinity purification (TAP) of TOX3 
2.6.1 TAP 
Tandem affinity purification (TAP) of TOX3 and interacting proteins was performed 
using the InterPlay Mammalian TAP Kit (Agilent Technologies) according to the 
manufacturer’s recommendations with the following changes made after optimisation 
of the protocol as described in the Results chapter. Briefly, HEK 293T cells were 
calcium phosphate-transfected with the NTAP-TOX3 lentiviral construct or the 
corresponding control construct as described above. 48 hours post transfection, 108 
transfected cells per condition were washed twice in cold PBS and scraped in PBS. 
Alternatively, 108 lentiviral-transduced HEK 293T cells were used per condition. All 
following steps were carried out at 4ºC, and all washes and incubation steps were 
performed with agitation of the sample. Cells were pelleted, and cell pellets were 
resuspended in 10 ml TAP lysis buffer (10 mM Tris-HCl pH 8.0, 400 mM NaCl, 
0.1% Nonidet-P40, 2 mM EDTA, 10 mM 2-mercaptoethanol), supplemented with 
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cOmplete protease and PhosSTOP phosphatase inhibitor cocktails (Roche 
Diagnostics) and 1 mM PMSF. Cells were lysed by three freeze-thaw cycles at -80ºC 
and centrifuged at 13,000 rpm in a microcentrifuge. The supernatant containing 
soluble protein was incubated with the streptavidin resin for 2 hours. Following three 
washes in 1 ml of streptavidin binding buffer (10 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 0.1% Nonidet-P40, 2 mM EDTA, 10 mM 2-mercaptoethanol) supplemented 
with all inhibitors, the TAP-tagged protein was eluted from the streptavidin resin by 
incubation in streptavidin elution buffer (10 mM Tris-HCl pH 8.0, 250 mM NaCl, 
0.1% Nonidet-P40, 2 mM biotin, 10 mM 2-mercaptoethanol) supplemented with all 
inhibitors protected from light for 1 hour. 1 ml of streptavidin eluate was 
supplemented with 20 µl streptavidin supernatant supplement at a final concentration 
of 50 mM magnesium acetate, 50 mM imidazole, 100 mM CaCl2. 1 ml of eluate was 
incubated with the calmodulin resin in 4 ml of calmodulin binding buffer (10 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Nonidet-P40, 1 mM magnesium acetate, 1 mM 
imidazole, 2 mM CaCl2, 10 mM 2-mercaptoethanol) supplemented with all inhibitors 
for 2 hours to overnight. Following three washes in calmodulin binding buffer, the 
TAP-tagged protein was eluted from the calmodulin resin by incubation in 400-500 µl 
calmodulin elution buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Nonidet-
P40, 1 mM magnesium acetate, 1 mM imidazole, 10 mM EGTA, 10 mM 2-
mercaptoethanol) for 1 hour. For silver stain and Western blot analysis, eluted protein 
was concentrated with trichloroacetic acid (TCA). To this end, TCA was added to the 
eluate to a final concentration of 15% (v/v). The solution was vortexed, incubated at 
4ºC for 30 minutes and centrifuged at 13,000 × g at 4ºC for 15 minutes in a 
microcentrifuge. The supernatant was carefully aspirated, and the precipitate was 
washed two times with 1 ml of ice-cold acetone and centrifuged at 13,000 g at 4ºC for 
10 minutes. The pellet was allowed to air-dry briefly and then resuspended in an 
appropriate volume of calmodulin elution buffer. For mass spectrometric analysis, 
eluted protein was concentrated using an Amicon Ultra-0.5 centrifugal filter device 
with a 10,000 nominal molecular weight limit (Millipore). 
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2.6.2 Optimisation of TAP conditions 
For optimisation of cell lysis, the following alternative lysis buffers were tested: KCl 
lysis buffer (20 mM Tris-HCl, pH 8.0, 400 mM KCl, 0.1% NP-40), which was 
modified from Dignam and Roeder buffers B and C for the preparation of nuclear 
extracts (Dignam et al., 1983), or NET buffer (50 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 1% NP-40, 5 mM EDTA). To optimise the streptavidin elution efficiency, SEB 
was supplemented with 400 mM NaCl or 4 mM biotin, alternatively. To block non-
specific binding of chromatin to the streptavidin beads, which could reduce the 
binding capacity of the resin for NTAP-TOX3, cell lysates were supplemented with 
100 µg/ml salmon sperm DNA. 
 
2.6.3 Silver stain analysis 
Proteins present in the individual fractions after each purification step were analysed 
by silver stain analysis using the Silver Stain Plus kit (Bio-Rad Laboratories) 
according to the manufacturer’s recommendations. 
 
2.6.4 Mass spectrometry 
For mass spectrometric analysis of purified NTAP-TOX3 and interacting proteins, 
concentrated protein was separated on a NuPAGE Bis-Tris 4-12% gradient gel 
(Invitrogen) and stained with Coomassie Brilliant Blue G-250 (colloidal blue; 30 g 
ammonium sulfate, 0.2 g Coomassie Brilliant Blue G-250, 6 ml orthophosphoric acid, 
40 ml ethanol, H2O ad 200 ml). The gel lane was separated into 16 sections. The 
protein was trypsin-digested, extracted from the gel and subsequently subjected to 
nano-scale liquid chromatographic tandem mass spectrometry (nLC-MS/MS) using a 
LTQ OrbiTrap spectrometer (Thermo Scientific). Identified peptide sequences were 
compared to the Homo sapiens UniProtKB/Swiss-Prot database 
http://www.expasy.org/sprot/. A detailed description of the mass spectrometric 
analysis is included in the Appendix. 
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2.6.5 Affinity purification of TOX3 antibody 
Rabbit polyclonal TOX3 Rb57 antibody was affinity-purified using NTAP-TOX3 
protein immobilised on streptavidin-coated magnetic beads. To this end, HEK 293T 
cells were transfected with the hPGK-NTAP-TOX3 lentiviral construct or the control 
construct, respectively, and cell lysates were prepared in TAP lysis buffer containing 
400 mM NaCl and protease inhibitors as described above. Following centrifugation to 
remove the cell debris, 5mM EDTA was added to the supernatant. Dynabeads MyOne 
Streptavidin C1 (Invitrogen) were washed three times in TAP lysis buffer 
supplemented with 5 mM EDTA and subsequently incubated with NTAP-TOX3 
lysate or NTAP control supernatant, respectively, for 1 hour at 4ºC. Beads were 
pulled down with the magnet and washed once with TAP lysis buffer containing 400 
mM NaCl, 5 mM EDTA, followed by two more washes in TAP lysis buffer 
containing 150 mM NaCl, 5 mM EDTA. TAP-tagged TOX3 was then cross-linked to 
the streptavidin-coated Dynabeads using 20 mM dimethyl pimelimidate (DMP) in 0.2 
M sodium borate, pH 9.0 for 30 minutes at room temperature. The reaction was 
stopped by incubation of the beads in 0.2 M ethanolamine, pH 8.0. Unbound NTAP-
TOX3 was removed by washing in 0.1 M glycine-HCl, pH 2.5. NTAP-TOX3-coated 
Dynabeads were subsequently incubated with TOX3 Rb57 antibody overnight at 4ºC. 
The following day, Dynabeads-NTAP-TOX3-antibody complexes were washed three 
times with 10 mM Tris-HCl pH 7.4, 150 mM NaCl. Purified TOX3 antibody (TOX3 
Rb57P) was eluted in five fractions using 200 µl of 0.1 M glycine-HCl, pH 2.5. To 
prevent denaturation of the antibody, elution fractions were neutralised immediately 
by addition of 50 µl of 1 M Tris-HCl pH 8.0. To remove antibody that bound non-
specifically to the TAP tag, the purified antibody fractions were incubated with TAP 
control-coated Dynabeads. Aliquots of each purification step were analysed by SDS-
PAGE and Coomassie Brilliant Blue staining, and the antibody specificity was tested 
by Western blot analysis. 
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2.7 Data analysis 
2.7.1 Microarray analysis 
Raw data from microarray analysis of 174 primary tumours using Affymetrix 
GeneChip Human X3P Arrays were analysed essentially as described (Farmer et al., 
2009; Farmer et al., 2005). Briefly, raw data were processed with the statistical 
programming language R (www.r-project.org), and Bioconductor packages 
(www.bioconductor.org). Gene expression was normalised with the robust multi-array 
(RMA) method implemented in the package affy. Probe sets were filtered to eliminate 
redundancy based on annotation to defined Entrez-gene entries, and for each Entrez-
gene only the most variable probe set was retained. Unsupervised clustering was 
performed using Cluster 3.0 for Mac and Java TreeView 1.1.3 with the following 
parameters: standard deviation greater than 1.5, median centre and normalize 3x, 
uncentred correlation, centroid linkage (de Hoon et al., 2004; Eisen et al., 1998; 
Saldanha, 2004). 
Selected data from microarray analysis of 51 breast cancer cell lines were taken from 
(Neve et al., 2006) and processed in Cluster 3.0 and Java Treeview as described 
above. 
Illumina microarray data of TOX3 expression in MCF-7 cells were filtered using the 
limma package in R. Normalised data were further interpreted using Cluster and Java 
Treeview. Alternatively, data were analysed by gene set enrichment analysis (GSEA) 
(Subramanian et al., 2005). Raw Illumina data (37,249 genes) were reduced to 7065 
differentially expressed genes by excluding all genes with a standard deviation of 
smaller than 0.1. The resulting data set was used as input for GSEA. Duplicates were 
removed based on HUGO gene symbols, resulting in a final set of 5988 genes. This 
gene set was used for GSEA. 
 
2.7.2 Multiple sequence alignment of amino acid and nucleotide sequences 
In order to identify evolutionary conservation, multiple sequence alignments of amino 
acid and nucleotide sequences were carried out using ClustalW, Version 2.1 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) (Chenna et al., 2003). 
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2.7.3 Analysis of amino acid and nucleotide sequences 
Plasmid sequences and chromatograms were analysed using the demo version 4.8 of 
Sequencher (Gene Codes Corporation, USA). Nucleotide and amino acid sequences 
were analysed using DNA Strider, version 1.4f6 (Douglas, 1995). Plasmid maps were 
created using A plasmid Editor, version 1.17 (ApE, 
http://biologylabs.utah.edu/jorgensen/wayned/ape/). 
 
2.7.4 Analysis of protein properties 
Physico-chemical properties of proteins and peptides were deduced from the protein 
or peptide sequence using the ProtParam tool on the ExPASy Proteomics Server 
(http://au.expasy.org/tools/protparam.html) (Gasteiger et al., 2005). 
 
2.7.5 Prediction of alternative splice sites 
Potential alternative splice sites in hUbiC-TOX3 and hUbiC-NTAP-TOX3 vectors 
were identified using two different internet-based splice site predictors 
(http://www.fruitfly.org/seq_tools/splice.html; http://spliceport.cs.umd.edu/) (Dogan 
et al., 2007; Reese et al., 1997). 
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3 Results 
3.1 Expression of TOX3 in the normal breast and breast cancer 
Several genome-wide association studies (GWAS) have identified TOX3 as a 
candidate breast cancer susceptibility gene. In addition, some of these studies suggest 
that the presence of SNPs in the regulatory region of the TOX3 gene is associated 
with an increased ER-positive breast cancer risk in particular. Using quantitative PCR 
analysis to compare TOX3 levels in human tissues, a recent study on TOX3 function 
in neurons showed that TOX3 is predominantly expressed in the brain (Dittmer et al., 
2010). However, to date no information has been available on TOX3 gene expression 
in normal breast tissue or in breast cancer. Therefore, I was interested to investigate 
TOX3 gene expression patterns in normal as well as breast cancer cells. 
 
3.1.1 TOX3 is expressed in the luminal cluster in ER-positive breast tumours 
Microarray expression analysis is an important tool to identify new genes that exhibit 
a tumour subtype-specific expression pattern, or even define a tumour subtype. 
Microarray analysis of 162 primary breast tumours and 3 normal samples from the 
EORTC 10994 clinical trial shows that TOX3 clusters with classic luminal genes such 
as GATA3, FOXA1, TFF1 and ESR1, suggesting a shared function for TOX3 and 
these genes. Moreover, TOX3 expression appears to be restricted to luminal tumours 
(Fig. 11). 
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Figure 11. TOX3 is expressed in the luminal cluster in ER-positive tumours. 
Expression microarray analysis of 162 primary breast tumours shows that TOX3 
clusters with luminal genes. Tumour samples are a subset of pre-treatment biopsies 
from patients enrolled in the EORTC 10994 clinical trial. The three main tumour 
clusters from left to right are basal-like, molecular apocrine/HER2 and luminal. 
 
3.1.2 Immunohistochemical analysis of tissue microarrays confirms TOX3 
expression in luminal tumours 
Immunohistochemical (IHC) staining of tumour samples for prognostic markers is a 
valuable technique in the clinical setting. IHC further provides information about the 
expression pattern of the protein of interest in situ in the tissue and cell type as well as 
about its subcellular localisation. I therefore wanted to develop an IHC staining 
protocol for the detection of TOX3 protein in tumour sections. I first tested a custom-
made rabbit polyclonal peptide antibody TOX3 Rb57 as well as the only antibody that 
was commercially available at the time, the rabbit polyclonal peptide antibody 
ab77432 (Abcam), by IHC staining of HEK 293T cells transfected with the lentiviral 
TOX3 expression vector pXS-39, which is described in the following section (Fig. 
12). The cells were formalin-fixed and paraffin-embedded prior to IHC staining. 
Neither antibody detected endogenous TOX3 protein in untransfected HEK 293T 
cells, while ectopically expressed TOX3 exhibited nuclear staining (Fig. 12). 
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Figure 12. Optimisation of TOX3 immunohistochemistry. 
HEK 293T cells were transiently transfected with the lentiviral TOX3 expression 
vector pXS-39. 48 hours post transfection, cells were pelleted, formalin-fixed, 
paraffin-embedded, and sectioned. Staining with TOX3 Rb57 (left) or TOX3 ab77432 
(Abcam) (right) antibody shows nuclear localisation of ectopically expressed TOX3. 
Low and high magnification are shown. 
 
Preliminary IHC staining of breast tumour samples using the TOX3 ab77432 antibody 
under optimised conditions showed only diffuse staining resembling the background 
staining of untransfected HEK 293T cells (data not shown). The diffuse staining was 
irrespective of the breast tumour subtype. I therefore decided to continue with the 
TOX3 Rb57 antibody for staining of tissue microarrays (TMAs) containing biopsies 
of ER-positive and ER-negative tumours as well as normal control tissue. Luminal 
tumours exhibited both nuclear and cytoplasmic TOX3 staining, while basal tumours 
were TOX3-negative. TOX3 expression was also observed in normal luminal 
epithelial cells and surprisingly, in myoepithelial cells. Moreover, stromal tissue, in 
particular lymphocytes, stain positive for TOX3 (Fig. 13). 
The finding that TOX3 localised to the cytoplasm was somewhat surprising as TOX3 
as a putative transcription factor would be expected to localise predominantly to the 
nucleus, as I observed for ectopically expressed TOX3, but it is not possible to 
conclude from the IHC results whether cytoplasmic staining is due to the quality of 
the antibody or to regulatory mechanisms that may sequester TOX3 in the cytoplasm. 
In order to rule out staining artefacts that are due to antibody background, I affinity-
purified the custom-made TOX3 Rb57 antibody, as described in detail in chapter 4. 
While the purified antibody proved useful for Western blot analysis of TOX3 
expression, it appeared to be too dilute as it gave no signal in immunohistochemical 
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staining of TOX3 even in the transfected positive control HEK 293T cells (data not 
shown). Unfortunately, I was not able to repeat the antibody purification due to time 
constraints. 
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Figure 13. TOX3 is expressed in luminal but not in basal tumours. 
TOX3 immunohistochemical staining of a tissue microarray of primary breast 
tumours. Luminal tumours exhibit both nuclear and cytoplasmic TOX3 expression 
(left column), while basal tumours are TOX3-negative (middle column). TOX3 
expression is also found in normal ductal tissue (right column, top panel) and stromal 
tissue (right column, bottom tissue). Luminal and basal tissue are shown at low (top 
panels) and high (bottom panels) magnification. 
 
3.1.3 A model system for endogenous TOX3 expression 
The establishment of a robust model system was crucial for the characterisation of 
TOX3 function both at the molecular and cellular level. Established breast cancer cell 
lines are very helpful as an initial model for the study of new genes. Unlike other 
luminal genes such as GATA3 or FOXA1, TOX3 is not expressed in the classic 
luminal breast cancer cell lines MCF-7 and T-47D (Fig. 14, 15). Therefore I turned to 
the comprehensive 2006 study of 51 breast cancer cell lines by Gray and colleagues 
(Neve et al., 2006). Notably, all TOX3-overexpressing cell lines in their study were 
classified as luminal, with the exception of two cell lines (SUM225 and SUM190PT), 
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which were basal. Based on the expression data provided by Gray et al. (Fig. 14) and 
availability, I chose to further investigate TOX3 expression in the luminal breast 
cancer cell lines BT-474, ZR-75-1, MDA-MB-361, MDA-MB-415 and UACC-812. 
 
 
Figure 14. TOX3 expression in 51 breast cancer cell lines. 
Unsupervised hierarchical clustering of 51 breast cancer cell lines based on their 
expression of TOX3 and a selection of genes defining the luminal and molecular 
apocrine breast cancer subtypes. Data taken from (Neve et al., 2006). 
 
Western blot analysis of a selection of breast cancer cell lines confirmed the absence 
of TOX3 expression in MCF-7, T-47D, CAMA-1, MCF-10A, MDA-MB-231, MDA-
MB-468, and MDA-MB-453 cells (Fig. 15 A, Table 7). Consistent with the 
expression data in the study by Gray and co-workers, TOX3 expression was 
detectable in BT-474, MDA-MB-361, MDA-MB-415, ZR-75-1 and UACC-812 cells 
to a varying degree (Fig. 15 B). Relative TOX3 expression appeared to be highest in 
BT-474 and MDA-MB-361 cells, followed by ZR-75-1, MDA-MB-415 and UACC-
812 cells. 
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Figure 15. Western blot analysis of TOX3 expression in breast cancer cell lines. 
Western blot analysis of TOX3 protein expression in different breast cancer cell lines. 
(A) Western blot analysis of cell lines that do not express TOX3 protein. (B) TOX3-
positive cell lines express TOX3 at varying levels. Whole cell lysates were prepared 
by direct lysis in 2x loading buffer. The unpurified TOX3 Rb57 antibody was used for 
the Western blot in (A), while affinity-purified antibody TOX Rb57 was used for 
Western blot analysis shown in (B). The open arrowhead marks a non-specific band 
and the filled arrowhead indicates a TOX3-specific band. 
 
Based on TOX3 expression levels and growth properties, I chose the following breast 
cancer cell lines as model systems to investigate TOX3 function. MCF-7 cells were 
selected for the majority of TOX3 overexpression experiments, as they do not express 
TOX3 but may provide an adequate luminal environment. BT-474 and MDA-MB-361 
were chosen as luminal cell model systems for endogenous TOX3 expression because 
they exhibited the highest relative TOX3 protein levels in Western blot analysis (Fig. 
15). MDA-MB-231 cells were used as a TOX3-negative basal-like tumour cell model. 
Immortalised MCF-10A cells do not express TOX3 (Fig. 42 B) and were used for 
differentiation assays. 
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Table 7. TOX3 status of breast cell lines 
Cell line TOX3 ER PGR HER2 Gene cluster 
BT-474 + + + + Luminal 
MDA-MB-361 + + - + Luminal 
MDA-MB-415 + + -  Luminal 
UACC-812 +/- + - + Luminal 
ZR-75-1 +/- + -  Luminal 
CAMA-1 - + -  Luminal 
MDA-MB-231 - - -  Basal 
MDA-MB-453 - - -  Luminal 
MDA-MB-468 - - -  Luminal 
MCF-7 - + +  Luminal 
MCF-10A - - -  Basal 
T-47D - + +  Luminal 
Data are taken from (Neve et al., 2006). TOX3 expression data were confirmed by Western blot 
analysis. 
 
3.1.4 TOX3 expression in the normal breast epithelium 
In addition to investigating TOX3 function in breast cancer, I aimed to understand the 
role of TOX3 in the normal breast epithelium. Using Western blot analysis I was not 
able to detect TOX3 expression in unsorted normal human mammary epithelial cells 
maintained in conventional HMM+ medium (termed HMEC in the following) or WIT 
medium (BPEC) (Fig.16 A) (Duss et al., 2007; Ince et al., 2007). Quantitative PCR 
analysis of unsorted cells freshly isolated from reduction mammoplasty tissue 
confirmed this finding (data not shown). In contrast, preliminary analysis of FACS-
sorted mammary epithelial cells using the surface markers CD10 and EpCAM to 
separate stem and progenitor-enriched CD10+ myoepithelial/basal and mature luminal 
EpCAM+ subpopulations, respectively, suggested that relative TOX3 expression was 
highest in the mature luminal subset (data not shown). Owing to the unavailability of 
sufficient mammoplasty sample, the data could not be normalised. 
However, the observed trend was consistent with expression array data from the 
Smalley group, which showed that relative TOX3 expression was highest in luminal 
ER+ cells (CD24high Sca-1+), while luminal ER- cells (CD24high Sca-1-) show 
significantly lower TOX3 levels and myoepithelial cells (CD24-/low Sca-1-) do not 
express TOX3 (Fig. 16 B) (Kendrick et al., 2008). A recent study by the Visvader 
group further confirmed that TOX3 expression was upregulated in the mature luminal 
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compartment (CD49f- EpCAM+) but not in the MaSC-enriched (CD49fhigh EpCAM-) 
and luminal progenitor (CD49f+ EpCAM+) subpopulations (Fig. 16 C). TOX3 did not 
appear to be expressed in stromal cells (CD49f- EpCAM-) (Fig. 16 C). Importantly, 
TOX3 was the 7th most conserved gene between the human and mouse mature 
luminal subsets (Table 8) (Lim et al., 2010). Interestingly, CITED1, which has been 
shown to cooperate with TOX3 to activate transcription in neurons (Dittmer et al., 
2008) ranked 10th in the list of conserved luminal genes (Table 8). The expression 
data from the Visvader group further showed that expression of LOC643714, the 
putative non-coding RNA gene just upstream of the TOX3 gene, did not change 
across epithelial subpopulations (Fig. 16 C). 
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Figure 16. TOX3 expression in the normal human and mouse mammary gland 
(A) Western blot analysis shows that unsorted BPEC and HMEC do not express 
endogenous TOX3 at levels that are detectable with the unpurified TOX3 Rb57 
antibody. BPEC stably expressing TOX3 under the control of the human PGK 
promoter (pXS-36) were used as a positive control. (B) Microarray analysis of mouse 
mammary epithelial subpopulations isolated using CD24 and Sca1, as described in the 
text. Relative expression of selected luminal genes and TOX3 in mature epithelial 
subpopulations is shown. Expression data were taken from (Kendrick et al., 2008). 
(C) Transcriptional profiling of human mammary epithelial subpopulations sorted 
using the markers CD49f and EpCAM, as described the text. Relative expression of 
selected genes including TOX3 is shown. Expression data were taken from (Lim et 
al., 2010). 
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Table 8. Conserved genes in the mature luminal epithelial subpopulation 
Symbol Human Log Fold Change Symbol Mouse Log Fold Change 
Average Log 
Fold Change 
FOXA1 4.85 Foxa1 2.90 3.87 
DNAJC12 4.44 Dnajc12 2.57 3.51 
MLPH 5.30 Mlph 1.67 3.48 
SPINK1 4.69 Spink3 2.05 3.37 
RASEF 4.55 Rasef 2.14 3.34 
BATF 4.84 Batf 1.45 3.15 
TOX3 4.09 Tox3 2.13 3.11 
HMGCS2 3.51 Hmgcs2 2.58 3.05 
EEF1A2 5.13 Eef1a2 0.85 2.99 
CITED1 2.90 Cited1 3.05 2.98 
ABCC8 3.59 Abcc8 2.23 2.91 
PRLR 3.22 Prlr 2.59 2.90 
SLC7A2 3.65 Slc7a2 2.07 2.86 
SLC16A5 2.57 Slc16a5 2.87 2.72 
ALDH3B2 4.01 Aldh3b2 1.18 2.59 
SLC40A1 3.58 Slc40a1 1.42 2.50 
WNT4 2.20 Wnt4 2.80 2.50 
SPDEF 2.79 Spdef 2.17 2.48 
REEP6 2.98 Reep6 1.95 2.46 
SULT2B1 2.90 Sult2b1 1.94 2.42 
PGR 2.22 Pgr 2.30 2.26 
PVALB 1.59 Pvalb 2.89 2.24 
MBOAT1 2.03 Mboat1 2.33 2.18 
TNFSF11 1.25 Tnfsf11 3.07 2.16 
TGM2 3.10 Tgm2 1.21 2.15 
FLVCR2 2.85 Mfsd7c 1.41 2.13 
FAAH 1.51 Faah 2.73 2.12 
SLC22A18 1.96 Slc22a18 2.17 2.07 
ESR1 2.39 Esr1 1.69 2.04 
MYB 2.44 Myb 1.59 2.01 
Table is adapted from and is described in (Lim et al., 2010). Fold changes were determined by pairwise 
comparison of gene expression in epithelial subpopulations for each species. 
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3.2 Identification of TOX3 interacting proteins by tandem affinity 
purification 
The sequencing of the human genome has made it possible to analyse complex 
biological networks of genes and the proteins they encode on a genome-wide basis. 
The identification of interactions between proteins is one way to obtain insight into 
their function. Traditionally, protein-protein interactions and new interacting partners 
of a given protein have been identified using large-scale two-hybrid screening (Ito et 
al., 2000; Uetz et al., 2000). Limitations of this method include the requirement of 
large libraries of fusion constructs as well the low degree of information provided, for 
instance the lack of information about the stoichiometry of protein interactions. 
Biochemical purification in combination with mass spectrometric analysis allows for 
the identification of interacting partners of a given protein in a proteome-wide 
approach. The availability of complete genomic and proteomic sequences facilitates 
rapid comparison of mass spectrometric profiles of the protein complexes and the 
identification of the contained proteins. The limiting factor in this case is the protein 
purification step, which requires the knowledge of the biochemical properties of 
target proteins. Affinity purification of proteins using an affinity tag largely 
circumvents this problem. 
To gain clues to the function of TOX3, I therefore chose tandem affinity purification 
(TAP) in combination with mass spectrometric analysis to purify TOX3 and identify 
its interacting proteins. TAP was originally developed in yeast for the purification of 
protein complexes under native conditions, even when expressed at physiological 
levels, without the requirement of prior knowledge of complex composition or 
function (Puig et al., 2001; Rigaut et al., 1999). Tandem affinity purification involves 
a two-step affinity purification of the protein of interest that is fused to a bipartite 
affinity tag. In the original study, the TAP tag consisted of two IgG-binding units of 
Staphylococcus aureus protein A and calmodulin binding peptide (CBP), which were 
separated by a TEV protease cleavage site, allowing for the purification of the protein 
of interest using an IgG column, followed by TEV protease cleavage of the protein A 
tag and subsequent purification using a calmodulin colum (Rigaut et al., 1999). I used 
the InterPlay Mammalian TAP protocol (Agilent Technologies), a modified tandem 
affinity purification protocol involving tandem purification via the affinity tags 
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streptavidin binding peptide (SBP) and CBP. SBP is a synthetic peptide that was 
identified in a screen for peptides that bind to streptavidin with high affinity (2 × 10-9 
M) and can be eluted from streptavidin with biotin (Keefe et al., 2001; Wilson et al., 
2001). The CBP tag is derived from a C-terminal fragment of myosin light-chain 
kinase and binds to calmodulin with high affinity (1 × 10-9 M) in the presence of 
calcium (Stofko-Hahn et al., 1992). Elution from the calmodulin resin is achieved by 
chelation of calcium with EGTA. I decided to use the InterPlay TAP protocol because 
it was optimised for the purification of proteins expressed at physiological levels in 
mammalian cells. In addition, since biochemical properties of TOX3 protein were 
unknown, I considered gentle wash conditions and small molecule elution instead of 
protease cleavage as advantageous. The TAP strategy is depicted in Figure 17. 
 
 
Figure 17. Tandem affinity purification protocol. 
Schematic of the tandem affinity purification protocol. NTAP-TOX3 is expressed in 
mammalian cells. In the first purification step, whole cell extracts are incubated with 
streptavidin resin. Following three washes, NTAP-TOX3 and interacting protein 
complexes are eluted using biotin. In the second purification step, NTAP-TOX3 is 
allowed to bind to calmodulin resin and subsequently eluted using EGTA. Eluted 
protein is concentrated, separated by SDS-PAGE and analysed by mass spectrometry. 
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3.2.1 Lentiviral NTAP expression constructs 
The goal of the tandem affinity purification of TOX3 was to identify the proteins in 
complex with TOX3 under physiological conditions. I ultimately intended to carry out 
the TAP purification using breast cancer cells as well as normal mammary epithelial 
cells. Therefore, I chose to express NTAP-TOX3 using lentiviral vectors, which 
readily infect dividing and quiescent cells and allow for the efficient creation of cell 
lines stably expressing the gene of interest. I created three sets of lentiviral expression 
vectors coding for TOX3 fused to an N-terminal TAP tag and their respective control 
vectors, which coded for the TAP tag only (Fig. 18 A and Appendix). The different 
vectors allowed the expression of NTAP-TOX3 at high levels using the CMV (pXS-
85 and pXS-72 as control) or human UbiC promoters (pXS-96 and pXS-99), or at low 
levels using the human PGK promoter (pXS-95 and control pXS-98). The human 
PGK promoter had previously been shown to be active in mammary epithelial 
progenitor and mature cells (Duss et al., 2007). Since the TAP tag (Fig. 18 B) was 
cloned from the parental pNTAP vector contained in the Mammalian Interplay TAP 
system (Agilent Technologies) only minimal optimisation of the purification protocol 
was expected. 
Transient transfection of the different TAP constructs into HEK 293T cells and 
subsequent Western blot analysis confirmed that both TOX3 and the TAP tag were 
expressed from all constructs (Fig. 19). The hUbiC and CMV promoters drove 
expression at a level that was about 10-fold higher than the level of hPGK promoter-
controlled expression. NTAP-TOX3 expression from both the CMV and the hPGK 
vector resulted in a band of approximately 75 kDa, consistent with the predicted size 
of 72 kDa (Fig. 18 C). In addition, CMV-NTAP-TOX3 produced two smaller bands 
at approximately 50 and 60 kDa (Fig. 19), which may be due to degradation products. 
Surprisingly, expression of NTAP-TOX3 from the hUbiC vector resulted in several 
bands, the biggest of which with an apparent molecular weight of approximately 100 
kDa. Like the CMV construct, the hUbiC-NTAP-TOX3 vectors produced several 
smaller bands, the most prominent one of which ran at approximately 80 kDa. 
Western blot analysis of TAP tag expression using an antibody against the CBP 
moiety of the tag confirmed this banding pattern (Fig. 19). Western blot analysis of 
the control constructs using the CBP antibody detected a band of approximately 35 
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kDa for the hUbiC and CMV control constructs, while the TAP tag was not detected 
by the CBP antibody in the hPGK control lane (Fig. 19). 
 
A
 
 
Figure 18. NTAP-TOX3 lentiviral expression vectors. 
(A) Schematic of the three different lentiviral NTAP-TOX3 expression constructs 
(pXS-85, pXS-95 and pXS-96) used in this study; the hPGK-NTAP control vector 
(pXS-98) is shown as an example of the corresponding control vectors. For an 
enlarged version of the maps, see Appendix. (B) Peptide sequence of the TAP tag 
components streptavidin binding peptide (SBP), calmodulin binding peptide (CBP) 
and linker regions. (C) Schematic of the NTAP-TOX3 protein domains. Molecular 
weights were determined using the ProtParam tool. HIV, Human immune deficiency 
virus; SV40, Simian vacuolating virus 40; ORI, origin of replication; ampR, 
ampicillin resistance gene; RSV, Rous sarcoma virus; LTR, long terminal repeat; SIN 
LTR, self-inactivating LTR; psi, packaging element; RRE, Rev responsive element; 
cPPT, central polypurine tract; attB, Gateway recombination site; WPRE, Woodchuck 
hepatitis post-transcriptional regulatory element; mPGK prom, murine 
phosphoglycerate kinase 1 promoter; hPGK prom, human PGK promoter; CMV 
prom, cytomegalovirus promoter; hUbiC, human ubiquitin C promoter; puroR (pac), 
puromycin resistance gene (puromycin N-acetyl-transferase). 
Results 
 97 
 
Since the correct plasmid sequence had been confirmed by DNA sequencing, the fact 
that the band corresponding to the TAP tag expressed from the hPGK vector was not 
detected was presumably due to the comparatively low expression level of the hPGK 
construct and the poor antibody quality. 
 
 
Figure 19. Western blot analysis of NTAP constructs. 
Western blot analysis of TOX3 and CBP expression of the different lentiviral NTAP-
TOX3 and control constructs. Western blot analysis for CBP did not detect the TAP 
tag in the hPGK control lane. 
 
Western blot analysis for ubiquitin ruled out posttranslational modification by 
ubiquitin as an explanation for the high molecular weight isoforms seen for the 
hUbiC-NTAP-TOX3 construct (data not shown). Notably, both the hUbiC and the 
CMV lentiviral vector backbone also contained the marker gene GFP under the 
control of the human PGK promoter (Fig. 18 A), which was expected to result in 
green fluorescence of cytoplasmic GFP upon transfection. HEK 293T cells 
transfected with the hUbiC-NTAP control vector exhibited cytoplasmic GFP 
fluorescence, while GFP in the hUbiC-NTAP-TOX3 transfected cells localised almost 
entirely to the nucleus (Fig. 20 A). This led me to speculate that this was due to an in-
frame fusion of the TOX3 ORF with the downstream GFP ORF through alternative 
splicing, which resulted in a functional TOX3-GFP fusion protein that localised to the 
nucleus due to the presence of the nuclear localisation signal (NLS) in TOX3. The 
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other TOX family members have been shown to localise to the nucleus (Kajitani et 
al., 2004; Lee et al., 2009; Wilkinson et al., 2002). 
  
 
 
Figure 20. The hUbiC lentiviral vector produces a TOX3-GFP fusion protein. 
(A) HEK 293T cells were transiently transfected with the hUbiC-NTAP control 
vector (left) or hUbiC-NTAP-TOX3. Subcellular localisation of GFP was analysed 
using an Olympus CKX41 fluorescent microscope at 20 × magnification (top panel, 
phase contrast; bottom panel, GFP). (B) Western blot analysis of GFP expressed from 
hUbiC-TAP constructs. Whole cell lysates from transiently transfected HEK 293T 
cells were separated by 10% SDS-PAGE analysed by Western blot. (C) Western blot 
analysis of TOX3 transiently expressed in HEK 293T cells from the hUbiC-TOX3 
vector (pXS-39) shows several isoforms of TOX3. (D) Confocal microscopy analysis 
of GFP subcellular localisation in MCF-7 cells transiently transfected with the hUbiC-
TOX3 (pXS-39, bottom panel) or a hUbiC-DsRed2 control vector (pXS-41, top 
panel). (E) Prediction of splice sites in the lentiviral plasmid sequence. The 3’ end of 
the TOX3 ORF is shown in yellow, the 5’ end of the GFP ORF is highlighted in 
green. Predicted splice donor/acceptor sites are marked in red. 
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E 
 
8641  AGTCTCAGAC ACAGACTCAA GTATTATCGC AG|GTCAGTAT TTTCTAGGAC CCAGCTTTCT 
      TCAGAGTCTG TGTCTGAGTT CATAATAGCG TC|CAGTCATA AAAGATCCTG GGTCGAAAGA 
 
8701  TGTACAAAGT GGTGATCGCG TGTCGAATTC CACGGGGTTG GGGTTGCGCC TTTTCCAAGG 
      ACATGTTTCA CCACTAGCGC ACAGCTTAAG GTGCCCCAAC CCCAACGCGG AAAAGGTTCC 
// 
9121  GGGGTGTGGG GCGGTAGTGT GGGCCCTGTT CCTGCCCGCG CGGTGTTCCG CATTCTGCAA 
      CCCCACACCC CGCCATCACA CCCGGGACAA GGACGGGCGC GCCACAAGGC GTAAGACGTT 
 
9181  GCCTCCGGAG CGCACGTCGG CAGTCGGCTC CCTCGTTGAC CGAATCACCG ACCTCTCTCC 
      CGGAGGCCTC GCGTGCAGCC GTCAGCCGAG GGAGCAACTG GCTTAGTGGC TGGAGAGAGG 
 
9241  CCAG|GGGGAT CCACCGGTCG CCACCATGGT GAGCAAGGGC GAGGAGCTGT TCACCGGGGT 
      GGTC|CCCCTA GGTGGCCAGC GGTGGTACCA CTCGTTCCCG CTCCTCGACA AGTGGCCCCA 
 
 
Yellow  TOX3 ORF 6960-8687 
Green  GFP ORF 9266-9985 
Red  Predicted splice donor/acceptor sites 
 
Donor: 
Start End Score Exon   Intron 
8666  8680 0.94 atcgcag|gtcagtat 
 
Acceptor: 
Start End Score Intron               Exon 
9224  9264 0.90 atcaccgacctctctccccag|ggggatccaccggtcgccac 
 
Figure 20. continued 
 
Analysis of the lentiviral plasmid sequence using splice site prediction software 
indeed revealed the presence of putative splice donor and acceptor sites at the 3’ end 
of the TOX3 ORF and just upstream of the 5’ end of the GFP ORF, respectively (Fig. 
20 E). Alternative splicing at these sites would delete only part of the last exon and 
stop codon of the TOX3 ORF. The presence of a TOX3-GFP fusion protein upon 
transfection of 293T cells was confirmed by Western blot analysis for GFP (Fig. 20 
B). Using the ProtParam tool, the size of the NTAP-TOX3-GFP fusion construct is 
predicted to be 99.2 kDa, which is consistent with the highest running band in the 
Western blot (Fig. 20 B). Correctly spliced GFP was expected to run at 27 kDa, which 
could be seen both in the control and NTAP-TOX3 lanes. Alternative splicing of the 
transcript prior to integration of the viral vector would also explain the observation 
that functional hUbiC-TOX3 lentiviral particles could, if at all, only be produced at 
very low titres as measured by green fluorescence of infected cells. Alternative 
splicing appeared to also affect the hUbiC-NTAP control vector, as part of the TAP 
tag, appeared to be fused to GFP and gave rise to a band at approximately 35 kDa in 
the Western blot (Fig. 19, 20). 
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Due to the GPF fusion, the hUbiC-NTAP-TOX3 construct was not used for the final 
tandem affinity purification experiments but prior to finding an explanation for the 
high molecular weight bands observed in the Western blot, I used the construct for 
preliminary optimisation of the TAP conditions because of its high protein yield. 
As discussed in the following chapter, I also created a hUbiC-TOX3 lentiviral 
construct (pXS-39) lacking the TAP tag (Fig. 31). Since the hUbiC-TOX3 vector 
differed from the hUbiC-NTAP-TOX3 vector only in the absence of the TAP tag, it 
was not surprising that the hUbiC-TOX3 vector, too, was alternatively spliced and 
produced a TOX3-GFP fusion protein. Western blot analysis for TOX3 confirmed the 
presence of the corresponding high molecular weight bands (Fig. 20 C), and 
microscopic analysis of GFP localisation in MCF-7 cells transiently transfected with 
the hUbiC-TOX3 vector showed exclusive nuclear localisation of GFP (Fig. 20 D). In 
contrast, GFP expressed from the corresponding control vector (pXS-41) localised 
both to the cytoplasm and the nucleus (Fig. 20 D). 
 
 
Figure 21. The CMV-NTAP control lentiviral vector produces an NTAP-GFP 
fusion protein. 
Western blot analysis of purified NTAP-TOX3 and control NTAP tag, which had 
been expressed from the CMV-NTAP vector set in HEK 293T cells. A prominent 
band at approximately 35 kDa in the control lane is detected by both the CBP and 
GFP antibodies and likely represents a TAP-tag GFP fusion protein. 
 
As the CMV-NTAP control vector shared large parts of the backbone of the hUbiC 
vector including the GFP ORF downstream of the TAP tag ORF (Fig. 19 A), it was 
not surprising that it gave rise to a GFP fusion protein (Fig. 21). As a consequence, 
the set of CMV-TAP vectors was not used for further TAP experiments. Curiously, 
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the alternative splice did not seem to take place in the CMV-NTAP-TOX3 vector 
(Fig. 21). 
 
3.2.2 Optimisation of TAP purification conditions 
For all initial TAP experiments that were carried out to optimise the purification 
conditions, HEK 293T cells were calcium phosphate transfected with the respective 
NTAP-TOX3 and control constructs, and cell lysates were prepared 48 hours post 
transfection. Pilot TAP purification experiments demonstrated that NTAP-TOX3 
could be successfully purified using the standard conditions recommended for the 
Agilent InterPlay Mammalian TAP System. The first purification step using 
streptavidin resin removed a large part of contaminants. Further purification was 
achieved by binding of TAP-tagged TOX3 to the calmodulin resin (Fig. 22). 
However, initial experiments also demonstrated that three steps in the purification 
protocol limited the final protein yield. The lysis buffer supplied with the InterPlay 
Mammalian TAP purification kit contained 150 mM NaCl in addition to 10 mM Tris-
HCl, pH 8.0, 0.1% NP-40 and 2 mM EDTA. It was not possible to extract the 
majority of TOX3 protein from the nucleus under these conditions, as a significant 
part of the protein appeared to remain in the cell debris pellet after centrifugation of 
the cell lysates (Fig. 22). I hypothesised that this was due to a strong association of 
TOX3 with chromatin. In addition, elution from both streptavidin and calmodulin 
resins was not efficient. This is a known caveat. Recovery rates of 50% for the CBP-
tag, for instance, have been reported (Rigaut et al., 1999). However, the recovery rate 
in my pilot experiments after binding to the calmodulin resin was below 50% as 
judged by silver stain and Western blot analysis. Therefore, I tested several 
modifications of the standard protocol but at the same time, I avoided to change the 
purification conditions too drastically so as not to disrupt potential TOX3-containing 
protein complexes. 
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Sample 
Equivalent of 
total material 
in percent 
Cell pellet 0.01 
Cell lysate 0.0025 
Streptavidin 
flowthrough 
0.0025 
Streptavidin 
resin + protein  
1 
Streptavidin 
resin post 
elution 
2 
Streptavidin 
eluate 
0.5 
Calmodulin 
flowthrough 
0.2 
Calmodulin 
resin + protein  
1.25 
Calmodulin 
resin post 
elution 
4 
Calmodulin 
eluate 
2.5 
 
Figure 22. Tandem affinity purification pilot experiment. 
Silver stain analysis of a typical TAP purification. HEK 293T cells were transfected 
with the UbiC-NTAP-TOX3 (pXS-96) construct. Tandem affinity purification was 
carried out using standard conditions recommended for the InterPlay Mammalian 
TAP system. Individual purification steps were verified by silver staining following 
10% SDS-PAGE. Amounts given in the table are relative to the total amount of 
sample at the respective purification step (equalling the starting material minus loss 
occurring at each step). The asterisk indicates the NTAP-TOX3-GFP fusion protein. 
Arrows indicate putative isoforms of NTAP-TOX3. Negative control samples are not 
shown. 
 
To optimise cell lysis and to increase solubility of TOX3, I compared the following 
lysis conditions: 150 mM NaCl/freeze-thaw (standard protocol), 400 mM 
NaCl/freeze-thaw, 400 mM KCl (modified Dignam and Roeder B/C buffer for the 
preparation of nuclear extracts)/freeze-thaw and NET buffer/freeze-thaw (Dignam et 
al., 1983). All conditions were tested without (standard protocol) or with sonication of 
the cell lysate (Fig. 23 A). Following lysis, cell lysates were centrifuged and both the 
pellet, which was expected to contain cell debris and genomic DNA and the non-
dissociated chromatin fractions, and the supernatant containing soluble protein were 
subjected to Western blot analysis for TOX3. I expected to see higher relative 
amounts of TOX3 in the supernatant in contrast to lower relative amounts in the pellet 
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as a result of more efficient extraction of TOX3 from cellular chromatin. However, no 
significant difference was observed between the different lysis conditions (Fig. 23 A, 
results for NET buffer not shown). Therefore, the original TAP lysis buffer was used 
for further large-scale TAP purification experiments. The salt concentration was 
increased to 400 mM NaCl nevertheless as some preliminary experiment had 
suggested that extraction of TOX3 from cellular chromatin was more efficient using 
this condition. 
 
 
 
Figure 23. Optimisation of TAP lysis and elution conditions. 
(A) TOX3 Western blot analysis of HEK 293T cells transiently transfected with the 
hPGK-NTAP-TOX3 (top) or hUbiC-NTAP-TOX3 vector (bottom). Cells were lysed 
using different salt concentrations with or without sonication, as described in the text. 
(B) TOX3 Western blot analysis of HEK 293T cells transiently transfected with the 
hUbiC-NTAP-TOX3 vector. Elution from the streptavidin resin was tested using 
different salt and biotin concentrations. Equal amounts were loaded across sample 
groups (for instance all eluate fractions) but not between samples from different 
purification steps, which are thus not directly comparable. 
 
To optimise the streptavidin elution efficiency, streptavidin elution buffer (SEB) was 
supplemented with 150 mM NaCl (standard concentration) or 400 mM NaCl. 
Alternatively, standard SEB was supplemented with 4 mM instead of 2 mM biotin, 
alternatively (Fig. 23 B). Doubling the biotin concentration did not increase the TOX3 
protein yield in the eluate, which is probably explained by that fact that the high 
affinity binding of biotin to streptavidin (dissociation constant Kd = 10-15 M) is 
already sufficient to replace SBP at all binding sites at a biotin concentration of 2 mM 
(Weber et al., 1989). Relative amounts of TOX3 protein remaining bound to the 
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streptavidin resin after the elution appeared to be lower in the presence of 400 mM 
NaCl but the relative amount of TOX3 was not higher in the corresponding eluate 
(Fig. 23 A). Due to the inconclusive results, the standard salt concentration of 150 
mM NaCl was used for large-scale experiments. To block non-specific binding of 
chromatin to the streptavidin beads, thereby reducing the binding capacity of the resin 
for NTAP-TOX3, cell lysates were supplemented with 100 µg/ml salmon sperm DNA 
during incubation with the streptavidin beads. This appeared to slightly increase the 
yield of TOX3 in the streptavidin eluate (data not shown) but the difference was 
deemed negligible and salmon sperm DNA was not used in later TAP purifications. 
Increasing the concentration of chelating agent EGTA, which was used to disrupt 
calcium-dependent binding of CBP to the calmodulin resin, was two-fold to 10 mM 
appeared to augment the TOX3 protein yield in the calmodulin eluate fraction (data 
not shown). The calmodulin elution buffer (CEB) was modified accordingly in further 
TAP purifications. 
 
3.2.3 Tandem affinity purification of TOX3 
To identify proteins that interact with TOX3, a large-scale TAP purification of 
NTAP-TOX3 was carried out. HEK 293T cells were transiently transfected with the 
hPGK-NTAP-TOX3 or hPGK-NTAP-TOX3 lentiviral vector. Transfected HEK 293T 
cells were chosen for the initial mass spectrometry analysis because HEK 293T cells 
can be easily produced in large quantities, and they can be transfected using calcium 
phosphate at an efficiency nearing 100%, thus maximising the final TOX3 protein 
yield. 48 hours following transfection, approximately 2 × 108 cells per condition were 
harvested using the optimised conditions. Correct NTAP-TOX3 expression was 
confirmed by silver stain and Western blot analysis (Fig. 24). 
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Figure 24. Silver stain and Western blot analysis of NTAP-TOX3 TAP. 
TAP purification of TOX3 expressed from the hPGK-NTAP-TOX3 lentiviral vector 
in HEK 293T cells. Proteins were separated by 4-12% gradient gel electrophoresis. 
Proteins present after each of the single affinity purification steps as well as 
concentrated purified protein are visualised by silver staining. Western blot analysis 
for CBP does not show the TAP tag in the control lane due to its small size of 
approximately 7 kDa. 
 
 
3.2.4 Mass spectrometric analysis of purified TOX3 and interacting proteins 
For mass spectrometric analysis, TOX3 protein purified from 108 cells was separated 
by gradient gel electrophoresis, stained with Coomassie Brilliant Blue G-250 
(colloidal blue) and analysed by nano-scale liquid chromatographic tandem mass 
spectrometry (nLC-MS/MS). For a detailed description, see the Materials and 
Methods and Appendix chapters. Identified peptide sequences were compared to the 
UniProtKB/Swiss-Prot human protein database. 
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Table 9. Mass spectrometry analysis of proteins associated with NTAP-TOX3 
Gel 
section 
Official 
gene 
symbol 
Name Accession no. 
Mol 
mass 
(Da) 
No. 
peptides 
matched 
No. 
different 
peptides 
% 
Coverage 
3-7, 
16 
CALM1 Calmodulin P62158 16,826 64 9 60 
3, 7-
16 HSPA8 
Heat shock 
70kDa protein 8 
P11142 70,854 126 28 48 
6, 7 RPS3 
Ribosomal 
protein S3 
A7E2S3 26,671 16 9 45 
6-16 HSPA1A 
Heat shock 
70kDa protein 
1A 
P08107 70,009 105 22 44 
8-10 YBX1 Y box-binding 
protein I 
P67809 35,903 24 9 43 
3, 8-
16 HSPA5 
Heat shock 
70kDa protein 5 Q24JP5 72,289 54 22 40 
3, 5, 
8, 12-
14 
UBB Ubiquitin B P0CG47 25,746 8 3 38 
4-6, 
11, 12 HSPA9 
heat shock 
70kDa protein 9 P38646 73,635 27 20 37 
3, 5, 
8, 12-
14 
UBC Ubiquitin C P0CG48 76,982 8 3 36 
5 HSBP1 
Heat shock 
factor binding 
protein 1 
O75506 22,768 4 4 36 
8-10, 
13-16 ACTB Actin, beta P60709 41,710 46 13 36 
8-10, 
13-16 ACTG1 Actin, gamma 1 P63261 41,766 46 13 35 
7, 8 RPSA Ribosomal 
protein SA P08865 32,833 11 7 35 
8-10, 
13, 14 TUBA1C Tubulin, alpha 1c Q9BQE3 49,864 34 13 34 
4 RPS18 Ribosomal 
protein S18 P62269 17,708 10 6 33 
7, 8, 
10 HNRNPA1 
Heterogeneous 
nuclear 
ribonucleoprotein 
A1 
P09651 29,368 16 8 31 
2-16 TOX3 
TOX high 
mobility group 
box family 
member 3 
O15405 72,054 416 15 30 
3, 5, 
8, 12-
14 
UBA52 
Ubiquitin A-52 
residue 
ribosomal 
protein fusion 
product 1 
P62987 14,719 8 3 30 
6-8 PHB2 Prohibitin 2 Q99623 33,276 13 7 29 
7 ELAVL1 
ELAV (embryonic 
lethal, abnormal 
vision, 
Drosophila)-like 
1 (Hu antigen R) 
Q15717 72,054 6 6 28 
Results were sorted consecutively by coverage, number of peptides matched, and number of different 
peptides matched. The gel lane had been separated into 16 sections (numbered from bottom to top). 
Keratins were omitted from the list. Protein accession numbers refer to the UniProtKB database 
(release 2011_06). 
Mass spectrometric analysis of the NTAP-TOX3 lane showed significant 
contamination with keratins (see Appendix for full list of MS results), which was 
reflected both in the number of scanned peptides and the percentage of coverage. The 
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presence of a large amount of keratins, which is a common problem when using 
sensitive protein detection techniques such as mass spectrometry, likely masked the 
scans of true interacting proteins present in the sample and thus greatly complicated 
the interpretation of the data. Due to the significant contamination with keratins, the 
control lane was not analysed by mass spectrometry. 
MS analysis of the NTAP-TOX3 lane further predominantly identified proteins that 
are expressed in abundance in the cell including heat shock and other chaperone 
proteins, proteosome components, cytoskeletal proteins such as actins, ribosomal 
proteins as well as translation factors (Table 9). Indeed, the only protein that was 
identified with what was considered sufficient confidence (coverage 43%, 9 unique 
peptide matches) and which did not belong to one of the latter groups of proteins was 
the transcription/translation factor Y box-binding protein 1 (YBX1, YB-1). YBX1 
was considered an interesting candidate for a TOX3 interacting protein as several 
studies have implicated YBX1 in malignant transformation, with evidence for it being 
involved in epithelial-mesenchymal transition (EMT), mammary stem cell self-
renewal and drug resistance (Evdokimova et al., 2009; To et al., 2010). Based on the 
transcriptional profiling data from the Visvader lab, YBX1 does not appear to exhibit 
a mammary subpopulation-dependent expression pattern (Fig. 16 C). 
 
 
Figure 25. Transient expression of NTAP-TOX3 induces heat shock proteins. 
Overexpression of NTAP-TOX3 following transient transfection of HEK 293T cells 
leads to the expression of heat shock proteins and subsequent enrichment of the 
chaperone proteins during TAP. An antibody detecting both HSPA1A (HSP70) and 
HSPA1B (HSP72) was used for Western blot analysis. 
 
Western blot analysis confirms the enrichment of heat shock protein 70/72 
(HSPA1A/B) in the TAP fractions (Fig. 25) but I did not pursue this result, as 
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induction and co-purification of chaperone proteins is a known artefact when 
overexpressing tagged proteins for affinity purification, presumably because 
overexpression of the protein of interest also increases the likelihood of protein 
misfolding (Gingras et al., 2005; Puig et al., 2001). 
Another caveat associated with the overexpression of the TAP-tagged protein by 
transient transfection are the resulting non-stoichiometric binding conditions, which 
may skew the association with interacting proteins and thus complicate the 
identification of physiological binding partners. To avoid the problem associated with 
overexpression of ectopic protein, I had originally designed the NTAP-TOX3 
constructs as lentiviral vectors to create cell lines stably expressing TAP-TOX3. I am 
currently performing tandem affinity purification of TOX3 from HEK 293T and 
MCF-7 lines stably expressing NTAP-TOX3. As mentioned above, 108 transfected 
HEK 293T cells had been used to purify protein for mass spectrometric analysis. 
Preliminary experiments showed that the same number of HEK 293T cells stably 
expressing NTAP-TOX3 under the control of the hPGK promoter did not produce 
protein amounts sufficient for mass spectrometric analysis (data not shown). 
Therefore, the goal of ongoing work is to obtain an adequate protein yield by 
increasing the number of cells stably expressing NTAP-TOX3 while at the same time 
ensuring an expression level of TOX3 that will not provoke protein misfolding and 
the association of chaperone proteins. 
 
3.2.5 Analysis of TOX3 protein interaction partners 
To confirm whether TOX3 interacted with the transcription/translation factor YBX1, I 
aimed to perform co-immunoprecipitation of the two proteins. In an initial 
experiment, I transiently expressed TOX3 in HEK 293T cells from the hPGK 
lentiviral vector. Immunoprecipitation of TOX3 using the custom-made rabbit 
polyclonal TOX3 Rb57 antibody failed, which was most likely due to the lack of 
affinity of the unpurified antibody (Fig. 26 A). We therefore created a lentiviral 
construct coding for N-terminally haemagglutinin (HA)-tagged TOX3 under the 
control of hPGK promoter (pER-47). The TOX3-deficient luminal breast cancer cell 
line MCF-7 as well as the TOX3-expressing cell lines BT-474 and MDA-MB-361, 
which all expressed YBX1 (Fig. 26 B), were transduced with the HA-TOX3 lentivirus 
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or a GFP control virus (pER-15). Expression of TOX3 and the HA-tag was confirmed 
by Western blot analysis (Fig. 26 C). To investigate the association of TOX3 with 
YBX1, I am currently immunoprecipitating HA-TOX3 using an antibody raised 
against the HA-tag. Co-immunoprecipitation of YBX1 will be examined by Western 
blot analysis for YBX1. In addition, endogenous YBX1 will be immunoprecipitated 
using an YBX1 antibody and co-precipitation of ectopically expressed HA-TOX3 will 
be examined by Western blotting for TOX3. 
 
Tandem affinity purification of TOX3 from HEK 293T cells provides insight into the 
composition of protein complexes that generally associate with TOX3. However, 
TAP performed in HEK 293T cells fails to provide information about mammary cell-
specific protein-protein interactions. For instance, HEK 293T cells do not express 
CITED1 (Fig. 26 B), a factor that has recently been shown to interact with TOX3 in 
neurons (Dittmer et al., 2010). Since CITED1 has been suggested to play a role in 
breast cancer and its interaction with ESR1 has been reported in several studies, I am 
currently investigating if the finding by Dittmer and colleagues can be reproduced in 
the breast cancer cell lines MCF-7, BT-474 and MDA-MB-361, which express 
CITED1 at varying levels (Fig. 26 B). 
 
 
Figure 26. Immunoprecipitation of TOX3. 
(A) Immunoprecipitation using the TOX3 Rb57 rabbit polyclonal antibody fails to 
pull down ectopically expressed TOX3. (B) Western blot analysis of YBX1 and 
CITED1 expression in HEK 293T and breast cancer lines. (C) Western blot analysis 
of the hPGK-HA-TOX3 lentiviral expression construct in MCF-7 cells. 
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3.2.6 Affinity purification of rabbit polyclonal TOX3 antibody 
The analysis of TOX3 protein expression has been complicated by the fact that no 
good antibody has been, and is, readily available. Since no antibody against TOX3 
was commercially available when this project was started, a rabbit polyclonal peptide 
antibody raised against amino acids NEEDADEANR (amino acids 217-226) 
contained in both isoforms of human TOX3 was custom-made (Abgent) (Fig. 27). 
Two rabbits were immunised with the KLH-conjugated peptide. The corresponding 
protein A-purified sera were termed TOX3 Rb57 and TOX3 Rb58, respectively. 
 
 
1   MDVRFYPAAAGDPASLDFAQCLGYYGYSKFGNNNNYMNMAEANNAFFAASEQTFHTPSLGDEEFEIPPITPPPESDPALG  80 
1   MKCQPRSGARRIEERLHYLITT----YLKFGNNNNYMNMAEANNAFFAASE-TFHTPSLGDEEFEIPPITPPPESDPALG  75 
 
81  MPDVLLPFQALSDPLPSQGSEFTPQFPPQSLDLPSITISRNLVEQDGVLHSSGLHMDQSHTQVSQYRQDPSLIMRSIVHM 160 
76  MPDVLLPFQALSDPLPSQGSEFTPQFPPQSLDLPSITISRNLVEQDGVLHSSGLHMDQSHTQVSQYRQDPSLIMRSIVHM 155 
 
161 TDAARSGVMPPAQLTTINQSQLSAQLGLNLGGASMPHTSPSPPASKSATPSPSSSINEEDADEANRAIGEKRAAPDSGKK 240 
156 TDAARSGVMPPAQLTTINQSQLSAQLGLNLGGASMPHTSPSPPASKSATPSPSSSINEEDADEANRAIGEKRAAPDSGKK 235 
 
241 PKTPKKKKKKDPNEPQKPVSAYALFFRDTQAAIKGQNPNATFGEVSKIVASMWDSLGEEQKQVYKRKTEAAKKEYLKALA 320 
236 PKTPKKKKKKDPNEPQKPVSAYALFFRDTQAAIKGQNPNATFGEVSKIVASMWDSLGEEQKQVYKRKTEAAKKEYLKALA 315 
 
321 AYRASLVSKAAAESAEAQTIRSVQQTLASTNLTSSLLLNTPLSQHGTVSASPQTLQQSLPRSIAPKPLTMRLPMNQIVTS 400 
316 AYRASLVSKAAAESAEAQTIRSVQQTLASTNLTSSLLLNTPLSQHGTVSASPQTLQQSLPRSIAPKPLTMRLPMNQIVTS 395 
 
401 VTIAANMPSNIGAPLISSMGTTMVGSAPSTQVSPSVQTQQHQMQLQQQQQQQQQQMQQMQQQQLQQHQMHQQIQQQMQQQ 480 
396 VTIAANMPSNIGAPLISSMGTTMVGSAPSTQVSPSVQTQQHQMQLQQQQQQQQQQMQQMQQQQLQQHQMHQQIQQQMQQQ 475 
 
481 HFQHHMQQHLQQQQQHLQQQINQQQLQQQLQQRLQLQQLQHMQHQSQPSPRQHSPVASQITSPIPAIGSPQPASQQHQSQ 560 
476 HFQHHMQQHLQQQQQHLQQQINQQQLQQQLQQRLQLQQLQHMQHQSQPSPRQHSPVASQITSPIPAIGSPQPASQQHQSQ 555 
 
561 IQSQTQTQVLSQVSIF 576 
556 IQSQTQTQVLSQVSIF 571 
 
Figure 27. Epitopes recognized by TOX3 antibodies. 
TOX3 isoforms 1 (NP_001073899) and 2 (NP_001139660) differ in their N-terminal 
amino acids (in green). Custom-made rabbit polyclonal antibodies TOX3 Rb57 and 
TOX3 Rb58 were raised against the sequence NEEDADEANRA (underlined), which 
is shared by both isoforms. For comparison, the commercially available antibody 
ab77432 (Abcam) was raised against amino acids AGDPASLDFAQC (underlined 
twice), which is contained in the TOX3 isoform 1 only. For orientation, the HMG-box 
core sequence (red), the consensus residues within the nuclear localisation signal that 
are shared by all TOX proteins (pink) and the glutamine-rich region (yellow) are 
shown. 
 
To characterise the TOX3 Rb57 and Rb58 antibodies, they were titrated by Western 
slot blot analysis of HEK 293T cells transiently transfected with a lentiviral TOX3 
expression vector (pXS-39) containing the hUbiC promoter or a control plasmid (Fig. 
28). Both vectors are described in the following chapter. Overexpression of hUbiC-
TOX3 resulted in several bands in the Western blot. pXS-39 contained the same 
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lentiviral vector backbone as the hUbiC-NTAP-TOX3 vector (pXS-96) described 
above, it also gave rise to a TOX3-GFP fusion construct. While this explained the 
high molecular weight isoforms of TOX3 seen in the Western blot, it did not appear 
to interfere with interpretability of the antibody titration. It remained unclear why the 
antibody also detected several isoforms that were smaller than the predicted size of 
full-length TOX3. While both undiluted antibodies had been provided at an 
approximately equal concentration (7.5 mg/ml for Rb57 and 7.4 mg/ml for Rb58), the 
TOX3 Rb57 antibody appeared to give a stronger signal (Fig. 28). I therefore chose to 
use the TOX3 Rb57 antibody for most following experiments. Expression of 
endogenous TOX3 was not detectable in control-transfected HEK 293T cells. 
 
 
Figure 28. Custom-made TOX3 antibody. 
To test the antibody, HEK 293T cells were calcium phosphate-transfected with the 
lentiviral hUbiC-TOX3 expression plasmid pXS-39. hUbiC-DsRed2 control plasmid 
(Ctrl, pXS-41) were used as a negative control. 48 hours post transfection, whole cell 
lysates were prepared by direct lysis of cells in SDS-PAGE loading buffer. To titrate 
the antibody, proteins were separated by SDS-PAGE using a single-well preparative 
comb. Following the transfer, the nitrocellulose membrane was cut into strips and 
probed with the TOX3 antibodies (Rb57 left panel, Rb58 right panel) at different 
concentrations. 
 
The custom-made rabbit polyclonal antibodies gave a clear specific signal without 
obvious background signal when TOX3 was overexpressed under the control of the 
hUbiC promoter in transfected HEK 293T cells (Fig. 28). To test the antibody under 
more physiological conditions, I infected MCF-7 cells, which do not express 
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endogenous TOX3 (Fig. 15), with lentivirus, which expresses TOX3 under the control 
of the human PGK promoter (pXS-36, described in the following chapter) or the 
negative control vector hPGK-GUS (Duss et al., 2007). Transduction of MCF-7 cell 
with the hPGK-TOX3 lentiviral vector resulted in TOX3 expression at levels that 
more closely resembled physiological expression levels. Western blot analysis of 
TOX3 at low levels revealed several background bands, one of which runs exactly at 
the same size as TOX3, as seen in the negative control lane (Fig. 29 A, E), which 
complicated the interpretability of results obtained with the TOX3 Rb57 antibody. 
Peptide blocking using the peptide that was used to immunise the rabbits for antibody 
production confirmed the presence of two overlapping bands, one specific and one 
non-specific, were overlapping. The problem with non-specific background staining 
became yet more evident when the detection of low levels of TOX3 required long 
exposure of Western blot membranes (Fig. 29 B). 
To achieve cleaner Western blots that would provide more information about TOX3 
expression and generally to improve antibody specificity, I took advantage of the TAP 
system to affinity-purify the TOX3 Rb57 antibody. To this end, NTAP-TOX3 cell 
lysates were prepared in TAP lysis buffer as described for tandem affinity purification 
above. In modification of a classic affinity column, NTAP-TOX3 was cross-linked to 
streptavidin-coated magnetic beads. TOX3 Rb57 antibody was allowed to bind to 
NTAP-TOX3 immobilised on the magnetic beads, washed several times and 
subsequently eluted in several fractions (Fig. 29 C, D). To remove any antibody that 
interacted non-specifically with the TAP tag, purified antibody was subsequently 
incubated with TAP control-streptavidin beads. Western blot analysis of ectopically 
expressed TOX3 showed that the major part of purified antibody was eluted in the 
first fraction (Fig. 29 D) and that affinity purification resulted in a cleaner antibody 
(Fig. 29 E). 
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Figure 29. Affinity-purification of polyclonal rabbit TOX3 Rb57 antibody. 
(A) Western blot analysis shows that the antibody detects TOX3 expressed at 
physiological levels. (B) High background originating from the TOX3 Rb57 antibody 
hampers the interpretation of TOX3 expression in several different breast cancer cell 
lines. (C) Coomassie blue staining shows successful cross-linking of NTAP-TOX3 to 
streptavidin-coated beads. The arrow indicates NTAP-TOX3 protein cross-linked to 
streptavidin beads after washing. (D) Western blot analysis of TOX3 expression in 
HEK 293T cells using purified antibody fractions. Most purified antibody is eluted in 
the first fraction. (E) Western blot analysis MCF-7 cells transduced with NTAP-
TOX3 confirms successful purification of the TOX3 antibody. Peptide blocking of the 
unpurified antibody demonstrates antibody specificity despite a high background. 
 
 
3.2.7 Knockdown of endogenous TOX3 using shRNAmir 
As discussed above, the luminal breast cancer lines ZR-75-1, BT-474, MDA-MB-
361, MDA-MB-415 and UACC-812 express endogenous TOX3 protein, albeit at 
levels that were difficult to detect using the available antibodies (Fig. 15 B). To 
confirm that the band I detected using the purified TOX3 Rb57 antibody 
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corresponded to endogenous TOX3, I chose to knockdown TOX3 in ZR-75-1, BT-
474 and MDA-MB-361 cells using two different lentiviral shRNAmir constructs 
directed against the sequences GACATACTGATGACTATAA (pXS-88, shTOX1 #1) 
and GCCTCTCTGAGTCATAGAA (pXS-89, shTOX1 #2) present in the 3’ 
untranslated region of the TOX3 gene. A scrambled shRNAmir vector was used as a 
negative control. In the first instance, I created ZR-75-1 cell lines stably expressing 
the three different shRNAmir constructs. Based on Western blot analysis of TOX3 
expression it was not possible to quantitate the extent of knockdown as the basal 
TOX3 expression levels in ZR-75-1 transduced with the control shRNAmir vector 
were barely detectable (data not shown). Knockdown of TOX3 had no obvious effect 
on ZR-75-1 cell morphology (Fig. 30 B). Therefore, I tested the lentiviral shRNAmir 
constructs in BT-474 and MDA-MB-231 cells, which exhibited higher relative TOX3 
levels (Fig. 15 B). Similar to ZR-75-1 cells, endogenous TOX3 was barely detectable 
by Western blot analysis in BT-474 and MDA-MB-361. However, transduction with 
the shRNAmir lentiviral vectors resulted in a reduction of a single band that was 
thought to represent endogenous TOX3, while the intensity of the other (non-specific) 
bands did not change (Fig. 30 A), thus confirming that the TOX3 antibody was able to 
detect endogenous TOX3. Quantitative PCR analysis of TOX3 mRNA expression in 
BT-474 cells confirmed a reduction in TOX3 expression upon transduction with the 
shRNAmir vectors by approximately 50% (shTOX3-1) and 40% (shTOX3-2), 
respectively (Fig. 30 C). 
While knockdown of TOX3 using the shRNAmir constructs confirmed that the 
affinity-purified TOX3 Rb57 antibody was able to detect TOX3, a more efficient 
knockdown of TOX3 levels would be desirable in order to investigate the effect of 
loss of endogenous TOX3 on the tumourigenic properties of luminal breast cancer 
cells in our human-in-mouse tumour model, which is described in the final chapter. 
Due to time constraints, I was not able to follow-up the effect of TOX3 knockdown in 
vitro or in vivo. However, a first experiment showed that no change of expression of 
the TOX3 target gene PGR (described in the following chapter) could be observed in 
the presence of the shRNAmir constructs targeting TOX3 in BT-474 and MDA-MB-
361 cells (Fig. 30 A), suggesting that either the efficiency of the knockdown was not 
sufficient to have a biological effect, or that knockdown of endogenous TOX3 does in 
fact not have an effect that is opposite to overexpression in TOX3-deficient cells. 
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Figure 30. Knockdown of endogenous TOX3 using shRNAmir vectors. 
(A) Western blot analysis of TOX3 and PGR expression levels in BT-474 and MDA-
MB-361 cells. Cells were stably transduced using lentiviral shRNAmir vectors 
targeting two different regions in the 3’ UTR of the TOX3 gene. A scrambled 
shRNAmir construct was used as a control. Successfully transduced cells were 
puromycin-selected. The closed arrow indicates the band corresponding to 
endogenous TOX3, while the open arrows mark non-specific bands. (B) Quantitative 
PCR analysis of TOX3 expression in transduced BT-474 cells. Analysis was done in 
triplicate, error bars represent the standard deviation. (C) Representative images of the 
morphology of ZR-75-1 cells transduced with the control or TOX3 shRNAmir 
vectors. 
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3.3 Identification of TOX3 target genes and signalling pathways 
To gain further insight into TOX3 function and identify target genes and signalling 
pathways TOX3 is involved in, I chose to perform microarray analysis of mammary 
epithelial cells ectopically expressing TOX3 or a control gene. 
 
3.3.1 Lentiviral expression vectors 
To study TOX3 expression, I created several lentiviral TOX3 expression vectors. As 
mentioned above, lentiviral vectors are an efficient way to express a gene of interest 
in any cell type. Lentiviruses infect both dividing and quiescent cells, which makes 
them particularly attractive for the transduction of non-dividing stem cells, which are 
generally difficult to transfect. Furthermore, since they readily integrate into the host 
cell’s genome, lentiviral vectors allow for easy creation of cell lines stably expressing 
the gene of interest. As the ultimate goal of this study was to create tumour models by 
quantitative transformation of normal mammary epithelial cells, lentiviral vectors 
were the ideal choice for transgene expression. 
The TOX3 open reading frame was cloned into the lentiviral backbone pSD-69 to 
create a lentiviral expression vector containing the human phosphoglycerate kinase 
(hPGK) promoter to drive TOX3 expression (Duss et al., 2007). As mentioned above, 
the hPGK promoter was chosen because it allows transgene expression at 
physiological levels. A second TOX3 expression vector was created by cloning the 
TOX3 ORF into the lentiviral backbone pJH-3982, which contains the human 
ubiquitin C promoter (UbiC) to control the expression of the gene of interest at high 
levels (Fig. 31). Both backbones had also been used to create the TAP vectors as 
described in the previous chapter. Expression of TOX3 from the two lentiviral vectors 
was confirmed by transient transfection of HEK 293T cells and subsequent Western 
blot analysis (Fig. 20 C). As expected, TOX3 protein expressed from the hPGK 
vector had an apparent molecular weight of just over 60 kDa, consistent with the 
predicted molecular weight of 63 kDa. In contrast, the hUbiC vector was subject to 
alternative splicing and, like the hUbiC-NTAP-TOX3 vector, produced a TOX3-GFP 
fusion protein, as discussed in the previous chapter. Western blot analysis and 
microscopic analysis of GFP localisation in MCF-7 cells confirmed that the hUbiC-
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TOX3 lentiviral plasmid encoded a TOX3-GFP fusion protein (Fig. 20 C, D). As a 
consequence, the hUbiC-TOX3 could not be used to study TOX3 function. 
 
 
Figure 31. TOX3 lentiviral expression vectors. 
Map of the lentiviral expression vectors pXS-36 (hPGK-TOX3) and pXS-39 (hUbiC-
TOX3), which were cloned to create stable TOX3 cell lines. For a legend of lentiviral 
features, see Figure 18. 
 
3.3.2 Microarray analysis of TOX3 target genes 
To identify TOX3 target genes and gain further insight into TOX3 function, initial 
expression array analysis was carried out using MCF-7 cells transduced with the 
hPGK-TOX3 lentiviral vector or a hPGK-GUS control vector (Duss et al., 2007). To 
this end, MCF-7 cells were infected at a multiplicity of 10 to ensure an infection 
efficiency of greater than 80%. 
In addition, in what had originally been designed as a separate experiment, MCF-7 
cells were transduced with the two lentiviral shRNAmir vectors or the scrambled 
shRNAmir control lentivirus, respectively, as described in the previous chapter. When 
it became evident that MCF-7 cells do not in fact express endogenous TOX3 (Fig. 14, 
15), the three shRNAmir samples were included in the microarray as additional 
negative controls. 72 hours post infection cells were lysed for extraction of total RNA. 
TOX3 expression was confirmed by Western blot (Fig. 32), and microarray analysis 
was performed using a HumanHT-12 Expression BeadChip (Illumina). 
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Figure 32. TOX3 expression in transduced MCF-7 cells. 
Western blot of TOX3 expression. MCF-7 cells were transduced with the hPGK-
TOX3 lentivirus at two different multiplicities of infection (MOI) or the hPGK-GUS 
control vector. 72 hours post infection, whole cell lysates were prepared and analysed 
for TOX3 expression using the rabbit polyclonal TOX3 Rb57 and the TOX3 Abcam 
antibody, respectively. Tubulin was used as a loading control. 
 
Initial filtering of the microarray data was carried out using the linear model for 
microarray (limma) package. Hierarchical unsupervised clustering of the most 
variable gene sets showed three predominating clusters of genes (Fig. 31 A). In TOX3 
transduced MCF-7 cells, proliferation genes such as MYC, CCNE1, CDC45 were 
upregulated, while inhibitors of proliferation such as cell cycle inhibitor cyclin-
dependent kinase inhibitor 1A (CDKN1A, p21) were downregulated compared to the 
controls (Fig. 31 A). A second cluster of genes that was downregulated in the 
presence of TOX3 contained luminal differentiation genes including GATA3, PGR, 
insulin receptor substrate 1 (IRS1), MUC1 and GREB1 (Fig. 33 A). TOX3 expression 
appeared to have a very weak repressive effect on ESR1 mRNA levels. The third 
main cluster showed a considerable induction of interferon response genes such as 
OAS1 in GUS transduced cells (Fig. 33 A). Induction of the interferon response as 
part of the innate immune response to viral infection is well established for wild-type 
viruses (Haller et al., 2006). In addition, induction of the interferon response can be 
caused by lentiviral vectors (Pebernard and Iggo, 2004). The upregulation of 
interferon response genes was most prominent in the GUS control, which complicated 
the interpretability of the microarray results and was the reason why the shRNAmir 
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samples were used as additional makeshift controls. To avoid experimental artefacts 
related to the acute cellular response to viral infection, an inducible TOX3 lentiviral 
vector system is currently being created, as discussed in chapter 3.5. A conditional 
expression vector will allow the uncoupling of viral infection and the expression of 
TOX3. 
Nevertheless, the result that TOX3 induced proliferation while repressing luminal 
differentiation genes was evident despite the interferon response artefact. To 
determine whether the TOX3 and control gene sets showed statistically significant 
differences and to obtain more biologically relevant information on the effect of 
TOX3 expression, I carried out gene set enrichment analysis (GSEA) of the TOX3 
versus the control gene sets as well as of GUS versus all other gene sets (Subramanian 
et al., 2005). GSEA of the GUS controls versus all other gene sets confirmed the 
upregulation of interferon response genes specifically in the GUS gene set (Fig. 33 C, 
D). 
GSEA of the TOX3 arrays confirmed the induction of proliferation genes including 
cyclin A (CCNA2), polo-like kinase 1 (PLK1), proliferating nuclear antigen (PCNA) 
and MYC and the repression of the cell cycle inhibitor CDKN1A (p21) (Fig. 31 E, G, 
I). Moreover, GSEA showed a statistically significant downregulation of luminal 
differentiation genes in TOX3 arrays cells including PGR, insulin receptor substrate 1 
(IRS1), GREB1, and MUC1 (Fig. 33 F, H). Somewhat surprisingly, the classic ESR1 
target gene TFF1 and its relative TFF3 showed no significant difference in expression 
(Fig. 33 I). FOXA1 expression did not change (data not shown), while TOX3 
repressed the expression of the related protein FOXC1 (Fig. 33 I). TOX3 further 
downregulated expression of the early response gene FOS, which is in contrast to 
observations by Yuan and colleagues who reported that TOX3 acted as a 
transcriptional activator of the FOS promoter in a calcium-dependent manner (Yuan 
et al., 2009). Other genes that show relatively strong downregulation in the presence 
of TOX3 include anterior gradient homolog 2 (AGR2), which has been implicated in 
hormone-dependent cancers of the breast and prostate and which is expressed in the 
luminal cluster in ER-positive breast cancers (Brychtova et al., 2011), the aldo-keta 
reductase AKR1C2 gene, which plays a role in steroid hormone metabolism (Penning 
and Byrns, 2009), the transcription factor CITED2, which has been implicated in 
tamoxifen response of estrogen receptor-positive breast cancers (van Agthoven et al., 
2009). TOX3 also inhibited the molecular apocrine gene activated leukocyte cell 
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adhesion molecule (ALCAM) (Farmer et al., 2005), and a number of histone genes 
(Fig. 33 B). 
 
 
Figure 33. TOX3 microarray. 
(A) Unsupervised hierarchical clustering using 2631 probes. MCF-7 cells were 
transduced with TOX3 or the control gene GUS. Illumina HumanHT-12 Expression 
BeadChip array results were analysed using the limma package in R, Cluster and 
TreeView. Black bars mark interesting gene clusters. (B) Heat map for the top 50 
ranked features in the dataset. Raw Illumina data (37,249 genes) were reduced to 
7065 differentially expressed genes by excluding all genes with a standard deviation 
of smaller than 0.1. Duplicates were removed based on HUGO gene symbols, 
resulting in a final set of 5988 genes. This gene set was used for GSEA. (C) GSEA 
enrichment plots showing enrichment in the GUS arrays for the “Interferon any 
response” gene set (top panel) and the “Interferon beta response” gene set (bottom 
panel), respectively. (D) Heat map showing the induction of interferon response genes 
in the GUS arrays. (E) GSEA enrichment plot showing upregulation of proliferation 
genes in the TOX3 arrays. (F) GSEA enrichment plot showing downregulation of 
genes expressed by ER-positive breast cancer. The enrichment score (ES) is the 
primary result of the GSEA, which reflects the degree to which a gene set is 
overrepresented at the top or bottom of a ranked list of genes. The nominal p value 
estimates the statistical significance of the enrichment score for a single gene set. The 
false discovery rate (FDR) is the estimated probability that a gene set with a given 
normalised enrichment score represents a false positive finding. (G-H) Heat map 
showing the induction of proliferation genes (G) and the suppression of genes 
upregulated in ER-positive breast cancer (H). (I) Relative change in expression of 
selected genes in the TOX3 versus the control arrays. 
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Figure 33. continued 
 
Taken together, microarray analysis of TOX3 expression suggested that TOX3 
attenuates luminal differentiation and simultaneously promotes proliferation in the 
context of MCF-7 luminal breast cancer cells. 
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3.3.3 TOX3 represses a subset of ER target genes 
Since the interpretation of the microarray results was hampered by the interferon 
response artefact seen in the control samples, I performed Western blot analysis of a 
selection of candidate TOX3 target genes in MCF-7 cells transduced with a TOX3 
lentiviral expression vector or a control vector (Fig. 34). In keeping with the 
microarray results, TOX3 expression resulted in consistent downregulation of PGR, 
AGR2 expression. Furthermore, TOX3 expression led to a decrease in p21 protein 
levels, however repression of p21 was not seen every time the experiment was 
repeated, which may reflect differences between individual experiments with respect 
to the proliferative state of the transduced cells prior to harvest. In contrast to the 
array results, expression of IRS1 did not appear to be decreased in the presence of 
TOX3. ESR1 expression appeared to be reduced in the presence of TOX3 but the 
effect was only weak (Fig. 34). Consistent with the microarray results, TOX3 had no 
significant effect on expression of the classic luminal gene FOXA1 (data not shown). 
 
 
Figure 34. TOX3 target gene expression 
Western blot analysis of the effect of TOX3 expression on a selection of genes 
identified as TOX3 target genes by microarray analysis. MCF-7 cells were infected 
with a TOX3 expression lentivirus or a control virus. Whole cell lysates were 
prepared by direct lysis in protein loading buffer at least one passage post infection. 
The image is representative of several independent experiments. 
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3.3.4 TOX3 has a global effect on transcription 
Since TOX3 repressed ESR1 target genes but appeared to have only a minor effect on 
ESR1 expression itself, I was interested to investigate if TOX3 had a direct effect on 
the transcriptional regulation of ESR1 target genes. 
 
 
Figure 35. TOX3 acts as a global transcriptional regulator. 
MCF-7 and T-47D cells were transiently co-transfected with different firefly 
luciferase ERE reporter vectors and a TOX3 expression vector or a DsRed2 control 
vector. Cells were treated with 1 µM fulvestrant (F, black bars) or 100 nM beta-
estradiol (E2, grey bars) 24 hours post transfection. Cells were harvested after an 
addition 24 hours and analysed for luciferase activity. (A) The Renilla luciferase pRL-
TK and pRL-SV40 were tested as an internal reporter control. (B) Log-normal 
representation of the transcriptional activation of the pGL3-basic and ERE-TK-luc 
reporter vectors by TOX3 versus the DsRed2 control plasmid. (C) Linear plot of the 
activation of two different ERE-containing reporter vectors. The data presented are 
the mean values ± standard error of the mean of a representative experiment 
performed in triplicate. Statistical significance was determined using a Student’s t-
test. Significant results (p > 0.05) indicated by one asterisk are in relation to the 
DsRed2 control for each condition, while two asterisks indicate significant results in 
relation to the fulvestrant-treated equivalents. 
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To this end, MCF-7 cells were transiently co-transfected with the TOX3 expression 
vectors or a DsRed2 control vector and an estrogen receptor response element (ERE)-
containing firefly luciferase reporter plasmid. The pS2-luc reporter vector contained 
the proximal TFF1 gene promoter in pGL3-basic, while the ERE-TK-luc vector 
contained the vitellogenin ERE together with the herpes simplex virus thymidine 
kinase (TK) minimal promoter. To control for transfection efficiency, the pRL-SV40 
Renilla luciferase vector containing the SV40 enhancer and early promoter elements 
or alternatively, the pRL-TK Renilla luciferase vector containing the herpes simplex 
virus thymidine kinase (TK) promoter were used. 24 hours post transfection, cells 
were treated with the estrogen receptor antagonist fulvestrant (Faslodex) or beta-
estradiol. In a preliminary experiment, MCF-7 cells had been maintained in phenol 
red-free medium supplemented with 5% charcoal-dextran treated FBS three days 
prior to transfection and treatment with beta-estradiol in order to exclude potential 
estrogenic effects of phenol-red (Shang and Brown, 2002). However, since MCF-7 
cells cultured this way displayed an abnormal morphology, treatment with the 
estrogen receptor antagonist fulvestrant in complete medium was chosen instead of an 
untreated control. 
The luciferase assay showed that TOX3 had an effect on the transcriptional activity of 
both internal control vectors (Fig. 35 A). Furthermore, activation of the TK promoter, 
which is supposed to provide luciferase expression at low to moderate levels, 
appeared to occur in a dose-dependent manner, since the hUbiC-TOX3 lentiviral 
construct, which produces higher expression levels of TOX3 than the hPGK-TOX3 
construct, induced a 2.5-fold higher activation of the TK promoter. As the induction 
of the TK promoter was not of primary interest to this study, dose-dependence was 
not further examined. In contrast, TOX3 appeared to repress the transcriptional 
activity of the strong SV40 enhancer/early promoter in the pRL-SV40 construct in 
MCF-7 and T-47D cells, although repression in MCF-7 cells was not statistically 
significant. Due to the effect that TOX3 had on the internal control vectors, Renilla 
luciferase activity could not be used to normalise the firefly luciferase results. Since 
all conditions had been carried out in triplicate with generally low standard 
deviations, the raw firefly results may be interpretable with some confidence. 
The unnormalised results suggested that in the absence of beta-estradiol induction, 
TOX3 had a weak activating effect on the two ERE-containing promoters compared 
to the DsRed2 control plasmid, however the induction was not statistically significant 
Results 
 125 
(Fig. 35 B, C). As expected, both ERE-containing promoter constructs were induced 
upon treatment with beta-estradiol, which led to an induction by approximately 4-fold 
for the ERE-TK-luc promoter and approximately 3-fold for the pS2/TFF1-luc 
promoter in the absence of TOX3. In contrast, the induction was only approximately 
2-fold in the presence of TOX3 (Fig. 35 C), suggesting that the inducibility of ERE-
dependent transcription by beta-estradiol was attenuated by TOX3. 
In summary, it is not possible to conclude from these findings whether TOX3 acts on 
ESR1 target promoters. TOX3-dependent transcriptional regulation of ERE-
containing promoters may depend on other transcriptional co-factors. Furthermore, it 
appears possible that TOX3 has a more global effect on transcription, which is 
difficult to assess with a luciferase assay. A more general regulatory function of 
TOX3 in the nucleus would be in keeping with the notion that many HMG-box 
proteins function as architectural chromatin elements. 
 
3.3.5 TOX3 localises to the nucleus 
Although preliminary microarray analysis suggested a function for TOX3 in the 
repression of luminal differentiation and the induction of proliferation, the underlying 
molecular mechanism of TOX3 function remained unclear. Based on sequence 
predictions, TOX3 contains the HMG-box DNA binding domain as well as a putative 
nuclear localisation signal (NLS) N-terminally adjacent to the HMG-box (Fig. 9). The 
presence of both domains suggests that TOX3 is a nuclear protein, which binds to 
DNA. To gain further cues about TOX3 function, I was thus interested in the 
localisation of TOX3 within the cell. Previous experiments using the hUbiC-TOX3 
constructs had shown that a C-terminal GFP moiety unintentionally fused to TOX3 
was able to localise to the nucleus (Fig. 20), presumably due to the presence of the 
NLS in TOX3. To further examine the subcellular localisation of TOX3, a C-terminal 
hPGK-TOX3-GFP lentiviral construct (pXS-71) was cloned. HEK 293T cells were 
transiently transfected with the hPGK-TOX3-GFP construct or a control construct 
coding for GFP (pER-15). Cells were fixed and GFP fluorescence was examined by 
confocal microscopy, showing that TOX3-GFP indeed localised exclusively to the 
nucleus, while control GFP localised to both the nucleus and the cytoplasm (Fig. 36), 
supporting the notion of TOX3 as a nuclear protein. Notably, GFP fluorescence levels 
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were markedly lower for the TOX3-GFP fusion protein than for the GFP control. One 
explanation for low GFP fluorescence of the TOX3-GFP fusion construct may be 
post-translational regulation of TOX3 protein stability. Preliminary analysis of 
TOX3-GFP fluorescence in transduced MCF-7 cells following treatment with the 
proteasome inhibitor MG132 suggested that inhibition of proteasome-dependent 
protein degradation did not visibly affect TOX3-GFP expression levels (data not 
shown). A deletion series of TOX3 domains would provide more accurate 
information about whether TOX3 contains domains that negatively affect its stability. 
 
 
Figure 36. TOX3 localises to the nucleus. 
HEK 293T cells were transiently transfected with the hPGK-TOX3-GFP fusion 
construct (pXS-71) or a GFP control (pER-15). 48 hours post transfection cells were 
treated with 1 µM etoposide (bottom panels) or vehicle alone (top panels) for 4 hours. 
Cells were fixed in 3.7% formaldehyde. γ-H2AX was visualised by indirect 
immunofluorescent staining. Nuclei were stained using DAPI and cells were analysed 
using a Zeiss LSM 510 Meta confocal microscope at 63 × magnification. 
 
A recent study has shown that the TOX family member TOX4 binds to DNA adducts 
caused by platinating agents, a property it shares with other HMG-box family 
members such as HMGB1 and human upstream binding factor (UBF) (Puch et al., 
Results 
 127 
2010). Therefore, I was interested to see if TOX3 was able to bind to damaged DNA. 
To this end, transiently transfected HEK 293T cells were treated with etoposide, 
which causes DNA double strand breaks (DSBs) by inhibiting topoisomerase II. One 
of the first events occurring following the formation of DSBs is the phosphorylation 
of the histone H2A variant H2AX at Ser 139 (γ-H2AX) by one or several of the 
kinases ATM, ATR and DNA-PK (Downs et al., 2007). Immunofluorescent staining 
of γ-H2AX thus marks sites of DSBs. γ-H2AX was not detected in DMSO-treated 
cells in the absence of TOX3, while cells stained positive for γ-H2AX following 
etoposide treatment (Fig 36, first and third row from top), indicating the induction of 
DSBs. Interestingly, some TOX3-transfected cells exhibited γ-H2AX staining in the 
absence of etoposide treatment, while neighbouring untransfected cells were negative 
for γ-H2AX (Fig. 36, second row from top). Conversely, some TOX3-transfected 
cells appeared to exhibit lower γ-H2AX levels than adjacent untransfected cells 
following etoposide treatment (Fig. 36, bottom row), suggesting a possible correlation 
between TOX3 expression and the presence of DNA damage. TOX3-GFP did not 
appear to colocalise with γ-H2AX, although co-localisation was difficult to assess, as 
etoposide treatment did not result in distinct γ-H2AX-containing foci. 
 
3.4 A role for TOX3 in lineage commitment of mammary epithelial 
cells 
As mentioned above, the prototypic member of the TOX family has a role in lineage 
commitment in the adaptive and innate immune systems (Aliahmad et al., 2010; 
Wilkinson et al., 2002). TOX expression appears to be highly regulated, and 
throughout lymphocyte development, the determination of CD4+ and CD8+ cell fate is 
controlled by changes in TOX expression (Wilkinson et al., 2002). It became clear in 
the course of this study that the analysis of TOX3 expression is challenging because 
both unsorted normal mammary epithelial cells and established breast cancer cell 
lines do not express abundant amounts of TOX3 protein. This suggests that 
endogenous TOX3, much like its relative TOX, may be subject to complex regulation. 
Therefore, the function of TOX3 in the regulation of mammary epithelial cell lineage 
commitment might best be assessed by functional assays. The basic experimental set-
up was the transduction of normal mammary epithelial cells (HMEC/BPEC), the 
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bipotent mammary epithelial cell line MCF-10A or established breast cancer cells 
with the hPGK-TOX3 lentiviral expression construct or a lentiviral control construct 
to create cell lines that stably express TOX3. The transduced cell lines were then 
characterised using the mammosphere, CFC and TDLU assays described in the 
Introduction and below (Fig. 37). 
Prior to characterising the phenotype of TOX3-expressing cells, different conditions 
for the culture of normal human primary mammary epithelial cells (HMEC/BPEC) 
were tested. As mentioned above, the choice of cell culture system for the propagation 
of normal and transduced mammary epithelial cells depends on the experimental goal. 
 
 
Figure 37. In vitro stem cell and progenitor assays. 
Schematic of the different in vitro cell culture assays used to characterise the 
phenotype of TOX3-expressing cells. The assays are described in detail in the text. 
MSP, mammosphere; CFC, colony-forming cell; TDLU, terminal ductal lobular unit. 
 
 
3.4.1 Culture of human mammary epithelial cells from organoids 
For all protocols involving the culture of HMEC and BPEC, tissue was obtained from 
reduction mammoplasties. Tissue samples were examined by a pathologist to exclude 
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any malignancies and pared down to obtain the ductal tissue, which was subsequently 
subjected to collagenase digestion to obtain organoids. 
The simplest way to culture primary mammary epithelial cells is to directly place the 
organoids on tissue culture dishes. Four to seven days after mammary organoids were 
plated on Primaria dishes in WIT medium (the derived cells were therefore termed 
BPEC, as described above) (Ince et al., 2007), outgrowth of a monolayer of cells was 
observed (Fig. 38). Initial outgrowths of cells from organoids generally grew at a 
higher rate than cells plated from a single-cell suspension, suggesting that the 
microenvironment provided by the proximity of the organoid structure was beneficial 
to primary cell growth. This was likely due to the presence of stromal components 
including fibroblasts, adipocytes, endothelial cells and diverse haemapoietic cell 
types. In addition, the initial high growth rate of organoid-derived BPEC (compared 
to their dissociated counterparts) indicates that the enzymatic and mechanical 
dissociation conditions that cells in single suspension undergo limit their viability and 
proliferative potential. BPEC originating from organoids formed mixed colonies 
consisting of an inner core of luminal cells and a surrounding ring of myoepithelial 
cells when growing in a monolayer, similar to cells from single cell suspensions 
(described below). After one to two passages, BPEC from organoid-derived 
monolayer cultures resembled cells from single cell suspensions with respect to their 
population doubling time and morphology (Fig. 38). While organoid culture proved to 
be a useful way to propagate and expand human mammary epithelial cells at low 
passages, organoids were not suited for viral infections or quantitative assays. 
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Figure 38. Organoid culture of human mammary epithelial cells. 
Ductal tissue from reduction mammoplasties (XS06) was mechanically dissociated 
and subsequently digested with collagenase to obtain organoids, which were cultured 
directly in WIT medium on Primaria cell culture dishes. Images are representative of 
the morphology of organoids and outgrowing cells at day 6 of passages 1 and 2. 
 
3.4.2 Propagation of stem and progenitor cells in mammosphere culture 
As discussed in the introduction, mammosphere culture of freshly dissociated and 
unsorted human mammary epithelial cells is thought to enrich for mammary stem and 
early progenitor cells that are thought to survive and divide in suspension culture 
while more differentiated epithelial cells undergo anoikis (Dontu et al., 2003). While 
the mammosphere culture model is arguably a less specific and controlled method for 
the isolation of stem and progenitor cells than cell sorting using stem and progenitor 
markers such as CD10, CD49f or ALDH (Bachelard-Cascales et al., 2010; Ginestier 
et al., 2007; Stingl et al., 2006), it is technically simpler and less detrimental to the 
viability of the cells. 
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Figure 39. Propagation of stem and progenitor cells in mammosphere culture. 
Representative image of morphology of mammospheres (left, bright field; right, 
GFP). A single cell suspension was prepared from reduction mammoplasty tissue 
(XS03). Cells were left to recover overnight and subsequently infected with a GFP 
lentiviral vector under the control of the CMV promoter. 5×104/ml cells were plated 
in MSPM medium on ultra-low attachment dishes. Images were taken at day five. 
 
The protocol I used for the mammosphere (MSP) culture was essentially adapted 
from the original protocol developed by Dontu and colleagues, with some minor 
modifications (Dontu et al., 2003). Single HMEC were maintained on ultra-low 
attachment dishes in DMEM/F12 medium supplemented with heparin, EGF and 
bFGF. To achieve optimal growth conditions for the formation of spheres and to 
avoid aggregation of neighbouring cells, HMEC were seeded at a density of not more 
than 5 × 104 cells per ml, which at passage 1 gave rise to approximately 50-100 
spheres with an average diameter of 100 µm after being in culture for five days (Fig. 
39). To passage the spheres, they were dissociated into single cells and re-seeded after 
four to seven days. Starting at day two after seeding, the formation of solid spherical 
structures could be observed. Dissociation of mammospheres and subsequent seeding 
of single cells at clonal density in adherent culture gives rise to mixed luminal and 
myoepithelial colonies, suggesting the presence of (at least) bi-potent progenitors in 
mammospheres (data not shown). 
HMEC could be passaged three to four times before their capacity to form 
mammospheres was exhausted. With every passage, the average mammosphere size 
and sphere-forming frequency decreased (data not shown), suggesting that the 
mammosphere culture conditions do not support long-term maintenance of mammary 
stem cells. However, one round of mammosphere suspension culture proved to be a 
useful tool to select against differentiated epithelial cells and stromal contaminants 
and for stem and progenitor cells. Brief mammosphere culture therefore also allowed 
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targeted introduction of a gene of interest into progenitor and/or stem cells by 
lentiviral infection, as discussed below. Successful lentiviral infection of 
mammosphere-forming cells was confirmed by transduction with the 
pRRLsin.ppTs.hCMV.GFPpre lentivirus (pXS-3), encoding the GFP ORF under the 
control of the cytomegalovirus (CMV) promoter (Fig. 39). 
Since my data suggested that TOX3 was implicated in mammary epithelial cell 
differentiation rather than stem cell maintenance, I did not use the mammosphere 
protocol as a quantitative in vitro stem cell assay. 
 
3.4.3 Propagation of luminal mammary epithelial cells in adherent culture 
As discussed in the introduction, long-term maintenance of normal human mammary 
epithelial cells in culture still poses a problem due to the influence of the cell culture 
conditions on the phenotype of the cultured cells and the creation of cell culture 
artefacts. Limiting the time of in vitro culture prior to analysis of the cellular 
phenotype and genotype is therefore paramount to avoid undesired differentiation of 
primary and lentivirally transformed cells. However, depending on the experimental 
set-up, a minimum amount of time of in vitro culture is often required, for instance to 
allow for lentiviral infection and antibiotic selection of infected cells as well as simply 
to expand cells for further analysis. In an attempt to minimise aforementioned cell 
culture artefacts, I tested various combinations of protocols for the culture of human 
primary mammary epithelial cells. To this end, organoids derived from reduction 
mammoplasty tissue were dissociated, and single cells were subjected to one passage 
of mammosphere culture, followed by adherent culture in HMM+ medium (the 
resulting cells are referred to as HMEC). Alternatively, single cells were plated in 
WIT medium on Primaria cell culture plastic as described by Ince and co-workers 
(Ince et al., 2007), with or without an initial mammosphere step. Outgrowing cells 
that formed a monolayer were termed breast primary epithelial cells (BPEC). Both 
cell populations were maintained at 5% CO2 and 5% O2. It has been suggested that 
low oxygen levels benefits the growth of primary mammary epithelial cells, although 
no obvious morphological differences were observed (data not shown).  
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Figure 40. Human mammary epithelial cells in adherent culture. 
Representative images of HMEC and BPEC morphology. Phase contrast images of 
HMEC (XS03 (A-C) and BPEC (XS08) (D-F) at different passages (M: number of 
passages as mammospheres, P: number of adherent passages). Immunofluorescent 
staining of adherent HMEC and BPEC. (G) K14 (green) and (H) K18 (red) staining of 
HMEC fixed at passage 3. (I) K14 staining of BPEC at passage 9. K18 staining of 
BPEC at passage 9 was negative (not shown). Nuclei were stained blue using DAPI. 
 
Under conventional conditions, HMEC at early passages gave rise to luminal, 
myoepithelial and mixed colonies (Fig. 40 A, G, H), which can be distinguished by 
their morphology. Luminal epithelial cells grew in colonies of tightly packed, flat 
cells that were generally surrounded by myoepithelial cells, which in turn were 
characterised by a rounder morphology and refractile edges. Myoepithelial and 
luminal differentiation was confirmed by immunofluorescent staining with the 
myoepithelial marker K14 and the luminal marker K18, respectively (Fig. 40 G, H). 
Since cells were plated at clonal density, I concluded that the presence of luminal, 
myoepithelial and mixed colonies reflected whether the cell of origin was bipotent or 
restricted to either mammary epithelial lineage. However, it was not possible to 
deduce if mixed colonies arose from multipotent mammary stem cells or bi-potent 
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progenitors. K14/K18 double-stained HMEC were not observed, which may be 
explained by the supposed low ratio of immature to differentiated cells in breast 
tissue, or alternatively may indicate that stem and progenitor cells do not express both 
keratins. Already at passage three HMEC were predominantly of myoepithelial 
differentiation (Fig. 40 G), suggesting that the HMM+ culture conditions do not allow 
the maintenance of luminal cells or strongly favour the proliferation of myoepithelial 
cells. HMEC typically divided for four to five passages (Fig. 40 A-C), after which 
they stopped dividing and exhibited a spread-out, senescent morphology (Fig. 40 B, 
C), suggesting that the cell culture conditions forced them to undergo replicative 
arrest. 
In contrast, I was able to maintain BPEC in WIT medium on Primaria plates over 
more than ten passages without apparent induction of terminal replicative arrest (Fig. 
40 D-F, I, Fig. 41 C), indicating that the WIT medium provides more appropriate 
conditions that favour more long-term replication and growth. Like HMEC, BPEC 
derived from single cell suspensions gave rise to mixed colonies (Fig. 40 D) at early 
passages, while BPEC derived from organoids predominantly grew in populations 
with myoepithelial morphology (Fig. 40 E), which was the overall phenotype at 
higher passages. Notably, BPEC XS08 divided with an average population doubling 
time of 1 doubling/24 hours at early passages and reached a plateau of 0.2 
doubling/24 hours around passage nine (Fig. 41 C), which was accompanied by a 
somewhat senescent cell morphology (data not shown). However, at passages ten and 
eleven BPEC colonies emerged that appeared to resume replication at a higher rate 
(Fig. 41 C). 
3.4.4 BPEC culture does not prevent the induction of p16 
To address the observation that the primary XS08 BPEC line appeared to have 
undergone transient replicative arrest, I analysed the p16 status of these cells. 
Induction of p16 expression is thought to cause the growth arrest that is commonly 
seen in HMEC maintained in conventional culture conditions. A subset of HMEC in 
culture overcomes this arrest by silencing the p16INK4A promoter by methylation 
(Holst et al., 2003; Romanov et al., 2001; Tlsty et al., 2004; Yaswen and Stampfer, 
2001). Western blot analysis of BPEC whole cell lysates showed p16 expression 
throughout passages seven to eleven (Fig. 41 A). My finding was consistent with 
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reports that show that induction of p16 expression commonly occurs in HMEC at 
higher passages and coincides with positive staining for senescence-associated β-
galactosidase, marking the onset of senescence (Brenner et al., 1998). Expression of 
p16 would indeed explain the decreased proliferation rate and senescent phenotype 
that was evident at passage 9. In contrast, Ince and colleagues observed p16 induction 
exclusively in HMEC but not in BPEC, thereby explaining why BPEC are able to 
proliferate indefinitely. Similarly, they reported p53 induction in HMEC but not in 
BPEC (Ince et al., 2007), while I saw both p53 and p21 expression in BPEC. I did not 
further confirm my findings using other BPEC lines. 
 
 
 
Figure 41. Growth properties of breast primary epithelial cells. 
Single primary breast epithelial cells were obtained after dissociation of fresh 
mammary tissue (XS08). Cells were maintained in WIT medium on Primaria plastic 
and serially passaged when they reached approximately 80% confluency. Whole cell 
lysates for Western blot analysis were prepared directly in SDS-PAGE loading buffer. 
(A) BPEC XS08 express p16 at passages 6-11. MDA-MB-231 breast carcinoma cells 
were used as a negative control. Ponceau S stain shows protein loading. (B) BPEC 
XS08 express p53 and p21 at passages 6 and 7. (C) Population doubling times at 
serial passages. 
 
These somewhat contradictory findings underline once more the caveats of long-term 
culture of primary mammary cells and emphasise that it is crucial to limit the time of 
in vitro culture until a reliable culture system has been developed. However, 
variations in the growth rate and morphology of BPEC may also be explained by 
differences between mammoplasty samples such as the age of the patient or the time 
required to process the sample. Another possible explanation may be that the cell 
culture conditions varied between laboratories due to the complexity of the WIT 
medium. 
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Nonetheless, comparison of BPEC and HMEC growth properties demonstrated that 
BPEC could be maintained in culture longer without undergoing senescence. In 
addition, using gene expression profiling of HMEC and BPEC, Ince and colleagues 
showed in their original study that culture in WIT medium favoured luminal 
differentiation of cells, while HMEC overexpressed more than twice as many 
myoepithelial genes as BPEC (Ince et al., 2007). Since my working hypothesis was 
that TOX3 was a regulator of luminal differentiation, I chose the BPEC/WIT protocol 
for further experiments with the intention to create a physiological environment for 
TOX3 function. 
 
3.4.5 TOX3 expression decreases the myoepithelial subpopulation  
To examine whether TOX3 had an effect on mammary lineage commitment, TOX3 
was expressed in non-transformed MCF-10A mammary epithelial cells. MCF-10A 
cells were chosen as a model system for initial experiments as they exhibit bipotent 
progenitor-like properties and recapitulate epithelial morphogenesis in three-
dimensional culture by forming acinar structures (Debnath and Brugge, 2005; 
Debnath et al., 2003; Herr et al., 2011), while their long-term culture is less 
challenging than that of primary mammary epithelial cells.The differentiation state of 
transduced cells was analysed using the colony-forming cell (CFC) assay as described 
by Bachelard-Cascales and co-workers (Fig. 37) (Bachelard-Cascales et al., 2010). 
MCF-10A cells plated at clonal density on a layer of irradiated mouse embryonic 
fibroblast (MEF) feeder cells gave rise to myoepithelial, luminal and mixed colonies, 
thus behaving like bipotent mammary epithelial progenitor cells (Fig. 42 A). To 
quantify the effect of TOX3 expression on MCF-10A differentiation, 2000 cells were 
transduced with the hPGK-TOX3 lentiviral vector or the hPGK-DsRed2 control 
vector. TOX3 expression was confirmed by Western blot analysis (Fig. 42 B), and 
colony formation was examined after seven days (Fig. 42 C). Cells expressing 
DsRed2 showed an abnormal morphology, suggesting that DsRed2 expression had a 
toxic effect (data not shown). Therefore, a no virus control was included in the 
analysis. Both DsRed2 and non-transduced cells gave rise to approximately five-fold 
more myoepithelial colonies than cells expressing TOX3, suggesting that TOX3 
inhibited differentiation of MCF-10A cells along the myoepithelial lineage. Cells 
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expressing TOX3 gave rise to approximately six times more luminal colonies than the 
DsRed2 control but the number of luminal colonies did not change significantly 
compared to non-transduced cells (Fig. 42 C). FACS analysis of the phenotype of 
TOX3 expressing cells was somewhat inconclusive. While TOX3 expression resulted 
in a decrease of the CD24+ subcompartment, it led to an increase in the percentage of 
EpCAM+ cells. Since both are markers of luminal differentiation, the significance of 
these observations was unclear. Interestingly, TOX3 expression resulted in a 
reduction of the CD10+ compartment, which was consistent with a potential inhibition 
of cells with a myoepithelial phenotype (Fig. 42 D), as seen in the CFC assay. 
Furthermore, TOX3 expression resulted in an increase of the CD10/EpCAM double-
positive subpopulation, while it decreased the CD10/CD49d double-positive 
subcompartment, which are thought to be enriched for luminal and myoepithelial 
progenitors, respectively (Fig. 42 D). 
It is tempting to speculate that TOX3 expression at an early stage of mammary 
epithelial development results in a decrease of the early progenitor population by 
forcing differentiation of MCF-10A cells along the luminal lineage, which in turn 
would result in an increased percentage of committed luminal progenitors and a 
simultaneous decrease of the committed myoepithelial progenitor and mature 
myoepithelial subpopulations. However, the CFC results and the phenotypic 
characterisation have to be interpreted with caution since DsRed2 expression was 
toxic for the control cells and the nontransduced cells are not a fully adequate control. 
The assays therefore need to be repeated with an appropriate lentiviral control vector. 
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Figure 42. TOX3 expression inhibits myoepithelial differentiation. 
(A) Representative images of colony-forming cell (CFC) assay read-out. MCF-10A 
cells were plated on a feeder layer of irradiated mouse embryonic fibroblasts (MEF). 
After seven days, cells were fixed in ice-cold methanol and stained with May-
Grünwald colorant. (B-C) To assess the effect TOX3 on mammary epithelial cell 
differentiation, MCF-10A cells were infected with hPGK-TOX3 lentiviral vector or 
hPGK-DsRed2 lentiviral control vector at a multiplicity of infection of 20. 2000 cells 
were seeded on a MEF feeder layer. Colony formation was analysed at day 7 
following infection. Non-transduced (no virus, NV) cells were included as a second 
control because DsRed2 overexpression appeared to be toxic to the cells. (B) Western 
blot analysis of TOX3 expression at day 7. (C) CFC assay. (D) FACS analysis of 
MCF-10A cells at day 7 after transduction with TOX3 lentivirus. 
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3.4.6 Expression of TOX3 does not change ESR1 expression in BPEC 
Due to time constraints I was not able to confirm the results of the CFC assay using 
freshly dissociated BPEC stably expressing TOX3. Preliminary analysis showed no 
obvious morphological difference between BPEC transduced with TOX3 or the GUS 
lentiviral control vector (Fig. 43). In contrast, expression of the estrogen receptor α 
(ESR1) quickly led to the induction of terminal differentiation in BPEC, resulting in a 
senescent, flattened phenotype (Fig. 43 C). The different phenotypes of cells 
expressing TOX3 or ESR1 were consistent with the MCF-7 microarray data discussed 
above. Western blot analysis confirmed that TOX3 expression in BPEC did not 
induce ESR1 expression, which was undetectable in control and TOX3-expressing 
cells (Fig. 43 A). 
 
 
Figure 43. TOX3 expression in breast primary epithelial cells (BPEC). 
BPEC XS11 were transduced with lentiviruses coding for GUS, TOX3 , or ESR1, 
respectively, at passage 3. (A) Western blot analysis of transduced BPEC. TOX3 does 
not alter ESR1 expression levels. (B) Representative phase contrast images of the 
morphology of BPEC expressing GUS, ESR1 or TOX3, respectively, at passage 4 
(magnification 20 ×). 
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3.4.7 Three-dimensional culture of TOX3-expressing cells 
As discussed above, in vivo reconstitution assays are the ultimate stem cell assay. An 
in vitro alternative is what has been termed the terminal ductal lobular unit (TDLU) 
assay, which is used to evaluate the capacity of cells to give rise to three-dimensional 
TDLU-like structures when embedded in a matrigel matrix (Bachelard-Cascales et al., 
2010). To investigate if TOX3 alters the property of cells to produce three-
dimensional structures, BPEC and MCF-10A cells transduced with TOX3 (pXS-36) 
or a lentiviral control vector coding for DsRed2 (pSD-136) or GFP (pER-15) were 
seeded at a single injection site in matrigel mixed with MEF feeder cells and 
maintained in WIT medium. In addition, the luminal breast cancer cell line MCF-7 
and the basal breast cancer cell line MDA-MB-231 were examined. For the successful 
outgrowth of tumour cells feeder cells were not required. While the TDLU assay had 
originally been developed to assess stem cell properties of primary mammary 
epithelial cells (Villadsen et al., 2007), my rationale was that TOX3 might alter the 
differentiation of established tumour cells that do not express endogenous TOX3. 
Three-dimensional growth was examined after 6 and 14 days. As observed in the CFC 
assay, expression of the fluorescent control genes DsRed2 (multiplicity of infection, 
MOI = 20) and GFP (MOI = 5) appeared to be toxic to the cells and impaired cell 
growth, as assessed by comparison to the no-virus control (NV). This effect did not 
appear to be due to the lentiviral infection per se but rather the efficient expression of 
the fluorescent marker genes at relatively high levels, even at low MOIs, or an 
underestimate of the true viral titre. TOX3-expressing cells were therefore compared 
to both negative controls. As expected, bipotent MCF-10A cells gave rise to three-
dimensional outgrowths that resembled duct-like and bulbous structures (Fig. 44). 
Microscopical analysis did not show significant morphological differences between 
outgrowths derived from TOX3- and control-infected cells but without histological 
analysis the formation of TDLU-like structures is difficult to interpret. To examine 
their differentiation state, three-dimensional outgrowths are currently being examined 
by immunohistochemical staining for keratins 14 and 18. While the TDLU assay 
confirmed the bipotent properties of the MCF-10A cell line, it gave no valuable 
information on the effect of TOX3 expression in the MCF-7 and MDA-MB-231 
tumour cell lines. MCF-7 cells in particular were not able to grow out in duct- and 
TDLU-like structures but rather formed a solid lump at the site of injection, and no 
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obvious morphological difference could be observed between TOX3-expressing and 
control cells (data not shown). MDA-MB-231 cells appeared to be able to grow out in 
the matrigel matrix to a greater extent. Control-infected cells formed thin tubular 
structures but no TDLU-like outgrowths (data not shown), while TOX3-transduced 
cells remained in a solid lump at the injection site, suggesting that TOX3 repressed 
growth of the basal tumour cell line but again, more sound conclusions can only be 
drawn upon phenotypic characterisation of the differentiation state of the outgrowths. 
Due to technical problems, characterisation of TOX3-expressing primary BPEC in the 
TDLU assay could not be concluded but is subject of current investigations. 
 
MCF-10A
Day 6
GFPNV TOX3
Day 14
 
Figure 44. TDLU assay. 
MCF-10A cells were trypsinised and infected with hPGK-GFP (pER-15) or hPGK-
TOX3 lentiviral vectors at a MOI of 5 and 20, respectively.  In addition, a no-virus 
control (NV) was included. Cells were subsequently injected into hardening matrigel 
mixed with MEF on a Lab-Tek chamber slide. Hardened matrigel was covered with 
medium. Outgrowths were examined at days 6 (top row) and 14 (bottom row). 
 
3.5 A TOX3 tumour model 
To test my working hypothesis that TOX3 is a transforming oncogene, I set out to 
create a luminal xenograft tumour model based on quantitative transformation of 
normal human mammary epithelial cells, as described in the Introduction. As an 
initial experiment, I chose to examine the effect of stable TOX3 expression in the 
luminal tumour cell line MCF-7. The rationale for using an established cell line was 
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twofold. First, microarray analysis of short-term TOX3 expression in MCF-7 cells 
had identified several TOX3 target genes. Secondly, the effect of TOX3 expression 
on the morphology and differentiation of normal human mammary epithelial cells and 
non-tumourigenic MCF-10A cell growth appeared rather subtle, suggesting that 
expression of TOX3 alone was not able to transform non-tumourigenic cells. MCF-7 
cells were chosen as a first model system as they are tumourigenic cells of luminal 
differentiation, thereby providing an appropriate environment for TOX3 function. 
 
3.5.1 TOX3 expression confers short-term growth advantage but does not alter 
long-term proliferation of MCF-7 cells 
To analyse stable TOX3 expression, MCF-7 cells were infected with hPGK-TOX3 
lentivirus (pXS-36) or a negative control vector expressing DsRed2 (pSD-136) or 
GFP (pER-15) at a multiplicity of infection that ensured a transduction efficiency of 
greater than 80%. Transduced cells were selected by puromycin treatment. In addition 
to MCF-7 cells, TOX3 was expressed in the basal breast cancer cell line MDA-MB-
231 to investigate whether TOX3 would alter the growth properties of basal tumour 
cells. TOX3 expression was examined by Western blot at day 7, 11, 15, and 22 post 
infection. 
While TOX3 expression did not have any obvious effect on the morphology of either 
MCF-7 or MDA-MB-231 cells (data not shown), Western blot analysis confirmed 
TOX3 expression but also indicated that expression was silenced in MCF-7 cells over 
time (Fig. 45 A). Several repeats of hPGK-lentivirus-based TOX3 expression in 
MCF-7 cells as well as HMEC AJ4 and T-47D cells confirmed that after 
approximately three weeks (or 6 to 7 passages), relative TOX3 expression was 
markedly decreased (data not shown). To date, I have not been able to find a 
conclusive explanation for the silencing of TOX3 expression. The microarray results 
suggested that TOX3 weakly repressed PGK expression (Table 14, Appendix), which 
would create a negative feedback loop. The silencing of TOX3 expression using our 
lentiviral model system posed a major problem for the creation of stable TOX3 cell 
lines and as a consequence also for the creation of a TOX3 tumour model. 
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Figure 45. Stable expression of TOX3 in MCF-7 and MDA-MB-231 cell. 
MCF-7 cells were transduced with hPGK-TOX3 (pXS-36) or hPGK-DsRed2 control 
vector and selected using puromycin. (A) Expression of TOX3 and its target gene 
PGR at day 7, 11, 15, and 22 post infection was examined by Western blot analysis. 
(B) TOX3 had no significant immediate effect on the proliferation rate of MCF-7 
cells. Cells were counted at day 1-7 following passage 1 post infection. The 
experiment was repeated three times. A representative growth curve is shown. (C) 
Effect of long-term TOX3 expression on the proliferation rate of MCF-7 cells. 
Transduced cells were maintained in culture for 21 days and passaged every 3 days. 
The same number of cells was seeded and cells were counted at every passage. The 
experiment was repeated three times. A representative growth curve is shown. Error 
bars represent the standard deviation. 
 
To circumvent the use of the constitutive hPGK-TOX3 expression vector, we are 
currently creating a drug-controllable lentiviral vector for inducible TOX3 expression 
using the KRAB repressor/tet-off system (Szulc et al., 2006). An inducible system 
will allow tight control of TOX3 expression. In addition, it will be possible to 
uncouple the time of lentiviral infection and the time of TOX3 expression, thus also 
temporally separating potential side-effects of lentiviral infection such as the 
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induction of the interferon response from TOX3-specific effects. Without an inducible 
TOX3 expression vector at hand, analysis of TOX3 expression had to be limited to 
approximately three weeks. During this period of time, TOX3 function could be 
confirmed by downregulation of the TOX3 target gene progesterone receptor (Fig. 45 
A). 
To examine whether TOX3 expression affected the proliferation rate of MCF-7 cells, 
I first followed cell growth over the course of seven days following the first passage 
post infection. TOX3 appeared to have no significant effect on the proliferation rate 
(Fig. 45 B). To examine whether TOX3 expression would have a more obvious effect 
over a longer period of time, MCF-7 cell proliferation was followed for 
approximately three weeks following the first passage after lentiviral infection. The 
proliferation rate was consistently increased at passage 2 post infection (equalling 
approximately one week) in the presence of TOX3 but the effect was no longer 
detectable at the following passage (1.5 weeks), despite continued TOX3 expression 
(Fig. 45 A), suggesting that the onset of TOX3 expression induced proliferation but 
sustained TOX3 expression did not maintain this effect. Preliminary cell cycle 
analysis using flow cytometry showed a corresponding transient small increase in the 
percentage of cells in S phase at passage 2 following infection in the presence of 
TOX3 (data not shown). However, albeit being detectable in several separate 
experiments, the increase was not statistically significant. 
 
3.5.2 TOX3 increases the tumour take in the MCF-7 luminal tumour model 
To test the tumourigenic potential of TOX3, MCF-7 cells expressing TOX3 or the 
control gene were xenografted in 6-week old female NSG mice by intraductal 
injection (Behbod et al., 2009). Tumour formation was followed by in vivo 
fluorescence imaging for 21 days, and mice were sacrificed and examined for tumour 
incidence at days 7 and 21 post injection. All control (8/8 mice) and TOX3 mice 
(11/11) developed tumours, demonstrating that both control and TOX3-expressing 
MCF-7 cells were able to engraft in the murine ducts, albeit with different efficiency. 
At day 7, the tumour load in TOX3 mice was significantly higher than in control mice 
(Fig. 46 A, B). However, at day 21, no difference in tumour load could be detected 
between TOX3 and control mice, suggesting that TOX3 increased the initial tumour 
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take in the MCF-7 luminal tumour model. It was not clear whether this was due to 
increased proliferation of the TOX3-expressing cells or whether TOX3 promoted 
engraftment of the cells in the ducts. Histological analysis showed that tumours were 
initially confined to the ducts but rapidly progressed to invade the fat pad (Fig. 46 C). 
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Figure 46. Intraductal TOX3 tumour model. 
TOX3 increases tumour take in the MCF-7 luminal breast cancer model. MCF-7 cells 
were infected with a GFP lentiviral vector not conferring puromycin resistance. 
Subsequently cells were superinfected with hPGK-TOX3 or DsRed2 lentivirus and 
subjected to puromycin selection. Cells were intraductally injected into the mammary 
gland of 6-8 week-old NSG mice and sacrificed at day 7. (A-B) Representative 
images of GFP fluorescence of MCF-7 cells in TOX3 mice (A) and control mice (B) 
at day 7. Tumour load in TOX3 mice was significantly higher than in control mice. 
(C) H&E staining of TOX3-expressing MCF-7 cells showing the presence of 
carcinoma invading the surrounding adipose tissue. (D) Immunohistochemical (IHC) 
staining for GFP confirming that the observed tumours were formed by injected 
MCF-7 cells. (E) IHC staining for estrogen receptor α. 
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3.5.3 Quantitative transformation of normal mammary epithelial cells 
In view of the problems related to the creation of breast cancer cell lines stably 
expressing TOX3, the technically more challenging transformation of normal 
mammary epithelial cells did not seem advisable without the creation of a conditional 
TOX3 lentiviral expression construct. As mentioned above, we are currently creating 
a drug-controllable lentiviral vector for inducible TOX3 expression using the KRAB 
repressor/tet-off system (Szulc et al., 2006), which will allow tightly controlled TOX3 
expression. 
While a reliable TOX3 lentiviral expression construct was unavailable, I carried out a 
small pilot experiment to establish a transformation protocol for normal human 
mammary epithelial cells. The protocol I decided to use was adapted from the luminal 
orthotopic xenograft tumour model that had previously been developed in our 
laboratory (Duss et al., 2007). In contrast to the original model, which used HMM+ 
medium for the culture of transformed HMEC on conventional plastic dishes, I chose 
to maintain cells in WIT medium on Primaria plastic. As discussed above, Ince and 
colleagues had shown that the latter culture method promoted luminal differentiation 
of primary mammary epithelial cells and prevented squamous differentiation of 
BPEC-derived tumours in immunodeficient mice, which is a problem commonly 
observed with HMEC-derived xenografts (Duss et al., 2007; Ince et al., 2007). 
For the transformation protocol (Fig. 47), mammary epithelial cells (BPEC) and 
human mammary fibroblasts (HMF) were obtained from reduction mammoplasties of 
healthy pre-menopausal women. Dissociated HMF were plated directly in adherent 
culture. Following dissociation, single BPEC were allowed to recover overnight in 
suspension before they were infected with lentiviruses encoding estrogen receptor α 
(hPGK-ESR1, pSD-82) and BMI1 (hPGK-BMI1, pSD-84). Negative control cells 
were infected with an hPGK-GFP lentiviral vector (pRRlsin.ppts.hPGKGFPpre, pXS-
17). Infected cells were cultured as mammospheres for one passage to enrich for 
progenitor cells. Subsequently, cells were plated in adherent culture, and successfully 
transduced cells were selected using puromycin. 
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Figure 47. Protocol for the creation of a luminal tumour model. 
Schematic of the protocol used to create a luminal tumour model using the 
quantitative transformation BPEC and subsequent xenograft to test tumourigenic 
potential of transformed cells. 
 
In a second round, BMI1/ESR1-positive cells were infected with lentiviruses coding 
for MYC (hPGK-MYC, pSD-94) and TERT (hPGK-TERT, pSD-83). In addition, 
cells were infected with the hPGK-DsRed2 lentivirus (pSD-136) for subsequent 
tracking in the mouse. DsRed2 transduction was confirmed by fluorescence 
microscopy (data not shown), while expression of the remaining transgenes was 
examined by Western blot (Fig. 48 A). While the expression of ESR1 and BMI1 was 
confirmed, TERT and MYC expression were only detected at very low levels. As all 
lentiviruses shared the pSD-69 lentivirus backbone that conferred resistance to 
puromycin, another selection step was not possible to ensure higher levels of TERT 
and MYC. To test their tumourigenic properties, 75,000 BPEC XS08.4 cells (passage 
8) expressing the four transgenes plus the DsRed2 marker were unilaterally co-
injected with 25,000 HMF mixed with 12.5 vol% matrigel into the fourth inguinal 
mammary gland of 30-week old female NSG mice one week post insertion of a 0.5-
mg slow-release beta-estradiol pellet. GFP-expressing BPEC (passage 6) were used as 
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a negative control, and HMEC AJ4 cells (passage 16) were used as a positive control. 
Mice were sacrificed after 15 days and analysed for tumour and metastasis incidence. 
The results are summarised in Table 10. 
 
Table 10. Tumour formation in NSG mice. 
BPEC/HMEC line Colour marker Tumours Metastases 
HMEC AJ4 (P16) CFP 1/1 0/1 
BPEC XS08.4 (M1P7) DsRed2 2/3 0/3 
BPEC XS08.ctrl 
(M1P5) 
GFP 0/1 0/1 
HMEC AJ4 and BPEC XS08.4 expressed ESR1, BMI1, TERT, and MYC; the control line BPEC 
XS08.ctrl expressed GFP. The passage number of injected cells is indicated in parentheses; P, adherent 
passage; M, mammosphere passage. 
 
As expected, the negative control cell line BPEC XS08.ctrl did not induce tumour 
formation in mice. Consistent with previous results from our group, AJ4 cells were 
able to form tumours in mice (Duss et al., 2007). However, they did not form 
metastases as had been observed previously, which was likely to be due to the 
relatively high passage number (Stephan Duss, personal communication). BPEC 
XS08.4 cells were able to form tumours in two out of three cases (Table 10, Fig. 48). 
Inconsistent with the reports from the Weinberg laboratory (Ince et al., 2007; 
McAllister et al., 2008), tumours were predominantly of squamous differentiation 
(Fig. 47 D, E). BPEC formed squamous tumours with an efficiency similar to the 
HMEC AJ4 line (data not shown). Consistent with the findings of Weinberg and 
colleagues, I observed a strong stromal reaction surrounding the BPEC-derived 
tumour tissue (Fig. 48 D, E), suggesting that BPEC XS08.4 cells represent instigating 
tumour cells capable of recruiting activated murine stromal cells by secreting 
osteopontin (McAllister et al., 2008). 
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Figure 48. Quantitatively transformed BPEC form tumours in NSG mice. 
(A) Western blot analysis of transgene expression. The HMEC tumour cell line AJ4 
was used as a positive control (Duss et al., 2007). (B) Phase contrast image of tumour 
at day 15. (C) DsRed2 fluorescent image of the same tumour area at day 15. (D) H&E 
staining of tumour tissue demonstrates squamous differentiation. Cross-section 
through tubular tumour structure. (E) Immunohistochemical staining of tumour cross-
section for cytokeratin 14 (brown) confirms the presence of squamous differentiation. 
The stained tumour tissue is surrounded by an area of extensive stromal reaction. 
 
In conclusion, in my hands BPEC-derived tumour cells exhibit some of the 
characteristics that Weinberg and colleagues described but differ in that they are not 
capable of forming adenocarcinomas. In addition, untransformed BPEC display 
different growth and differentiation properties than the cells in the original study, as 
described in the previous chapter. It has to be noted that a larger number of mice was 
not available at the time of the experiment, which impairs the statistical relevance of 
the data I obtained from this preliminary experiment. However, BPEC could be 
oncogenically transformed using a combination of TERT, MYC, BMI1 and ESR1. I 
was thus able to confirm the tumourigenic properties of quantitatively transformed 
mammary epithelial cells in the xenograft model. All tools are thus set up to test the 
tumourigenic potential of TOX3 once the inducible BPEC-derived cell lines have 
been created. 
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4 Discussion 
Estrogen receptor α (ERα, ESR1) expression is a major determinant of the breast 
cancer phenotype and biology. As a result, the mechanisms underlying ERα-positive 
breast cancer have been the subject of extensive research. However, to date many 
questions have remained unanswered including the paradox that estrogen acts as a 
potent mitogen in ERα-positive breast cancer but induces differentiation in normal 
mammary epithelial cells. The identification of new luminal breast cancer genes and 
the establishment of model systems that accurately mimic the human disease and 
allow the characterisation of these genes are therefore of great interest. 
In the present study, I have investigated the function of the previously uncharacterised 
putative breast cancer predisposition gene TOX3 in the normal breast and ERα-
positive breast cancer. 
The broader context of this work was the characterisation of new candidate breast 
cancer genes in the ERα-positive human-in-mouse tumour model that had previously 
been established in our laboratory (Duss et al., 2007). The latter model was developed 
by transformation of normal human mammary epithelial cells with the genes TERT, 
BMI1, MYC and ESR1. The resulting cells gave rise to ERα-positive tumours with 
high efficiency and were estrogen-dependent for growth. SNP chip analysis showed 
that the human tumour cells were genetically normal after growth in the mouse, 
suggesting that transformation was caused by expression of the four transgenes alone 
(therefore termed “quantitative” transformation). In addition, the cells formed 
metastases, thus displaying several properties of human ERα-positive breast cancer. 
However, histological examination of the tumour tissue showed large regions of 
squamous differentiation, which is rare in human ERα-positive tumours. While the 
formation of squamous carcinoma has been linked to inappropriate cell culture 
conditions (Ince et al., 2007), another explanation may be that the combination of 
transgenes used to create the model did not adequately reflect the genetic changes 
causing the human disease, thus inducing an aberrant transcriptional programme, 
which results in differentiation into keratinised epithelial cells. It appears likely that 
ESR1 along with BMI1 and MYC caused the formation of tumours but the correct 
cellular differentiation and thus development of adenocarcinoma may require the 
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expression of additional co-regulators of ESR1. The rationale of the present work was 
therefore to characterise such potential co-factors of ESR1. 
TOX3 was chosen as a candidate gene because it clusters with classic luminal genes 
such as GATA3, FOXA1, and XBP1 in expression array data of primary breast 
tumours previously described by our group (Fig. 11) (Farmer et al., 2005). The fact 
that augmented TOX3 expression correlates with expression of the luminal 
differentiation genes in ERα-positive suggests that TOX3 may be subject to a 
regulatory mechanism that is similar to that of FOXA1 and GATA3 and that TOX3 
may have a related function. In addition, recent genome-wide association studies had 
linked single nucleotide polymorphisms in the regulatory region of the TOX3 gene to 
an increased susceptibility to ERα-positive breast cancer (Easton et al., 2007; Stacey 
et al., 2007). 
As TOX3 gene function was entirely uncharacterised at the time of the start of this 
project, the present study was designed as a broad approach to investigate the 
biological role of TOX3. 
 
4.1 TOX3 is a luminal gene 
In the normal mammary epithelium overall expression of TOX3 protein was 
comparatively low, as it was not detectable by Western blot analysis of unsorted 
BPEC (Fig. 16 A). Due to the unavailability of sufficient amounts of fresh reduction 
mammoplasty tissue I was not able to investigate TOX3 expression in FACS-sorted 
mammary epithelial cells by quantitative PCR analysis myself. However, expression 
data were available from two recent microarray studies from the Smalley and 
Visvader groups (Kendrick et al., 2008; Lim et al., 2010). Based on these data, TOX3 
is expressed almost exclusively in the mature luminal epithelial compartment but not 
mammary stem cells or luminal progenitors in the human breast (Fig. 16 C) (Lim et 
al., 2010), which may suggest that TOX3 is predominantly involved later in luminal 
differentiation but that it does not function as a regulator of early luminal cell fate 
determination. The mouse data from the Smalley group further showed relatively high 
expression of TOX3 in ERα-positive luminal cells versus low expression in ERα-
negative luminal cells (Fig. 16 C) (Kendrick et al., 2008). The evolutionarily 
conserved expression pattern of TOX3 (Table 8) suggests a function late in the 
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differentiation of luminal epithelial cells. It remains to be determined how exactly 
TOX3 regulates luminal cell fate. Possible scenarios may involve active promotion of 
luminal differentiation (Fig. 49), which would be consistent with the observation that 
TOX3 expression in MCF-10A cells increased the EpCAM+ subpopulation (Fig. 42 
D). Alternatively, TOX3 may favour differentiation along the luminal cell lineage by 
inhibiting myoepithelial cell differentiation (Fig. 49). This would be in keeping with 
the observation that TOX3 expression in MCF-10A cells resulted in a decrease in 
myoepithelial colony formation in the CFC assay (Fig. 42 B) as well as in a decrease 
of the CD10+ and CD49d (ITGA4)/CD10 double-positive myoepithelial 
subpopulations (Fig. 42 D). It is tempting to speculate that TOX3 expression in 
normal epithelial cells maintains luminal cell differentiation by inhibiting the 
commitment to a myoepithelial cell fate. This would be in analogy to the related 
family member TOX, which regulates the development of both CD4+ and CD8+ cells 
in the thymus in a lineage-specific manner (Aliahmad and Kaye, 2008; Aliahmad et 
al., 2004; Wilkinson et al., 2002). Such a dual role for TOX3 in mammary epithelial 
cell development would likely involve the interaction with other transcriptional co-
regulators such as YBX1 (Table 9) and CITED1, which is discussed in more detail 
below. 
Taken together, evidence from the transcriptional profiling studies and the CFC assay 
suggest a role for TOX3 in the biology of luminal epithelial cells but further 
functional assays will be required to identify its exact function. For instance, it would 
be of interest to express TOX3 in the different mammary epithelial subpopulations to 
examine its effect on lineage choice and differentiation. 
 
4.2 A transcriptional network that regulates luminal epithelial 
development and differentiation 
4.2.1 TOX3 is a nuclear protein 
I show here for the first time that TOX3 is a nuclear protein. An ectopically expressed 
TOX3-GFP fusion protein localised exclusively to the nucleus of MCF-7 and HEK 
293T cells. TOX3-GFP exhibited an overall diffuse nuclear localisation that was 
interspersed with regions that appeared to be in more condensed, ring-like or patchy 
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conformations. TOX3 was further excluded from nucleoli (Fig. 20, 36). The 
subnuclear localisation pattern of the TOX3-GFP fusion protein bore resemblance to 
those of canonical HMGB proteins, which in turn have been described to recapitulate 
the localisation pattern of histones and other chromatin-bound proteins as well as 
DNA itself (Catez and Hock, 2010). Nuclear localisation of transiently and stably 
expressed TOX3 was confirmed by indirect immunofluorescent staining but owing to 
the impurity of the custom-made TOX3 Rb57 antibody, high background levels 
complicated the interpretation (data not shown). Nuclear localisation of TOX3 is in 
keeping with the predicted nuclear localisation signal adjacent to the HMG-box on its 
N-terminal side. Like TOX3, the related proteins TOX and TOX2 have been shown to 
localise to the nucleus (Aliahmad and Kaye, 2006; Kajitani et al., 2004). 
Immunofluorescent analysis of TOX3-GFP and γ-H2AX co-localisation was 
inconclusive due to the relatively diffuse subnuclear localisation of both proteins in 
etoposide-treated cells (Fig. 36). γ-H2AX typically localises to distinct foci at sites of 
DSBs caused by ionising radiation (Nakamura et al., 2010). A possible explanation 
for the diffuse localisation of γ-H2AX that I observed may be that cells were treated 
with etoposide for four hours, while phosphorylation of H2AX occurs rapidly after 
the induction of DNA damage. To investigate whether TOX3 localises to γ-H2AX 
foci at sites of DSBs, it would perhaps be preferable to cause DNA damage using 
ionising radiation and to analyse subnuclear localisation of both proteins shortly after 
the induction of DNA damage. Surprisingly, TOX3-transfected cells stained positive 
for γ-H2AX, which may suggest that TOX3 plays a role in the recognition or repair of 
damaged DNA like the related protein TOX4 (Puch et al., 2010). Phosphorylation of 
H2AX in TOX3-expressing cells requires further analysis and could be verified by 
Western blot analysis. Expression of TOX3-GFP under the control of a stronger 
promoter such as the CMV promoter would hopefully produce microscopy data of 
higher quality that would facilitate the analysis of TOX3 localisation. 
In contrast to the localisation of TOX3-GFP, IHC staining of TOX3 in luminal 
tumours was both cytoplasmic and nuclear (Fig. 12). The discrepancy between IHC 
data and localisation of TOX3-GFP may be due to different posttranslational 
modification of endogenous TOX3 and ectopically expressed TOX3, which may 
result in its localisation to the nucleus in the normal breast (or cells that do not 
express endogenous TOX3) but may lead to its sequestration in the cytoplasm in 
tumour cells. Nuclear export or translocation to the nucleus is a common mechanism 
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to regulate the activity of transcription factors. On the other hand, cytoplasmic 
staining may be an artefact and simply due to insufficient purity of the TOX3 Rb57 
antibody that was used. To characterise subcellular localisation of TOX3, it would be 
of interest to create a deletion series of TOX3-GFP fusion constructs. 
As mentioned above, various functions have been ascribed to HMG box-containing 
proteins that are independent of their role in classic transcriptional regulation. With 
respect to a potential involvement in DNA damage recognition or repair, it may be of 
interest that the microarray experiment showed that a number of histone genes were 
among the most downregulated genes in TOX3-expressing MCF-7 cells (Fig. 33 B). 
Histone gene expression is known to be regulated in a cell cycle-dependent manner. 
Therefore, the observed downregulation of histone genes may also be related to the 
changes in replication gene expression (Fig. 33). 
 
4.2.2 Transcriptional regulators of luminal differentiation 
As mentioned above, evidence for a role for TOX3 in ERα-positive breast cancer 
comes from the finding that TOX3 is expressed in luminal tumours but not in ERα-
negative tumours and importantly, because it clusters with the genes that define the 
luminal breast cancer subtype (Fig. 11). Based on sequence predictions, the HMG-
box motif in TOX3 is thought to bind DNA without sequence specificity, similar to a 
multitude of HMG-box proteins that organise chromatin structure as architectural 
proteins (O'Flaherty and Kaye, 2003). It has to be noted that the present study does 
not provide direct proof that TOX3 acts as a transcriptional regulator in mammary 
cells but evidence that TOX3 is a transcription factor comes from studies showing 
that TOX3 cooperates with CREB and CITED1 to activate transcription in neurons 
(Dittmer et al., 2010; Yuan et al., 2009). It is thus plausible that, like other luminal 
transcription factors, TOX3 plays a role both in the normal development and 
differentiation and in the oncogenic transformation of luminal epithelial cells. Beside 
the Ets transcription factor ELF5, which regulates luminal alveolar cell fate (Oakes et 
al., 2008a), FOXA1 and GATA3 are probably the best-characterised luminal 
transcription factors (Asselin-Labat et al., 2007; Bernardo et al., 2010; Kouros-Mehr 
et al., 2008; Kouros-Mehr et al., 2006). In keeping with their role in luminal cell 
differentiation, expression of FOXA1 and GATA3 in breast cancer correlates with a 
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good prognosis (Badve et al., 2007; Habashy et al., 2008; Mehra et al., 2005; Sorlie et 
al., 2003). Although the correlation between ESR1, FOXA1 and GATA3 expression 
in luminal breast cancer is well established, surprisingly little is known about the 
interplay between these factors. A recent study showed that FOXA1, aside from its 
role as a co-regulator of ESR1-dependent transcription, also regulates expression of 
ESR1 but not of GATA3 (Bernardo et al., 2010). FOXA1 in turn has been shown to 
be a downstream target of GATA3 (Kouros-Mehr et al., 2006). In breast cancer cells, 
FOXA1 appears to mediate, at least in part, the pro-proliferative properties of ESR1 
as it is required for transcriptional activation of cyclin D1 (CCND1) by ESR1 
(Eeckhoute et al., 2006). Similarly, GATA3 functions in a positive cross-regulatory 
loop with ESR1 in breast cancer cells (Eeckhoute et al., 2007). 
It is conceivable that TOX3, too, functions in the transcriptional network that controls 
luminal differentiation. Western blot and microarray analysis showed that TOX3 had 
no effect on FOXA1 protein or mRNA levels (data not shown). With respect to its 
expression in luminal cells (Fig. 16), TOX3 mirrors the expression pattern of FOXA1 
more than that of other luminal transcription factors. For instance, GATA3 is 
expressed at comparable levels in both luminal progenitors and mature luminal cells, 
while FOXA1 is predominantly expressed in mature luminal cells (Fig. 16 C), thus 
correlating with ERα expression levels. This is in keeping with its function as a 
pioneer factor of ERα-dependent transcription. FOXA1 binds at distal enhancer 
elements by displacing histones and opening up the chromatin structure, thereby 
facilitating the recruitment of ERα and the transcriptional machinery at proximal 
target gene promoters (Carroll and Brown, 2006; Cirillo et al., 2002). It is tempting to 
speculate that TOX3 functions in a way that is similar to FOXA1 to enable ERα-
dependent transcription. TOX3 binding to distal enhancer elements rather than in 
proximity of ERα response elements (ERE) would explain why it TOX3 had no effect 
on ERE-dependent transcription in the luciferase assay (Fig. 35) since the reporter 
constructs only contained isolated ERE or short proximal promoter elements. 
The preliminary TOX3 microarray data showed a TOX3-dependent decrease in 
GATA3 expression (Fig. 33). Loss of GATA3 in early tumours is linked to a loss of 
differentiation and marks tumour progression in a GATA3-MMTV-PyMT tumour 
model (Kouros-Mehr et al., 2008), and SNPs in the GATA3 gene have been shown to 
be associated with an increased breast cancer susceptibility (Garcia-Closas et al., 
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2007). In the context of the luminal transcriptional network, it would certainly be of 
interest to further investigate a correlation between TOX3 and GATA3 expression. 
 
4.2.3 TOX3 and ESR1 
GSEA of the TOX3 microarray data suggested that TOX3 had, if any, a weak 
suppressive effect on ESR1 expression itself (Fig. 33 I), and Western blot analysis 
confirmed this finding (Fig. 34). Since ESR1 expression is not detectable in unsorted 
primary mammary epithelial cells, it was not surprising that no difference in ESR1 
levels was detected in TOX3 versus control transduced BPEC (Fig. 43 A). In keeping 
with the microarray data, separate overexpression of TOX3 and ESR1 in BPEC did 
not result in the same cell morphology, indicating that the regulation of luminal 
differentiation by TOX3 does not depend on ESR1 and vice versa, or at least not to a 
great extent (Fig. 43 B). This is not surprising, as it is not expression of ESR1 that 
ultimately defines the luminal phenotype, a notion that is exemplified by the absence 
of ESR1 expression in a subset of normal mature luminal cells. Moreover, ESR1 
expression is restriction to the luminal A and B breast cancer subtypes, while other 
luminal differentiation genes are expressed in the “broad luminal” subgroup that also 
includes molecular apocrine tumours, which are ERα-negative tumours that are 
characterised by androgen signalling and do not classify as basal (Farmer et al., 
2005). In keeping with a role for TOX3 in a more widely defined luminal cell 
differentiation, TOX3 also repressed the molecular apocrine gene activated leukocyte 
adhesion molecule (ALCAM) (Fig. 33 I). 
GSEA further showed that TOX3 expression resulted in downregulation of the classic 
ESR1 target gene growth regulation by estrogen in breast cancer 1 (GREB1) (Fig. 33 
I), expression of which has been shown to closely reflect S phase entry of MCF-7 
cells upon stimulation by beta-estradiol (Deschenes et al., 2007; Rae et al., 2005). In 
contrast, another classic ESR1 target gene, TFF1, was not suppressed by TOX3 (Fig. 
33 I), which is consistent with TOX3 having no transcriptional effect on the TFF1 
promoter (Fig. 35). 
As discussed below, due to the quality of the data, the relevance of the TOX3 
microarray results is unclear at this point. 
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4.2.4 TOX3 and CITED1 
To date, only two studies have been published that characterise TOX3 function at the 
molecular level, both of which are concerned with the role of TOX3 in neurons. 
Using deletion mapping, these studies have shown that TOX3 contains an N-terminal 
transactivation domain that regulates transcription in concert with the HMG-box, 
while the C-terminal domain interacts with TOX3 binding partners CREB and 
CITED1 (Dittmer et al., 2010; Yuan et al., 2009). CITED1 is of particular interest 
because it has been implicated in ERα signalling (Kim et al., 2011; McBryan et al., 
2007; Yahata et al., 2001) and has been shown to act as a transcriptional co-activator 
in numerous hormone-regulated tissues, including the mouse mammary gland, 
pituitary and ovaries (Kim et al., 2011; McBryan et al., 2007; Sriraman et al., 2010). 
Moreover, the Visvader study ranked both TOX3 and CITED1 among the ten genes 
that show the highest conservation between human and mouse in the mature luminal 
subpopulation (Table 8), and the expression pattern of CITED1 resembles that of 
TOX3 in the mammary epithelial subpopulations (Fig. 16) (Lim et al., 2010). 
It is intriguing to speculate that both proteins also interact in mature luminal cells to 
activate a luminal-specific transcriptional programme. However, a potential 
interaction of TOX3 and CITED1 in mammary cells is purely speculative at this 
point. Using co-immunoprecititation, I am currently investigating if TOX3 interacts 
with CITED1 in mammary cells. If the outcome is positive, it will be of interest to 
examine whether TOX3 is dependent on cooperation with CITED1 to activate 
transcription of ERE-containing promoters, as observed by Dittmer and colleagues. I 
observed that TOX3 alone was not able to act as a transcriptional activator of ERE-
containing minimal promoter elements (Fig. 35). It is unclear why my luciferase data 
contradict the observations made by Dittmer and co-workers, although it has to be 
noted that the latter reported an increase of target promoter activity of approximately 
fivefold (Dittmer et al., 2010), which appears rather small. Differences in TOX3 
activity may further be due to the use of different cell types, a lack of required co-
activators such as CITED1, which facilitate binding to the DNA binding site or 
mediate interaction with a third transcriptional regulator such as ESR1. It appears 
unlikely that CITED1 alone is capable of recruiting of TOX3 to target promoters 
because it lacks a DNA-binding domain. Tandem affinity purification did not yield 
any information about a possible interaction between TOX3 and CITED1 since 
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CITED1 is not expressed in HEK 293T cells (data not shown). It remains unclear how 
TOX3 regulates luminal mammary epithelial cell differentiation without being 
involved in estrogen-dependent signalling but treatment of MCF-7 cells with beta-
estradiol did not change TOX3-dependent transcriptional regulation of ERE-
containing promoters (Fig. 35), nor did it have an influence on TOX3 expression 
levels themselves (data not shown). This was consistent with the findings by Dittmer 
and colleagues, who showed that treatment with fulvestrant did not inhibit TOX3-
dependent transcriptional activation of ERE-containing promoters (Dittmer et al., 
2010). The significance of this finding is unclear, as both the work presented here and 
the latter study examined a limited number of artificial promoter constructs. 
Regulation of ERα target genes by TOX3 may be more complex. The microarray 
analysis of TOX3 target gene expression in MCF-7 cells supports this notion, as some 
ERα target genes such as PGR were repressed in the presence of TOX3 while others 
such as TFF1 were not inhibited  (Fig. 33 I). Similarly, transcriptional co-regulation 
of ERα target genes by CITED1 appears to be gene-specific, as in MCF-7 cells, 
CITED1 activates transcription of TGF-α in an E2-dependent manner but not of TFF1 
(Yahata et al., 2001). Microarray analysis of untreated versus E2-treated TOX3 
expressing cells may be useful to shed light on estrogen-dependence of TOX3 
transcriptional regulation. It is of note that I did not find any effect of TOX3 on 
CITED1 expression (data not shown) but the microarray data suggested that TOX3 
expression resulted in downregulation of the related transcription factor CITED2 (Fig. 
33). No data regarding a potential interplay between CITED1 and CITED2 in the 
breast has been reported to date but it has been shown that they are differentially 
expressed in the developing kidney (Boyle et al., 2007). 
 
4.2.5 TOX3 potentially interacts with YBX1 
Using tandem affinity purification in combination mass spectrometric analysis of 
TOX3, I have identified the transcription/translation factor Y-box binding protein 1 
(YBX1, YB-1) as a potential TOX3 interacting protein. However, since the mass 
spectrometry data were of low quality due to high keratin contamination, only very 
abundant proteins were detected in the NTAP-TOX3 sample, such as chaperone 
proteins cytoskeletal proteins. The expression data from the Visvader group appear to 
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confirm that YBX1 is an abundant protein in all mammary subpopulations (Fig. 16 C) 
(Lim et al., 2010). Therefore, the mass spectrometry results need to be considered 
with some caution, and the interaction between TOX3 and YBX1 needs to be 
confirmed by co-immunoprecipitation. In addition, since the NTAP control sample 
was not analysed by mass spectrometry because of the keratin contamination, the 
possibility cannot be excluded that YBX1 in fact bound to the TAP tag and not to 
TOX3. Nevertheless, YBX1 would be a potentially interesting candidate as it is 
known to act as a breast cancer oncogene that promotes tumour growth through a 
multitude of functions including the induction of genes such as EGFR, ERBB2, 
PCNA, PIK3CA and ATP-binding cassette, sub-family B (MDR/TAP), member 
1/multidrug resistance protein 1 (ABCB1/MDR1) (Astanehe et al., 2009; Bargou et 
al., 1997; Ise et al., 1999; Jurchott et al., 2003; Stratford et al., 2007; Wu et al., 2006). 
YBX1 is phosphorylated at serine residue 102 in response to mitogenic stimulation, 
which is thought to be required for its transcriptional activity (Stratford et al., 2007). 
A recent study showed that YBX1 was phosphorylated in response to KRAS 
activation, which in turn was induced by ERBB1 signalling or ionising radiation and 
was mediated through the PI3K or MAPK1 axes (Toulany et al., 2011). Using 
chromatin immunoprecipitation on chip (ChIP-on-chip) analysis, Dunn and co-
workers identified the met proto-oncogene (hepatocyte growth factor receptor) 
(MET), CD49f and CD44 as well as several members of the NOTCH and WNT 
pathways as YBX1 transcriptional target genes (Finkbeiner et al., 2009). In a follow-
up study they showed that YBX1 enhances self-renewal and promoters growth as well 
as drug resistance of basal breast cancer cells through induction of the CD49f and 
CD44 genes (To et al., 2010). 
I am currently carrying out co-immunoprecipitation of HA epitope-tagged TOX3 and 
YBX1 in MCF-7 and BT-474 cells to confirm the association of TOX3 and YBX1 in 
a luminal environment. Several studies have suggested that YBX1 plays a role in 
basal breast cancer cells in particular (Finkbeiner et al., 2009). It would therefore also 
of interest to investigate whether TOX3 physically interacts with YBX1 in a basal 
breast cancer line such as MDA-MB-231 in a manner that is different to the luminal 
cell lines. What function a potential interaction between TOX3 and YBX1 could have 
remains to be determined but since both act as transcriptional activators, it appears 
likely that they co-regulate a set of target genes. Preliminary comparison of my TOX3 
microarray data and YBX1 target genes did not reveal any obvious genes that were 
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regulated by both transcription factors (Finkbeiner et al., 2009), although both 
proteins appear to have a pro-proliferative function. Alternatively, one could 
speculate that TOX3 inhibits YBX1 by binding to it, thereby preventing YBX1-
dependent upregulation of CD49f and CD44 and self-renewal of normal progenitor 
cells. 
As discussed in the Results section and above, keratin contamination and association 
of misfolded TOX3 with chaperone proteins likely prevented the identification of 
further TOX3 interacting proteins by mass spectrometric analysis of tandem affinity 
purified TOX3. However, the proteomic approach promises to be a valuable 
technique to identify TOX3 interacting proteins. In recent years, the Agilent InterPlay 
Mammalian tandem affinity purification (TAP) protocol has been successfully used to 
identify protein-protein interactions in a number of studies, including interactions 
between chromatin-binding polycomb proteins BMI1 and polycomb group ring finger 
2 (PCGF2) as well as the antiviral apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3G (APOBEC3G) and YBX1 (Gallois-Montbrun et al., 2007; 
Wiederschain et al., 2007). It is of note that in the latter study, YBX1 bound to 
APOBEC3G in ribonucleoprotein (RNP) complexes and stress granules and that the 
interaction could be abolished by RNase treatment (Gallois-Montbrun et al., 2007). 
The significance of the RNA-binding properties of YBX1 for a potential interaction 
with TOX3 is unclear but should be considered during further analysis. To identify 
further proteins that TOX3 forms a complex with, I am currently repeating the tandem 
affinity purification using lentivirally transduced HEK 293T cells. Separation of the 
purified proteins by SDS-PAGE and subsequent colloidal blue staining of the gel will 
be carried out in a clean room to avoid keratin contamination as much as possible. 
While HEK 293T cells are commonly used for TAP experiments (Gallois-Montbrun 
et al., 2007), they are not suited for the identification of mammary cell-specific 
TOX3-containing complexes. Therefore, I plan to carry out TAP using MCF-7 cells 
transduced with the TAP-TOX3 constructs as the luminal MCF-7 breast cancer cell 
line may provide a more physiological setting for the identification of TOX3 protein-
protein interactions. For the same reason, TOX3-containing protein complexes would 
ideally be purified from cells that express endogenous TOX3, such as the BT-474 cell 
line. I have created BT-474 cells that stably express TAP-TOX3 (data not shown) but 
BT-474 cells have proved to proliferate slowly and the large number of cells required 
for TAP and subsequent mass spectrometric analysis are limiting factors for the use of 
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this cell line. Similarly, although I initially set out to use primary mammary epithelial 
cells for TAP, it simply does not appear to be feasible to use BPEC transduced with 
TAP-TOX3 for the protein purification owing to the large numbers of cells required. 
 
4.3 A role for TOX3 in luminal breast cancer 
4.3.1 TOX3 is expressed in luminal breast tumours 
Immunohistochemical (IHC) staining of primary breast tumour sections showed 
TOX3 expression in luminal but not in basal-like breast tumours (Fig. 12), which 
confirmed the tumour expression array data (Fig. 11). In contrast, IHC staining of 
normal tissue adjacent to tumour tissue in the tumour microarray biopsies further 
detected TOX3 in both luminal and myoepithelial cells (Fig. 12), which was at odds 
with the available transcriptional profiling data of myoepithelial cells (Fig. 16). A 
possible explanation is the lack of purity of the TOX3 antibodies used for 
immunohistochemistry. Western blot analysis showed that the custom-made rabbit 
polyclonal TOX3 antibody successfully detected ectopically expressed TOX3 (Fig. 
28, 29). However, high non-specific background staining complicated the analysis of 
endogenous TOX3 protein expressed at lower levels (Fig. 15, 29). The unavailability 
of a high-quality TOX3 antibody hampered the analysis of TOX3 protein expression 
throughout this project and has to be addressed in future investigations. To determine 
whether TOX3 is a good prognostic marker that can be used for IHC staining in the 
clinical setting, the availability of a high-quality TOX3 antibody is of particular 
interest. 
 
4.3.2 TOX3 induces proliferation and represses luminal differentiation genes in 
MCF-7 cells – a tentative interpretation 
The above data leave open the question of how TOX3 contribute to the formation of 
ERα-dependent breast cancer. Gene set enrichment analysis of the TOX3 microarray 
showed that TOX3 expression led to the downregulation of genes that are usually 
overexpressed in ERα-positive breast cancer such as GREB1 and GATA3, as 
described above. In addition, TOX3 expression in MCF-7 cells resulted in the 
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induction of proliferation genes such as MYC, CCNA2, PCNA, PLK1 as well as 
inhibition of CDKN1A (Fig. 33). However, the low quality of the expression data 
must be considered when interpreting the results. Not only did the induction of 
interferon response genes in the control samples complicate the interpretability of the 
results (Fig. 33) but the proliferation signature itself should be considered with 
caution as it may have been caused by inadvertent interference with cell proliferation 
and subsequent release of the cells into the cell cycle caused by the lentiviral 
infection. 
Taking into account these caveats, based on preliminary interpretation of the 
microarray data, it is tempting to speculate that TOX3 plays a role in the development 
of ERα-positive breast cancer by attenuating luminal cell differentiation through 
inhibition of a subset of ERα target genes and by simultaneously inducing 
proliferation (Fig. 49). Inhibition of differentiation genes would allow ERα-positive 
cells to switch from a paracrine to an autocrine mode with respect to growth-
promoting signalling, thus enabling them to directly respond to estrogen stimulation. 
It remains to be determined how this can be reconciled with a role for TOX3 in the 
differentiation of normal luminal epithelial cells. Tight spacial and temporal control 
of TOX3 expression during luminal cell development may be a requirement for its 
appropriate function. TOX3 expression levels in turn may be influenced by the 
polymorphisms in the regulatory region of the gene that have been associated with an 
increased breast cancer risk. 
As in vitro and in vivo analysis of TOX3 expression in MCF-7 cells showed, 
overexpression of TOX3 was associated with an initial transient growth advantage 
both in culture and in xenografts but this proliferative advantage could not be 
maintained over a longer period of time (Fig. 45, 46), suggesting that TOX3 may 
exert a potential oncogenic effect in a manner that is more complex than a simple 
induction of proliferation. One possible explanation may be that TOX3 facilitates the 
adhesion or invasiveness of TOX3 expressing cells, which promote initial 
engraftment of transformed cells in the neighbouring normal tissue, as seen in the 
intraductal xenograft model (Fig. 46). The TOX3 microarray data suggest an 
upregulation of both the chemokine (CXC motif) ligand 14 (CXCL14) and the 
chemokine (C-X-C motif) receptor 4 (CXCR4) in TOX3-expressing cells. The Polyak 
group has shown that CXCL14 promotes invasion, migration and proliferation, while 
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recent studies have demonstrated that CXCR4 mediates E2-induced proliferation of 
ERα-positive tumour cells and is capable of transforming MCF-10A cells (Allinen et 
al., 2004; Boudot et al., 2011; Su et al., 2011). Furthermore, microarray analysis of 
ESR1 expression in normal HMEC previously conducted in our lab revealed CXCL14 
as one of the genes that was most strongly induced by ESR1 expression in a ligand-
independent manner (S. Duss, personal communication). Again, based on the poor 
expression data, the observed induction may be an artefact but it may be of interest to 
further investigate the relationship between TOX3 and these mediators of chemokine 
signalling. It is of note however, that TOX3 expression also resulted in a significant 
downregulation of AGR2 expression (Fig. 33, 34). AGR2 has been shown to promote 
tumour growth and metastasis (Brychtova et al., 2011). The implications of the 
seemingly opposing roles of TOX3 in repression and induction of oncogenic genes 
remain to be determined. 
In the context of mammary epithelial cell regulation, a potentially interesting result 
was that TOX3 expression resulted in a strong repression of progesterone receptor 
(PGR) expression in MCF-7 cells (Fig. 33). PGR as well as insulin receptor substrate 
1 (IRS1) were in fact among the most downregulated genes. Like aforementioned 
luminal genes, PGR and IRS1 are ESR1 target genes. In addition, both are involved in 
a complex regulatory relationship with ESR1 in mammary cells (Chan and Lee, 2008; 
Conneely et al., 2003). 
IRS-1 is a signal transduction protein that binds directly to insulin-like growth factor 
1 receptor (IGFR1) and insulin receptor (IR) in the canonical signalling pathway. 
Downstream effectors of IRS-1 and the structurally and functionally closely related 
IRS-2 include phosphoinositide-3-kinase (PI3K) and mitogen-activated protein kinases 
1 and 3 (MAPK1/3) in a multitude of tissues including the mammary gland. IRS1 
functions in mammary gland development, and in keeping with the function as a 
transducer of mitogenic signals, IRS1 has been shown to be a transforming oncogene 
in the breast (Chan and Lee, 2008). Interestingly, in mice, loss of IRS1 leads to an 
increase in metastasis due to compensation by IRS2-mediated signalling (Ma et al., 
2006), which would be consistent with the model of TOX3 function that I propose 
(Fig. 49). However, in MCF-7 cells downregulation of IRS1 has been shown cause 
apoptosis (Nolan et al., 1997). It remains to be determined how these opposing 
findings can be reconciled and if and how TOX3 regulates IRS1 expression, as 
Western blot analysis did not confirm repression of IRS1 by TOX3 (Fig. 34). 
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In contrast, Western blot analysis did confirm that TOX3 repressed both isoforms 
PGR-A and PGR-B in MCF-7 and T-47D cells (Fig. 34 and data not shown). 
Knockdown of endogenous TOX3 does not appear to upregulate PGR levels in BT-
474 and MDA-MB-361 cells, which may be explained by insufficient knockdown 
efficiency of the shRNAmir constructs (Fig. 30). An alternative explanation may be 
differences in the regulation of PGR expression in TOX3-decificient MCF-7 cells and 
BT-474 or MDA-MB-361 cells. As discussed above, the functional relationship 
between TOX3 and ESR1 remains unclear but it is possible that the effect of TOX3 
on PGR expression is independent of ESR1. Despite a degree of cross-talk between 
estrogen and progesterone signalling, notably the induction of PGR expression by 
estrogen at the onset of puberty (“estrogen priming”) (Haslam and Shyamala, 1979), 
ESR1-mediated control of mammary gland development predominates during 
puberty, while PGR governs side-branching during estrous cycles and, in concert with 
the prolactin receptor (PRLR), pregnancy (Brisken and O'Malley, 2010). 
Reconstitution studies in mice have shown that PGR-/- cells are capable of generating 
chimeric mammary glands when mixed with wild-type cells, demonstrating that the 
mitogenic stimulus that leads to the proliferation of MaSC and early progenitor cells 
is exerted in a paracrine manner (Brisken et al., 1998). As discussed above, RANKL 
and WNT4 have been identified as mediators of progesterone signalling and MaSC 
activation during the estrous cycle (Asselin-Labat et al., 2010; Brisken et al., 2000; 
Joshi et al., 2010). Progesterone stimulation induces proliferation in neighbouring 
cells at least in part by activating expression of cyclin D1 (CCND1) (Sicinski et al., 
1995) but the exact mechanism of paracrine stimulation of proliferation including the 
involvement of other transcription factors acting upstream of PGR are poorly 
understood. 
Considering the pro-proliferative role of PGR in mammary gland development and 
MaSC activation, it is difficult to conceive how TOX3 would promote oncogenic 
transformation by downregulating PGR expression in luminal cells. In addition, the 
majority of luminal tumours are PGR-positive, which is at odds with TOX3-
dependent repression of PGR. 
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4.3.3 Creation of a luminal tumour model by quantitative transformation of 
normal human mammary epithelial cells 
As discussed above, the possibility remains that the TOX3 microarray results are 
simply an experimental artefact and that the observed repression of luminal 
differentiation and induction of proliferation were not caused by TOX3 expression. 
Alternatively, MCF-7 cells may be entirely unsuited as a model system and 
expression of the potential luminal differentiation factor TOX3 in MCF-7 cells does 
not reproduce what happens in vivo in normal human cells or in human breast cancer. 
To test if TOX3 is a transforming oncogene, it is therefore preferable to express 
TOX3 in normal human mammary epithelial cells. To this end, I have successfully 
established a culture system that combines the initial enrichment for progenitor cells 
by mammosphere suspension culture with subsequent adherent culture in WIT 
medium on Primaria plastic, which allows longer maintenance of primary mammary 
epithelial cells (BPEC) in culture than conventional cell culture media (Fig. 41). 
Despite improved longevity of primary human mammary cells in culture owing to 
increasingly sophisticated culture methods, it remains preferable to limit the in vitro 
culture as much as possible. Even when using optimised culture conditions, it is 
evident that the cellular phenotype changes over the course of time and a certain 
degree of differentiation cannot be avoided. For instance, despite their improved in 
vitro life span, BPEC grown in WIT medium exhibited a secretory phenotype after 
the first passages, which was characterised by the appearance of large vacuole-like 
inclusions in the cytoplasm (data not shown). On the other hand, this phenotype was 
not always detectable, suggesting a certain variability of the WIT medium-based cell 
culture system. In addition, culture of organoid-derived BPEC in WIT medium 
resulted in progressive disappearance of cells of luminal epithelial differentiation 
(Fig. 40), which is a feature of HMEC cultured in HMM+ medium but which is not 
consistent with the report by Ince and colleagues (Ince et al., 2007). In my hands, 
culture in WIT medium therefore was not able to maintain the different mammary 
epithelial subpopulations but favoured myoepithelial differentiation. In addition, 
BPEC invariably underwent growth arrest and displayed a senescent phenotype, 
which was in contrast to the claim made by Ince and co-workers that culture in WIT 
medium allowed theoretically infinitive maintenance of BPEC (Ince et al., 2007). A 
further difference to the culture system described by the Weinberg lab was that BPEC 
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transformed with TERT, MYC, BMI1 and ESR1 (BPEC XS08.4) failed to form 
adenocarcinomas in NSG mice but gave rise to tumours of squamous differentiation, 
much like transformed HMEC (Fig. 48), while BPEC transformed with TERT, SV40 
large T antigen and oncogenic HRAS-V12 were reported to form adenocarcinomas in 
the xenograft model (Ince et al., 2007; McAllister et al., 2008). Squamous 
differentiation of BPEC XS08.4-derived tumours was likely due to inadequate 
differentiation of the cells while in culture or to the expression of a combination of 
genes that do not exactly mirror the set of genes that are overexpressed in human 
luminal tumours, or both. Our group is currently testing different combinations of 
transgenes in order to prevent squamous differentiation of BPEC-derived tumours. 
Considering the role of GATA3 in luminal differentiation, it is an interesting 
candidate transgene to test. Furthermore, the next step will be to express and 
characterise TOX3 in the BPEC luminal tumour model. 
In my opinion, it is crucial to shorten the in vitro cell culture time as much as possible 
in order to avoid cell culture artefacts. With respect to the establishment of a luminal 
breast cancer model by lentiviral transduction of normal cells, this means that it is 
indispensable to optimise lentiviral expression systems in order to shorten the time 
required for serial transduction and selection. One limitation of the lentiviral system 
presented here is that all transgenes were expressed from the same lentiviral 
backbone, which complicates the selection of successfully transduced cells, which 
was seen in the BPEC XS.08 line (Fig. 48). To ensure simultaneous transduction with 
multiple viruses, the use of a combination of different fluorescent and antibiotic 
resistance markers that allow for visual, flow cytometric and antibiotic selection 
would be ideal. Simultaneous expression of multiple transgenes further requires the 
production of viral preparations at high titres. At the same time, overly high 
multiplicities of infection (MOI) must be avoided as they may trigger an acute 
interferon response in infected cells, as exemplified by the MCF-7 GUS control cells 
used in the microarray experiment (Fig. 33). Other possible causes for the induction 
of interferon responses include the contamination of plasmid preparation with 
endotoxin, which can be reduced by employing appropriate plasmid purification 
methods, and the innate immunity to viral intermediates such as RNA-DNA hybrids 
or misfolded RNAs. Wild-type lentiviruses have evolved to inactivate mediators of 
the host cell interferon response (Haller et al., 2006) but since the majority of viral 
genes have been deleted from lentiviral vectors for safety considerations, viral 
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intermediates most likely cause an interferon response in packaging cells at the time 
of virus production as well as in target cells at the time of infection. To avoid 
interferon response artefacts, it is therefore preferable to analyse the effect of 
transgene expression later than 48 hours following lentiviral infection to allow for the 
acute interferon response to subside. However, if the immediate effects of transgene 
expression are of interest, this may cause a problem. Albeit technically more 
challenging than constitutive vectors, the use of inducible lentiviral vector systems 
allows to separate the time of infection and the time of transgene expression. The 
KRAB repressor/tet-off conditional lentiviral system for TOX3 expression (Szulc et 
al., 2006) will hopefully also help to prevent silencing of TOX3 expression that was 
observed with the hPGK lentiviral construct. Alternatively, silencing of TOX3 may be 
tested in the context of other promoters, although the hPGK promoter had been 
originally been chosen for its constitutive expression across the cell types of interest, 
while expression from other promoters such as the CMV promoter appeared to vary 
considerably between cell types (Duss et al., 2007 and S. Duss, personal 
communication). Variegation due to epigenetic silencing is a problem frequently 
encountered with lentiviral expression systems (Golding et al., 2010; Zhang et al., 
2010). One way to avoid silencing of transgenes by methylation, histone deacetylation 
and chromatin condensation is to introduce silencing-resistant elements into the 
promoter region of lentiviral expression vectors (Williams et al., 2005). However, 
what speaks against silencing of the hPGK promoter is that the same lentiviral 
backbone has been used successfully in our laboratory to express a number of 
transgenes without obvious silencing effects. This would suggest that the observed 
silencing was intrinsic to the TOX3 ORF and that TOX3 expression was subject to 
negative regulation, possibly because its expression was disadvantageous to the cell. 
The microarray data suggested that TOX3 itself did not repress PGK1 expression 
(Fig. 33 I). In addition, regulation of TOX3 expression did not appear to occur at the 
protein level as treatment with the proteasome inhibitor MG132 had no obvious effect 
on TOX3 protein levels (data not shown). The cause for TOX3 silencing remains to 
be determined but the problem shows that the choice of lentiviral expression system is 
of great importance. 
 
In this study, two different xenograft methods were used. The intraductal injection 
method worked very well for the MCF-7 breast cancer cell line (Fig. 46) and arguably 
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represents the currently available method that most accurately replicates the site of 
tumour initiation in the human breast (Behbod et al., 2009). In contrast, unpublished 
data from our lab have shown that transformed BPEC are not able to proliferate in the 
ducts following intraductal injection, presumably because they are not invasive 
enough to replace murine epithelial cells in their niches, or because they lack the 
adhesion molecules that allow engraftment in the murine ducts. For the quantitative 
transformation BPEC model, I therefore chose the orthotopic injection into the forth 
mammary gland, which had proved successful for the assessment of the tumourigenic 
properties of HMEC transformed with BMI1, MYC, TERT and ESR1 in that tumours 
formed readily and cells were able to metastasise to distant organs (Duss et al., 2007). 
In keeping with results from the luminal HMEC model, quantitatively transformed 
BPEC injected into the fourth mammary gland efficiently gave rise to tumours (Fig. 
48). The choice of xenograft model system has been subject of much recent research 
and commonly employed alternatives to the orthotopic xenotransplantation model 
include subcutaneous injections and, particularly for human mammary stem cells 
assays, injections under the renal capsule (Eirew et al., 2010). My rationale for 
choosing the orthotopic xenograft model was that, despite the aforementioned 
differences between humans and mice, the murine mammary gland resembles the 
human breast in its stromal microenvironment and ductal architecture more closely 
than other possible sites of injection. A second point of recent discussion has been the 
use of slow-release estrogen pellets to mimic serum estrogen levels of pre-
menopausal women (Anderson et al., 1998). No obvious difference was observed 
between insertion of estrogen pellets one week before or at the time of xenografts 
(data not shown). However, HMEC transformed with TERT, BMI1, ESR1 and MYC 
failed to grown in the absence of exogenous estrogen (Duss et al., 2007). A recent 
study by the Vonderhaar group found no significant difference in tumour growth or 
latency between xenotransplants of patient-derived human breast cancer cells in the 
presence versus absence of E2 supplements (Fleming et al., 2010). This is in contrast 
to our findings but is likely due to the phenotype of the injected cells. Furthermore, I 
found that injection of an admixture of transformed BPEC (or HMEC) and human 
mammary fibroblasts as well as 12.5% matrigel gave the best results in terms of 
tumour incidence, suggesting that a certain degree of “humanisation” of the murine 
mammary fat pad benefits engraftment of human cells. 
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4.3.4 The predicted non-coding RNA gene LOC643714 
The SNPs that are associated with an increased breast cancer risk are located in the 
upstream regulatory region of the TOX3 gene, which overlaps with the most 3’ exon 
of the predicted non-coding RNA gene LOC643714 (Easton et al., 2007; Ruiz-
Narvaez et al., 2010; Stacey et al., 2007; Udler et al., 2010). The possibility therefore 
exists that the genetic variations associated with breast cancer predisposition are in 
fact linked to the LOC643714 gene and not to TOX3. To date, the LOC643714 gene 
remains uncharacterised but regulatory non-coding RNAs are known to affect the 
expression of their target genes in various ways, ranging from interference with cis-
acting binding sites for regulatory proteins in the promoter regions of adjacent genes 
to regulating transcript stability. An example for the former is the regulation of X 
chromosome inactivation by Xist RNA, while the latter is exemplified by trans-acting 
miRNAs (Mattick, 2009). What speaks against a causative role for LOC643714 is that 
while it appears to be expressed in the human breast, its expression levels remain 
constant across the different mammary epithelial subpopulations as well as the stroma 
(Fig. 16 C), although the lack of variability could mean that the microarray probe 
gave no signal. 
 
4.4 How does TOX3 cause breast cancer? 
A central question of this study was whether SNPs in the TOX3 gene lead to a gain or 
a loss of TOX3 function. The MCF-7 GSEA results and the MCF-7 xenograft model 
suggest that TOX3 is an oncogene, which leaves open the question how a potential 
oncogene can be so closely linked to terminal differentiation. Figure 48 summarises 
the currently available data in a tentative model of TOX3 function in normal and 
luminal breast cancer cells. It remains to be seen whether TOX3 determines terminal 
differentiation or whether it is only part of a functioning differentiated luminal 
epithelial cell like genes such as AGR2 or XBP1. 
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Figure 49. Model of TOX3 function in normal and tumour cells 
Schematic of potential TOX3 function and the factors regulated by TOX3 in the 
normal mammary epithelium and luminal breast cancer. Potential TOX3 target genes 
are in blue, while potential TOX3 interacting proteins are in black. 
 
 
4.5 Concluding remarks and future perspectives 
I here present evidence that the nuclear HMG-box protein TOX3 is involved in the 
regulation of both mammary epithelial cell fate in the normal breast and the 
oncogenic transformation of luminal epithelial cells. This work could only be an 
initial characterisation of TOX3 function but it will hopefully serve as a starting point 
for further investigations. 
Future work will focus on the characterisation of TOX3 function by lentivirus-based 
expression in normal human mammary epithelial cells. Comparison of the effect of 
ectopic expression of TOX3 in luminal tumour cell lines such as MCF-7 and the 
bipotent immortalised cell line MCF-10A will permit to examine TOX3 function in a 
variety of environments. It will be of great interest to repeat the microarray analysis of 
TOX3 target genes in normal human mammary epithelial cells to identify differences 
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in TOX3 function in normal versus cancerous cells. The inducible lentiviral TOX3 
vector will permit to better control TOX3 expression. Transcriptional profiling of 
TOX3-expressing MCF-7 cells has already provided a list of candidate target genes, 
the most interesting of which will be subject of further investigation. The oncogenic 
potential of TOX3 is currently being tested in the quantitative transformation protocol 
for BPEC that I have established. Knockdown of endogenous TOX3 in the luminal 
breast cancer lines will provide further insight into TOX3 function. Characterisation 
of the transcriptional activity of TOX3 is of major interest. Genome-wide mapping of 
TOX3 binding sites using chromatin immunoprecipitation (ChIP) analysis requires 
reliable antibodies, which is currently a limiting factor in the analysis of TOX3 
protein. An alternative to classic ChIP analysis using TOX3-specific antibodies 
involves in vivo biotinylation of TOX3 and subsequent affinity capture using a 
streptavidin-coupled matrix (Kim et al., 2008; Wang et al., 2006). Forced TOX3 
expression in a transgenic mouse model as well as TOX3 knockout mice will 
ultimately show whether TOX3 has a function in development of the mammary gland. 
Transcriptional regulators are not prime drug targets for the treatment of breast cancer 
but if a role for TOX3 in breast cancer development can be confirmed, TOX3 
expression in luminal tumours and the possibility to test for inherited genetic 
variations in the breast cancer susceptibility gene TOX3 may have prognostic value. 
Furthermore, identification of the signalling pathways that TOX3 is involved in may 
contribute to tailoring therapeutic approaches. 
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6 Appendix 
6.1 Plasmid vectors used in this study 
Table 11. Plasmid vectors used in this study. 
pXS 
plasmid 
name 
Original 
plasmid 
name 
Description 
Supplier/ 
cloned by 
pXS-3 pRLLsin.PPTs.hCMV.GFPpre 
CMV-GFP pRRL lentiviral expression 
vector 
L. Naldini 
pXS-10 
Ultimate ORF clone 
IOH61112 
TOX3-pENTR221 Gateway entry vector Invitrogen 
pXS-11 pMD2.G 
VSV-G envelope protein construct for 
lentivirus pseudotyping 
L. Naldini 
pXS-16 PCMVdR8.74 Lentivirus gagpol packaging construct D. Trono 
pXS-17 pRRLsin.ppts.hPGKGFPpre GFP under control of hPGK promoter L. Naldini 
pXS-32 pNTAP-A 
Interplay Mammalian TAP system 
parental cloning vector 
Stratagene 
Agilent 
Technologies 
pXS-35 pDONR201 Gateway acceptor entry vector Invitrogen 
pXS-36 pXS-36 
hPGK-TOX3-mPGK-puro pRRL lentiviral 
vector 
X. Schmidt 
pXS-37 pSD-104 pENTR-DsRed2 S. Duss 
pXS-38 pJH-3982 
cPPT-hUbiC-attR-hPGK-EGFP-WPRE-
pRRL destination lentiviral vector 
J. Huelsken 
pXS-39 pXS-39 
cPPT-hUbiC-TOX3-hPGK-EGFP-WPRE-
pRRL lentiviral vector 
X. Schmidt 
pXS-41 pXS-41 
cPPT-hUbiC-TOX3-hPGK-EGFP-WPRE-
pRRL lentiviral vector 
X. Schmidt 
pXS-48 pJH-4282 
cPPT-CMV-attR-mPGK-GFP-WPRE-
pRRL dest lenti 
J. Huelsken 
pXS-62 Clone ID RHS4346 
pGIPZ shRNAmir scrambled negative 
control lentiviral vector 
Open 
Biosystems 
pXS-70 pXS-70 TOX3-GFP Gateway entry vector X. Schmidt 
pXS-71 pXS-71 
hPGK-TOX3-GFP-mPGK-puro pRRL 
lentiviral vector 
X. Schmidt 
pXS-72 pXS-72 
cPPT-CMV-TAP-mPGK-GFP-WPRE-pRRL 
lentiviral vector 
X. Schmidt 
pXS-85 pXS-85 
cPPT-CMV-NTAP-TOX3-mPGK-GFP-
WPRE-pRRL lentiviral vector 
X. Schmidt, 
E. Richard 
pXS-88 
Clone ID RHS4430-98480880 
- V2LHS_75758 
pGIPZ shRNAmir lentiviral vector 
against TOX3 #1 – Target sequence: 
GACATACTGATGACTATAA 
Open 
Biosystems 
pXS-89 
Clone ID RHS4430-99157247 
- V2LHS_75830 
pGIPZ shRNAmir lentiviral vector 
against TOX3 #2 – Target sequence: 
GCCTCTCTGAGTCATAGAA 
Open 
Biosystems 
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Table 11. continued 
pXS-93 pXS-93 NTAP-TOX3 Gateway entry vector X. Schmidt 
pXS-95 pXS-95 
hPGK-NTAP-TOX3-mPGK-puro pRRL 
lentiviral vector 
X. Schmidt 
pXS-96 pXS-96 
cPPT-hUbiC-TAP-TOX3-hPGK-EGFP-
WPRE-pRRL lentiviral vector 
X. Schmidt 
pXS-97 pXS-97 TAP control Gateway entry vector X. Schmidt 
pXS-98 pXS-98 
hPGK-NTAP-mPGK-puro pRRL lentiviral 
vector 
X. Schmidt 
pXS-99 pXS-99 
cPPT-hUbiC-TAP-TOX3-hPGK-EGFP-
WPRE-pRRL lentiviral vector 
X. Schmidt 
pXS-102 pGL3-PS2-luc 
proximal PS2 promoter Luc reporter in 
pGL3-basic 
G. Reid 
pXS-103 ERE-TK-luc 
Vitellogenin ERE-5’ minimal TK (TATA) 
reporter Luc 
G. Reid 
pXS-104 pGL3-basic pGL3-basic Promega 
pXS-105 pRL-CMV pRL-CMV Promega 
pXS-106 pCF-332 pRL-SV40 Promega 
pXS-107 pCF-333 pRL-TK Promega 
pXS-108 pEGFP-N1 CMV-MCS-EGFP Clontech 
pSD-69 pSD-69 
hPGK-attR-mPGK-puro pRRL lentiviral 
destination vector 
S. Duss 
pSD-82 pSD-82 
hPGK-ESR1-mPGK-puro pRRL lentiviral 
vector 
S. Duss 
pSD-83 pSD-83 
hPGK-TERT-mPGK-puro pRRL lentiviral 
vector 
S. Duss 
pSD-84 pSD-84 
hPGK-BMI1-mPGK-puro pRRL lentiviral 
vector 
S. Duss 
pSD-94 pSD-94 
hPGK-MYC-mPGK-puro pRRL lentiviral 
vector 
S. Duss 
pER-6 pRLLsin.cPPT.MND.LUC.wpre MND-luciferase lentiviral vector E. Richard 
pER-15 pER-15 
hPGK-GFP-mPGK-puro pRRL lentiviral 
vector 
E. Richard 
pER-47 pER-47 
hPGK-HA-TOX3-mPGK-puro pRRL 
lentiviral vector 
E. Richard 
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Figure 50. Maps of lentiviral vectors used for tandem affinity purification. 
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6.2 Antibodies used in this study 
Table 12. Antibodies used in this study. 
Antigen 
(Clone/epitope) 
Supplier, 
Catalogue 
number 
Raised in Application (Dilution) 
MW of antigen 
(kDa) 
AGR2 Abnova mouse mc WB (1:1000) 20 
BMI1 (F6) 
Millipore 
05-637 
mouse mc WB (1:1000) 40-44 
CBP epitope tag 
Millipore 
07-482 
rabbit pc 
WB (1:2000) 
IF 
depend. on 
rec. protein 
CITED1 
Abcam 
ab15096 
rabbit pc WB (1:250) 21 
ESR1 (Sp1) 
Lab Vision 
Thermo Fisher 
Scientific 
RM-9101 
rabbit mc 
WB (1:1000) 
IF 
67 
ESR1 (1D5) Dako mouse mc IHC 67 
GFP Abcam ab290 rabbit WB (1:2000) 27 
GFP (B-2) 
Santa Cruz 
sc-9996 
mouse mc WB (1:1000) 27 
HA probe 
(F-7) 
Santa Cruz 
sc-7392 
mouse mc WB (1:250) 
depend. on 
rec. protein 
phospho-H2AX 
(JBW301) 
Upstate mouse mc IF (1:200) 15 
HSP70 
(SPA-810) 
Stressgen, 
Enzo Life 
Sciences 
mouse mc WB (1:1000) 70 
IRS1 (4.2.2) 
Millipore 
05-1085 
mouse mc WB (1:1000) 185 
KRT14 (LL001) Birgit Lane mouse mc IF (1:5) 50 
KRT14 Dako mouse mc IHC 50 
KRT18 (LDK18) Birgit Lane mouse mc IF (undiluted) 50 
KRT18 Dako mouse mc IHC 50 
MYC (9E10) 
Santa Cruz 
sc-40 
mouse mc WB (1:500) 67 
p16 
Novocastra 
NCL-p16 
mouse mc WB (1:200) 16 
p21 (C-19) 
Santa Cruz 
sc-397 
rabbit pc WB (1:200) 21 
p53 (DO1) David Lane mouse mc WB (1:1000) 53 
PGR (A/B) (636) Dako mouse mc WB (1:200) 81/116 
TERT 
Rockland 
Immuno-
chemicals 
600-401-252 
rabbit pc WB (1:500) 127 
TOX3 
Rb57 
Abgent, 
not TOX3 
affinity-
purified 
rabbit pc WB (1:1000), IHC, IP 63 
TOX3 
Rb57P 
Abgent, 
TOX3 affinity-
purified 
rabbit pc WB (1:500) 63 
TOX3 
Abcam, 
ab77432 
goat pc WB (1:250), IHC 63 
α-Tubulin 
(B-5-1-2) 
SIGMA mouse mc WB (1:2000-1:5000) 50 
YBX-1 
Abcam, 
ab12148 
rabbit pc WB 36/50 
Alexa 488-
conjugated anti 
rabbit 
Invitrogen 
Molecular 
Probes 
 IF (1:200) - 
Alexa 568-
conjugated anti 
mouse 
Invitrogen 
Molecular 
Probes 
 IF (1:200) - 
Goat IgG Santa Cruz donkey WB (1:10,000) - 
Mouse IgG GE healthcare donkey WB (1:10,000) - 
Appendix 
 201 
Table 12 continued 
Rabbit IgG GE Healthcare donkey WB (1:10,000) - 
IgG1-PE-Cy5 
(G18-145) 
BD 
Biosciences 
551497 
mouse Flow cytometry - 
CD10-PE-Cy7 
(HI10a) 
341112 mouse Flow cytometry - 
CD24-PE (ML5) 555428 mouse Flow cytometry - 
CD29-PE-Cy5 
(MAR4) 559882 mouse Flow cytometry - 
CD49d (9F10) 560972 mouse Flow cytometry - 
CD49f-PE 
(GoH3) 
555736 mouse Flow cytometry - 
WB, Western blot; IHC, immunohistochemistry; IP, immunoprecipitation; IF, immunopfluorescence; 
mc, monoclonal; pc, polyclonal. 
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6.3 Ethics approvals 
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6.4 Mass spectrometry 
6.4.1 Mass spectrometry specifications and data analysis 
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6.4.2 Mass spectrometry results including keratins 
Table 13. Mass spectrometry results including keratins 
Protein 
family Family rank Reference 
# MS/MS 
Scan 
# 
Different 
Peptides 
Coverage MW 
<1> Father 
sp|P04264|K2C1_HUMAN Keratin, 
type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 
523 31 45.65217 65998.94 
<2> Father TAP-TOX3 full length (N->C: CBP-spacer-SBP-linker -TOX3) 416 15 30.30303 72053.97 
<3> Twin P35527|K1C9_HUMAN Keratin, type I cytoskeletal 9 - Homo sapiens 331= 22= 40.77047 62091.76 
<3> Twin 
sp|P35527|K1C9_HUMAN Keratin, 
type I cytoskeletal 9 OS=Homo 
sapiens GN=KRT9 PE=1 SV=3 
331= 22= 46.70947 62026.66 
<4> Twin P13645|K1C10_HUMAN Keratin, type I cytoskeletal 10 - Homo sapiens 309= 21= 20.57336 59474.79 
<4> Twin 
sp|P13645|K1C10_HUMAN Keratin, 
type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 
309= 21= 30.30822 58791.59 
<5> Father 
sp|P35908|K22E_HUMAN Keratin, 
type II cytoskeletal 2 epidermal 
OS=Homo sapiens GN=KRT2 PE=1 
SV=2 
308 28 56.33803 65393.19 
<6> Independant 
P35908|K22E_HUMAN Keratin, type 
II cytoskeletal 2 epidermal - Homo 
sapiens 
295 28 43.56589 65825.37 
<7> Father Q6EIY9|K2C1_CANFA Keratin, type II 
cytoskeletal 1 - Canis familiaris 201 11 13.73183 63751.03 
<8> Father Q6IMF3|K2C1_RAT Keratin, type II cytoskeletal 1 - Rattus norvegicus 144 7 5.28 64791.01 
<9> Independant P02535|K1C10_MOUSE Keratin, type I cytoskeletal 10 - Mus musculus 144 9 11.05263 57734.96 
<10> Independant Q6IFW6|K1C10_RAT Keratin, type I cytoskeletal 10 - Rattus norvegicus 142 12 11.59696 56470.55 
<11> Twin P02533|K1C14_HUMAN Keratin, type 
I cytoskeletal 14 - Homo sapiens 137= 15= 27.54237 51589.5 
<11> Twin 
sp|P02533|K1C14_HUMAN Keratin, 
type I cytoskeletal 14 OS=Homo 
sapiens GN=KRT14 PE=1 SV=4 
137= 15= 30.9322 51529.44 
<12> Father 
sp|P11142|HSP7C_HUMAN Heat 
shock cognate 71 kDa protein 
OS=Homo sapiens GN=HSPA8 PE=1 
SV=1 
126 28 48.45201 70854.35 
<13> Father 
sp|P08779|K1C16_HUMAN Keratin, 
type I cytoskeletal 16 OS=Homo 
sapiens GN=KRT16 PE=1 SV=4 
109 15 29.80972 51236.25 
<14> Father 
sp|P08107|HSP71_HUMAN Heat 
shock 70 kDa protein 1A/1B 
OS=Homo sapiens GN=HSPA1A 
PE=1 SV=5 
105 22 43.83775 70009.18 
<15> Independant Q61781|K1C14_MOUSE Keratin, type 
I cytoskeletal 14 - Mus musculus 104 9 16.94215 52833.94 
<16> Twin P13647|K2C5_HUMAN Keratin, type 
II cytoskeletal 5 - Homo sapiens 93= 17= 14.40678 62340.01 
<16> Twin 
sp|P13647|K2C5_HUMAN Keratin, 
type II cytoskeletal 5 OS=Homo 
sapiens GN=KRT5 PE=1 SV=3 
93= 17= 22.88136 62340.01 
<17> Twin Q6IFZ6|K2C1B_MOUSE Keratin, type II cytoskeletal 1b - Mus musculus 88= 5= 3.846154 61321.59 
<17> Twin Q6IG01|K2C1B_RAT Keratin, type II cytoskeletal 1b - Rattus norvegicus 88= 5= 4.238921 57219.73 
<18> Independant Q6IFV3|K1C15_RAT Keratin, type I cytoskeletal 15 - Rattus norvegicus 82 6 6.71141 48840.15 
<19> Father 
sp|P04259|K2C6B_HUMAN Keratin, 
type II cytoskeletal 6B OS=Homo 
sapiens GN=KRT6B PE=1 SV=5 
80 14 14.71631 60030.33 
<20> Father Q6P6Q2|K2C5_RAT Keratin, type II cytoskeletal 5 - Rattus norvegicus 76 12 11.28472 61787.72 
<21> Independant P00761|TRYP_PIG Trypsin precursor 
- Sus scrofa 76 4 21.64502 24393.81 
<22> Independant 
sp|Q86YZ3|HORN_HUMAN Hornerin 
OS=Homo sapiens GN=HRNR PE=1 
SV=2 
37 14 14.91228 282225.7 
<23> Independant Q5XQN5|K2C5_BOVIN Keratin, type 
II cytoskeletal 5 - Bos taurus 72 13 10.81531 62898.35 
<24> Twin 
sp|P62979|RS27A_HUMAN Ubiquitin-
40S ribosomal protein S27a 
OS=Homo sapiens GN=RPS27A 
PE=1 SV=2 
8= 3= 18.58974 17953.49 
<24> Twin 
sp|P0CG48|UBC_HUMAN 
Polyubiquitin-C OS=Homo sapiens 
GN=UBC PE=1 SV=2 
8= 3= 36.20438 76981.61 
<24> Twin 
sp|P0CG47|UBB_HUMAN 
Polyubiquitin-B OS=Homo sapiens 
GN=UBB PE=1 SV=1 
8= 3= 37.99127 25745.84 
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Table 13. continued 
<24> Twin 
sp|P62987|RL40_HUMAN Ubiquitin-
60S ribosomal protein L40 OS=Homo 
sapiens GN=UBA52 PE=1 SV=2 
8= 3= 29.6875 14718.96 
<25> Independant 
sp|P62158|CALM_HUMAN Calmodulin 
OS=Homo sapiens GN=CALM1 PE=1 
SV=2 
64 9 60.40268 16826.84 
<26> Independant 
sp|P34931|HS71L_HUMAN Heat 
shock 70 kDa protein 1-like 
OS=Homo sapiens GN=HSPA1L PE=1 
SV=2 
64 11 24.18097 70331.45 
<27> Father 
sp|P48668|K2C6C_HUMAN Keratin, 
type II cytoskeletal 6C OS=Homo 
sapiens GN=KRT6C PE=1 SV=3 
63 15 17.7305 59988.35 
<28> Twin P02538|K2C6A_HUMAN Keratin, type 
II cytoskeletal 6A - Homo sapiens 63= 16= 19.68085 60008.32 
<28> Twin 
sp|P02538|K2C6A_HUMAN Keratin, 
type II cytoskeletal 6A OS=Homo 
sapiens GN=KRT6A PE=1 SV=3 
63= 16= 21.4539 60008.32 
<29> Independant P04259|K2C6B_HUMAN Keratin, type 
II cytoskeletal 6B - Homo sapiens 60 14 14.71631 59989.3 
<30> Independant 
sp|P11021|GRP78_HUMAN 78 kDa 
glucose-regulated protein OS=Homo 
sapiens GN=HSPA5 PE=1 SV=2 
54 22 39.75535 72288.52 
<31> Father 
sp|P08238|HS90B_HUMAN Heat 
shock protein HSP 90-beta 
OS=Homo sapiens GN=HSP90AB1 
PE=1 SV=4 
51 22 27.48619 83212.16 
<32> Independant 
Q3TTY5|K22E_MOUSE Keratin, type 
II cytoskeletal 2 epidermal - Mus 
musculus 
51 5 3.253182 70879.83 
<33> Twin 
sp|P60709|ACTB_HUMAN Actin, 
cytoplasmic 1 OS=Homo sapiens 
GN=ACTB PE=1 SV=1 
46= 13= 35.73333 41709.74 
<33> Twin 
sp|P63261|ACTG_HUMAN Actin, 
cytoplasmic 2 OS=Homo sapiens 
GN=ACTG1 PE=1 SV=1 
46= 13= 35.46667 41765.8 
<34> Father 
sp|Q04695|K1C17_HUMAN Keratin, 
type I cytoskeletal 17 OS=Homo 
sapiens GN=KRT17 PE=1 SV=2 
35 9 15.74074 48076.11 
<35> Father 
sp|P07437|TBB5_HUMAN Tubulin 
beta chain OS=Homo sapiens 
GN=TUBB PE=1 SV=2 
35 12 27.7027 49639.01 
<36> Father 
sp|Q9BQE3|TBA1C_HUMAN Tubulin 
alpha-1C chain OS=Homo sapiens 
GN=TUBA1C PE=1 SV=1 
34 13 33.63029 49863.5 
<37> Father 
sp|P68371|TBB2C_HUMAN Tubulin 
beta-2C chain OS=Homo sapiens 
GN=TUBB2C PE=1 SV=1 
34 12 27.64045 49799.04 
<38> Independant 
sp|P17066|HSP76_HUMAN Heat 
shock 70 kDa protein 6 OS=Homo 
sapiens GN=HSPA6 PE=1 SV=2 
34 5 10.88647 70984.36 
<39> Independant Q4FZU2|K2C6A_RAT Keratin, type II cytoskeletal 6A - Rattus norvegicus 32 5 5.615942 59212.74 
<40> Father 
sp|Q13885|TBB2A_HUMAN Tubulin 
beta-2A chain OS=Homo sapiens 
GN=TUBB2A PE=1 SV=1 
31 11 25.61798 49874.99 
<41> Twin 
sp|P13646-3|K1C13_HUMAN Isoform 
3 of Keratin, type I cytoskeletal 13 
OS=Homo sapiens GN=KRT13 
31= 9= 15.47619 45838.65 
<41> Twin 
sp|P13646|K1C13_HUMAN Keratin, 
type I cytoskeletal 13 OS=Homo 
sapiens GN=KRT13 PE=1 SV=4 
31= 9= 14.19214 49557.43 
<42> Twin 
sp|P68032|ACTC_HUMAN Actin, 
alpha cardiac muscle 1 OS=Homo 
sapiens GN=ACTC1 PE=1 SV=1 
30= 8= 23.07692 41991.89 
<42> Twin 
sp|P68133|ACTS_HUMAN Actin, 
alpha skeletal muscle OS=Homo 
sapiens GN=ACTA1 PE=1 SV=1 
30= 8= 23.07692 42023.86 
<43> Twin 
sp|P07900-2|HS90A_HUMAN Isoform 
2 of Heat shock protein HSP 90-alpha 
OS=Homo sapiens GN=HSP90AA1 
30= 20= 22.01405 98099.4 
<43> Twin 
sp|P07900|HS90A_HUMAN Heat 
shock protein HSP 90-alpha 
OS=Homo sapiens GN=HSP90AA1 
PE=1 SV=5 
30= 20= 25.68306 84606.72 
<44> Independant P13646|K1C13_HUMAN Keratin, type I cytoskeletal 13 - Homo sapiens 30 9 14.19214 49555.45 
<45> Independant O77727|K1C15_SHEEP Keratin, type I cytoskeletal 15 - Ovis aries 30 4 8.609271 48740.15 
<46> Twin 
sp|P78527-2|PRKDC_HUMAN 
Isoform 2 of DNA-dependent protein 
kinase catalytic subunit OS=Homo 
sapiens GN=PRKDC 
27= 26= 8.201123 465201 
<46> Twin 
sp|P78527|PRKDC_HUMAN DNA-
dependent protein kinase catalytic 
subunit OS=Homo sapiens 
GN=PRKDC PE=1 SV=3 
27= 26= 8.139535 468786.9 
<47> Independant 
sp|P38646|GRP75_HUMAN Stress-70 
protein, mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 SV=2 
27 20 36.81885 73634.83 
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Table 13. continued 
<48> Twin P19013|K2C4_HUMAN Keratin, type 
II cytoskeletal 4 - Homo sapiens 27= 9= 16.29214 57249.88 
<48> Twin 
sp|P19013|K2C4_HUMAN Keratin, 
type II cytoskeletal 4 OS=Homo 
sapiens GN=KRT4 PE=1 SV=4 
27= 9= 16.29214 57249.88 
<49> Independant 
sp|P67809|YBOX1_HUMAN Nuclease-
sensitive element-binding protein 1 
OS=Homo sapiens GN=YBX1 PE=1 
SV=3 
24 9 42.59259 35902.7 
<50> Independant 
sp|P13804|ETFA_HUMAN Electron 
transfer flavoprotein subunit alpha, 
mitochondrial OS=Homo sapiens 
GN=ETFA PE=1 SV=1 
24 1 5.705706 35057.59 
<51> Independant 
sp|P04350|TBB4_HUMAN Tubulin 
beta-4 chain OS=Homo sapiens 
GN=TUBB4 PE=1 SV=2 
24 10 27.7027 49553.94 
<52> Independant 
sp|Q13509|TBB3_HUMAN Tubulin 
beta-3 chain OS=Homo sapiens 
GN=TUBB3 PE=1 SV=2 
22 7 19.11111 50400.28 
<53> Twin 
sp|Q9Y520-3|BA2L2_HUMAN Isoform 
3 of Protein BAT2-like 2 OS=Homo 
sapiens GN=BAT2L2 
20= 19= 8.700481 295648.5 
<53> Twin 
sp|Q9Y520|BA2L2_HUMAN Protein 
BAT2-like 2 OS=Homo sapiens 
GN=BAT2L2 PE=1 SV=3 
20= 19= 9.00932 316813.7 
<53> Twin 
sp|Q9Y520-7|BA2L2_HUMAN Isoform 
7 of Protein BAT2-like 2 OS=Homo 
sapiens GN=BAT2L2 
20= 19= 8.106243 316983.8 
<53> Twin 
sp|Q9Y520-5|BA2L2_HUMAN Isoform 
5 of Protein BAT2-like 2 OS=Homo 
sapiens GN=BAT2L2 
20= 19= 8.245614 312540.4 
<53> Twin 
sp|Q9Y520-4|BA2L2_HUMAN Isoform 
4 of Protein BAT2-like 2 OS=Homo 
sapiens GN=BAT2L2 
20= 19= 8.339248 308514.2 
<54> Independant 
sp|P07195|LDHB_HUMAN L-lactate 
dehydrogenase B chain OS=Homo 
sapiens GN=LDHB PE=1 SV=2 
20 9 26.94611 36615.16 
<55> Independant 
Q28810|K2C8_POTTR Keratin, type 
II cytoskeletal 8 (Fragment) - 
Potorous tridactylus 
19 2 5.806452 35148.81 
<56> Twin 
sp|P68104|EF1A1_HUMAN 
Elongation factor 1-alpha 1 
OS=Homo sapiens GN=EEF1A1 PE=1 
SV=1 
18= 7= 19.04762 50109.18 
<56> Twin 
sp|Q5VTE0|EF1A3_HUMAN Putative 
elongation factor 1-alpha-like 3 
OS=Homo sapiens GN=EEF1AL3 
PE=5 SV=1 
18= 7= 19.04762 50153.22 
<57> Twin P12035|K2C3_HUMAN Keratin, type II cytoskeletal 3 - Homo sapiens 18= 5= 4.769475 64464.63 
<57> Twin 
sp|P12035|K2C3_HUMAN Keratin, 
type II cytoskeletal 3 OS=Homo 
sapiens GN=KRT3 PE=1 SV=3 
18= 5= 5.89172 64377.6 
<58> Independant 
Q29426|K2C3_RABIT Keratin, type II 
cytoskeletal 3 - Oryctolagus 
cuniculus 
18 5 3.17965 64301.73 
<59> Independant 
sp|Q14204|DYHC1_HUMAN 
Cytoplasmic dynein 1 heavy chain 1 
OS=Homo sapiens GN=DYNC1H1 
PE=1 SV=5 
17 16 4.412398 532071.8 
<60> Father 
sp|Q00839|HNRPU_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein U OS=Homo 
sapiens GN=HNRNPU PE=1 SV=6 
17 13 18.30303 90528.01 
<61> Independant P08730|K1C13_MOUSE Keratin, type I cytoskeletal 13 - Mus musculus 17 5 6.636156 47724.3 
<62> Independant 
sp|P23396|RS3_HUMAN 40S 
ribosomal protein S3 OS=Homo 
sapiens GN=RPS3 PE=1 SV=2 
16 9 44.85597 26671.44 
<63> Twin 
sp|P09651-2|ROA1_HUMAN Isoform 
A1-A of Heterogeneous nuclear 
ribonucleoprotein A1 OS=Homo 
sapiens GN=HNRNPA1 
16= 8= 25.625 34175.24 
<63> Twin 
sp|P09651|ROA1_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A1 OS=Homo 
sapiens GN=HNRNPA1 PE=1 SV=5 
16= 8= 22.04301 38723.01 
<63> Twin 
sp|P09651-3|ROA1_HUMAN Isoform 
2 of Heterogeneous nuclear 
ribonucleoprotein A1 OS=Homo 
sapiens GN=HNRNPA1 
16= 8= 30.71161 29368.24 
<64> Father Q08D91|K2C75_BOVIN Keratin, type 
II cytoskeletal 75 - Bos taurus 16 6 9.392265 58999.61 
<65> Father 
sp|Q92945|FUBP2_HUMAN Far 
upstream element-binding protein 2 
OS=Homo sapiens GN=KHSRP PE=1 
SV=4 
15 11 25.87904 73070.13 
Shown are the top ranking peptides according to the number of scans. 
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6.5 Gene set enrichment analysis of the TOX3 microarray 
Table 14. Top ranked genes in TOX3 arrays 
Gene 
Enrichment 
score 
Gene 
Enrichment 
score 
GP2 2.1259015 BCYRN1 0.39984468 
HLA-DRB1 1.1881273 FOXD2 0.39857835 
KRT86 1.1044508 LGALS8 0.39836216 
TGFBI 1.0102248 TRIP13 0.3976165 
HLA-DRB4 0.914595 TFF2 0.3975265 
ACOX2 0.90986234 INHBB 0.3942466 
SLC16A6 0.87592816 LOC399942 0.39258313 
CXCL14 0.85513693 CDCA5 0.3919771 
HLA-DRB3 0.8402379 SLC29A1 0.38992715 
HS.570095 0.8361645 ITGB5 0.38981685 
HLA-DRB6 0.78940094 ITPRIPL2 0.3896616 
HS.579631 0.78474545 CLDN23 0.38955027 
HLA-DRB5 0.7835287 HRASLS3 0.38900054 
LOC145837 0.7684144 HNRNPA1 0.38854802 
ACACB 0.6672306 PRR11 0.38745415 
MT2A 0.63128906 LOC642031 0.3831716 
UCK2 0.62720376 ECHS1 0.37764066 
ENDOGL1 0.62679964 FJX1 0.37719676 
MT1A 0.6104609 DOK7 0.3765319 
IFT122 0.6014796 SLC25A19 0.3763162 
CYP24A1 0.6012127 SYT13 0.37492865 
HBA2 0.5927987 RPP40 0.37312594 
APOD 0.59222525 SRM 0.37118223 
DUT 0.58851224 C12ORF24 0.36954233 
FGFBP2 0.5743703 SRPRB 0.36862534 
C20ORF100 0.5710592 TMEM158 0.36776766 
CRCT1 0.5602652 PCSK6 0.36752793 
CXCR4 0.5372532 EXOSC5 0.3642964 
KRT81 0.5292781 LOC652903 0.36298683 
DNPEP 0.5239767 EFHD2 0.36079088 
BTG2 0.5127981 CD320 0.3599116 
HES1 0.5082694 MSMB 0.35867983 
TTC12 0.50128824 ECHDC3 0.3583621 
MUCL1 0.49363706 SCN1B 0.35690814 
CCDC86 0.49300033 MTHFD1L 0.35689217 
SERPINA3 0.46371156 MCM2 0.35475674 
CDT1 0.4535114 MT1F 0.3534334 
BMP7 0.44970667 GPRC5A 0.3531575 
MT1X 0.44575307 
BGN 0.43882295 
sep.05 0.43523532 
WWC3 0.43507227 
PITX1 0.43279195 
SCNN1A 0.43040892 
TM4SF1 0.42984325 
LOC441019 0.42983177 
GAL 0.42867112 
LINGO1 0.42225155 
CDC45L 0.42196092 
PPM1G 0.42102593 
MYEOV 0.41971403 
SNORD13 0.4197067 
TGFBRAP1 0.41917968 
TRPM5 0.41780734 
ASNS 0.41679037 
MYC 0.41395298 
H19 0.41376397 
CCNF 0.40846977 
BOP1 0.4072227 
LOC648638 0.40501574 
HLA-DRA 0.40302932 
NKD2 0.40237397 
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Table 14. continued 
Gene 
Enrichment 
score 
Gene 
Enrichment 
score 
PMAIP1 -0.3431231 CRABP2 -0.48186928 
DHRS7 -0.34358507 ANKRD50 -0.48382285 
TMEM219 -0.3451259 GLRA3 -0.48604712 
CD68 -0.34623927 MTMR11 -0.49011192 
MCL1 -0.34807625 CDH18 -0.49786615 
ALPP -0.34889764 KYNU -0.49875888 
ADSSL1 -0.34993732 KRT15 -0.5125905 
GBP2 -0.35209325 P2RX2 -0.5186959 
KIAA1598 -0.35334307 HIST2H2AA3 -0.5228775 
HS.72200 -0.3539912 AKR1C4 -0.5252687 
NFKBIZ -0.35542876 GOLSYN -0.52785534 
APH1B -0.35582617 IGSF5 -0.53350025 
ARL6IP5 -0.35854757 HIST1H1C -0.5371729 
PKIB -0.35925603 C9ORF169 -0.53864473 
HS.570308 -0.36087173 C3ORF57 -0.5456896 
RAB31 -0.36282858 AKR1C2 -0.55995816 
C9ORF61 -0.3647469 FAM102B -0.56625473 
TNFRSF12A -0.3679186 HIST2H2BE -0.58837926 
S100A10 -0.36886626 TXNIP -0.59814936 
ABCA12 -0.37049028 ALCAM -0.60435754 
PPP2R5A -0.37100032 HS.545589 -0.6061255 
LMBR1 -0.37298113 SELENBP1 -0.60846287 
DYNLT3 -0.37335628 HS.132305 -0.6180323 
PLK2 -0.38181692 CITED2 -0.62579614 
MGST3 -0.38485086 FOS -0.6275685 
HS.25318 -0.38616636 DNASE1L2 -0.6386161 
NMD3 -0.3871124 TMEM83 -0.6388018 
LOC643431 -0.38807777 ID3 -0.638891 
ISG20 -0.38888982 HIST1H2AC -0.64390415 
RDX -0.3891502 HIST1H2BD -0.6503556 
CLIC3 -0.39500543 HIST2H4A -0.65143585 
LGALS3 -0.39560676 IRS1 -0.654315 
HIST1H3D -0.39565018 PGR -0.65791076 
LOC653610 -0.39651054 C9ORF152 -0.67408407 
POLR3GL -0.40045652 HIST1H4H -0.7547063 
SLC39A8 -0.40074855 ANXA1 -0.7867647 
PAM -0.40076363 PCP4 -0.81518114 
TM7SF2 -0.40293956 ASCL1 -0.8370308 
CDKN1A -0.40652168   
DUSP4 -0.40686473   
SLC6A14 -0.40836972   
S100A14 -0.4095575   
NCAM2 -0.41011342   
GPR126 -0.41262463   
ENTPD8 -0.41447031   
CPE -0.42258647   
RNFT1 -0.4249869   
CD44 -0.42541674   
RN7SK -0.42837477   
SSFA2 -0.4299735   
LOC493869 -0.44072345   
S100A7 -0.4485618   
AKR1C3 -0.45039082   
ERP27 -0.4554434   
ELP3 -0.45647278   
HS.571151 -0.4635652   
INPP4B -0.46599945   
TP53INP1 -0.46662062   
FAM83B -0.4673862   
S100A6 -0.47148132   
FAM113B -0.48061037   
BNIPL -0.48172164 
 
  
The 100 top and bottom ranking genes in the TOX3 arrays were selected based on to their GSEA 
enrichment score. 
